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ABSTRACT
DEFINING THE ROLE OF NEUROPILIN-2 IN TUMOR ASSOCIATED
MACROPHAGES: IMPLICATIONS IN PANCREATIC CANCER
SOHINI ROY
University of Nebraska Medical Center, 2017

Advisor: Kaustubh Datta, PhD.
Macrophages are extremely heterogeneous and highly plastic hematopoietic cells that
reside in all tissues and act as a bridge between the innate and adaptive arms of the
immune responses. Besides, they undertake a wide array of housekeeping functions like,
clearance of cellular debris that arise due to regular turnover in tissues, iron homeostasis,
immune surveillance as well as tissue repair processes post inflammation. They are also
causally associated with several clinical conditions, including cancer where the infiltration
of macrophages contribute to disease progression, metastasis and therapy resistance,
and thereby poor clinical outcome.
Neuropilins (NRPs) are non-tyrosine kinase cell surface glycoproteins expressed in all
vertebrates and widely conserved across species. The two isoforms, NRP1 and NRP2 are
mainly known for their role as co-receptors for class III Semaphorins and for members of
the vascular endothelial growth factor (VEGF) family of molecules. Both NRP1 and NRP2
are overexpressed in many cancers, exert pleiotropic effects in various aspects of cancer
pathobiology and correlate with the stage and grade of the disease and poor survival.
Intriguingly, additional immunoregulatory roles for NRPs have been reported in myeloid
and lymphoid cells, in normal physiological as well as different pathological conditions,
including cancer, various immunological disorders, and bone diseases. In comparison to
NRP1, the overall comprehensive function of NRP2 in macrophages and factors that
govern those functions is not well known. Therefore, the enveloping goal of this
dissertation is to comprehensively understand the role and function of NRP2 in
macrophages and their implication in tumor associated macrophages in solid tumor.
In the first part of the dissertation, we primarily investigated the expression pattern of
NRP2 during the differentiation of macrophages under inflammatory (M1) and
immunosuppressive (M2) polarizing conditions. We observed although NRP2 is not
expressed at a detectable level in monocytes, its expression is upregulated during the
differentiation of monocytes precursors to either M1 or M2 type mature macrophages. We
identified a novel function of NRP2 in regulating phagocytosis in macrophages by
modulating the levels of Rab5+ early phagosomes and Rab7+ late phagosomes. In NRP2
depleted macrophages clearance of bacteria or yeast components was delayed and these
cells exhibited elevated number or early phagosomes and decreased number of late
phagosomes.

vi
Since pancreatic cancer (PC) typifies the complex architecture of a tumor stroma and
tumor associated macrophages are abundantly present here, the second part of the
dissertation is aimed at elucidating the implication of NRP2 regulated phagocytosis in
TAMs in this lethal disease. The expression NRP2 in TAMs in human and mouse PC
tissues was assessed. Due to nutrient limiting conditions and rapid proliferation of tumor
cells in the TME, many of the cancer cells undergo apoptosis. TAMs efferocytose these
dying tumor cells, an event that polarizes them further to pro-tumoral type and contribute
to relapse and therapy resistance. We observed that in the absence of NRP2, clearance
of apoptotic cells was delayed. The implication of this observation in PC progression was
tested using a subcutaneous tumor model. Upon depletion of NRP2 in TAMs, tumors were
smaller. Of note, NRP2 depletion did not affect TAM recruitment to, or angiogenesis but
recruited and activated anti-tumor CD8 cells into the TME. Further, RNA-Seq analysis of
CD11b+ TAMs isolated from tumors indicated that many genes associated with either
endosomal/phagosomal maturation, recycling and exocytosis, immune modulation and
leukocyte recruitment and activation are deregulated following NRP2 depletion. Further,
NRP2 depletion downregulated many of the immunosuppressive genes and cytokines in
macrophages that may be important for either suppression of T cell response or induce
Treg formation. The data further suggested that NRP2 is important for efferocytosis and
maintaining TAM-like phenotype in intratumoral macrophages, thus helping to create a
tumorigenic immunosuppressive environment in the TME.
Taken together, studies in this dissertation document a requirement for NRP2 in
macrophage phagocytosis. Further, regulation of efferocytosis in TAMs by NRP2 have
implications in TAM functions and tumor progression. Hence, targeting NRP2 axis in TAMs
may help re-engineer the immunosuppressive stroma in the TME and emerge as potential
therapy in combination with chemotherapy or other adjuvant therapies.
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Chapter I
Introduction

*A part of this chapter has been published under the title “Multifaceted Role of
Neuropilins in the immune System: Potential Targets for immunotherapy” in
collaboration with Sohini Roy, Arup K. Bag, Rakesh K. Singh, James E. Talmadge,
Surinder

K.

Batra

and

Kaustubh

(https://doi.org/10.3389/fimmu.2017.01228).

Datta

in

Frontiers

in

Immunology.

2
1.1.1. Macrophages: A brief summary

Macrophages belong to the mononuclear phagocytic system. They are the
most plastic cell type among the hematopoietic family and extremely diverse in
functions. Macrophages bridge the innate and adaptive arms of the immune
response. They are also endowed with a variety of house-keeping functions, like
clearance of cellular debris through phagocytosis, immune sentinel in tissues and
priming adaptive responses as well as developmental processes, metabolism and
homeostasis. Macrophages are also causally associated with various diseases,
like diabetes, multiple sclerosis, autoimmunity, rheumatoid arthritis, asthma,
atherosclerosis, as well as cancer. In the following sections, we will briefly
summarize and discuss the development, different polarization states of
macrophages and their role and function in normal physiology as well as some
clinical conditions.
1.1.2. Origin and different monocyte subsets
Myelopoiesis starts in the yolk sac 3-4 weeks into gestation in human and
embryonic day 8 in mice. Myeloid progenitors developing from the primitive
ectoderm give rise to the embryonic macrophages. The first hematopoietic stem
cell (HSC) seeds the fetal liver around 5weeks of gestation and expand and mature
to erythroid, lymphoid and myeloid cells. Extra embryonic hematopoiesis stops at
around 10-12 weeks into gestation in human and E12 in mice. The liver remains
the primary site of hematopoiesis until birth in mice and week 20-24 of gestation in
humans. The HSC from liver gradually colonize the thymus and spleen and finally
the bone marrow just before birth in mice (and second trimester in human). The
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HSC gives rise to monocytes through the granulocyte-macrophage progenitor
(GMP), the macrophage-dendritic cell precursor (MDP) and common monocyte
progenitor (CMP) intermediates, in a sequential manner (1). There are different
monocyte populations in both mouse and human. In humans, monocytes can be
divided into the following groups: a major population called the classical monocytes
(CD14++CD16-), intermediate monocytes (CD14++CD16+) and a minor population
called the non-classical monocytes (CD14+CD16++) (2). The classical monocytes
express significant levels of CCR2 and CD62L, and low levels of CX3CR1 whereas
the non-classical type expresses a high level of CX3CR1. Extensive transcript
enrichment analyses have shown homology between Ly6ChiCX3CR1loCCR2hi (in
mouse)

and

CD14++CD16-

monocytes

(in

human)

and

between

Ly6CloCX3CR1hiCCR2lo (in mouse) and CD16+ monocytes (in human) (3-5).
During infection or injury, chemokines and pro-inflammatory cytokines released
from the inflamed tissue induce the egress of monocytes from the bone marrow.
The classical monocytes are targeted towards the site of infection where they
differentiate to mature macrophages and either exhibit cell mediated cytotoxicity
towards infected cells or can even migrate to the lymph nodes to prime DC or naïve
T cells for adaptive immune responses (6). The non-classical monocytes which
mainly patrol the endothelium, can also be recruited to sites of infection where they
secrete TNF and other inflammatory cytokines (7).
The tissue resident macrophages are heterogeneous, seed different tissues and
are maintained by self-renewal. They can origin atleast from three different
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sources: yolk sac derived macrophages, fetal liver monocytes or bone marrow,
depending on the tissue and the stage of development (8).
1.1.3. Macrophage polarization states
Macrophage polarization refers to the activation state of the cells at a given
point of time under a certain condition. As mentioned earlier, macrophages are
highly plastic in nature and respond rapidly to the cues they receive from their
surroundings. Tissue resident macrophages act as immune sentinels. Following a
pathogen insult or inflammatory reaction, they get skewed into an activated state.
Additional monocytes from circulation as are recruited which further differentiate
to activated inflammatory macrophages. These activated cells, called M1
macrophages are robust inducers of T cell response and are cytotoxic. They
secrete a wide variety of inflammatory cytokines and other molecules to eliminate
the infection. Post infection or inflammation, these cells engage in a tissue repair
program. At this stage, they are polarized towards an anti-inflammatory or
alternatively activated state (M2). These M2 macrophages are inducers of
regulatory T cells, release angiogenic growth factors and molecules and enzymes
to remodel and repair the damaged tissue. Finally, most of the infiltrating
macrophages either egress from the site of infection or die at the end of the
resolution phase.
Agents for M1 type polarization: Macrophages exposed to G-MCSF and
TLR agonists, like LPS and IFN-Y and Tumor Necrosis Factor (TNF) are polarized
to the inflammatory M1 type. Once activated, they produce M1 associated hallmark
molecules like IL-12, inducible Nitric Oxide Synthase (iNOS), IL-6, IL-1β and

5

reactive oxygen and nitrogen species (ROS and RNS respectively). They also
activate the helper CD4+ T cells and cytotoxic CD8+ T cells.
G-MCSF, upon binding to its receptor, triggers JAK2/STAT5 signaling,
resulting in the activation of ERK and AKT pathways as well as the nuclear
translocation of NF-κβ and IRF5 (9). G-MCSF stimulates the macrophages to
produce inflammatory cytokines like, IL-6, IL-8, G-CSF, M-CSF, TNF, and IL-1β.
TLR agonists like LPS trigger MyD88 and MaL/Tirap (Toll-interleukin 1 receptor
domain containing adaptor protein)-dependent pathways that subsequently
activate the NF-κB, activator protein 1 (AP-1), IRFs, STAT1, and EGR (early
growth response) family members. LPS induced macrophages produce robust
inflammatory cytokines like IFN-β, IL-12, TNF, IL-6, IL-1β, chemokines, antigen
presentation molecules and several co-stimulatory molecules. IFN-Y signals
through the receptors, IFNGR-1 and IFNGR-2. Following ligand binding, the
receptors activate the JAK1 and JAK2 proteins which then recruit molecules like
STAT1, IRF-1 and IRF-8 (10). Although a combination of LPS and IFN-Y is used
to polarize M1 macrophages in vitro, the gene signature profiles of the combination
is different from that of macrophages treated with either LPS or IFN-Y alone. This
highlights the heterogeneity of the macrophage population existing in vivo and
cautions us to carefully extrapolate our in vivo or in vitro findings.
Agents for M2 type polarization: M2 macrophages are further classified into
three groups, based on the polarizing cytokine they are exposed to and the
signaling pathways that get triggered thereafter. Alternative activation triggered by
IL-4 or IL-13 was termed as M2a, cells exposed to and polarized by Fc receptors
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and immune complexes belong to M2b and that by IL-10 and glucocorticoid
receptors was named M2c subgroup. M-CSF alone can also skew the cells
towards an anti-inflammatory M2 phenotype. However, in a tissue environment,
macrophages form a mixed population and it is impossible to distinguish them as
either M2a or M2b or M2c type. These cells are a potent source of
immunosuppressive cytokines like IL-10, TGF-β, angiogenic molecules like VEGF
family of members and tissue remodeling factors like MMPs. They also suppress
the activation of helper and cytotoxic T cells and induce the formation of T regs.
M2 inducers like M-CSF when binds to the cognate receptor, induces the
dimerization and autophosphorylation of the receptor and subsequent activation of
ERK, phosphatidylinositol 3-kinase, phospholipase C and finally the nuclear
translocation of Sp1. IL-4 activates JAK1 and JAK3 which results in the activation
of STAT6. IL-4 can act through different receptor pairs: IL-4Rα1 can pair with the
common gamma chain, Yc; or it can heterodimerize with the IL-13Rα1 chain that
can bind both IL-4 and IL-13. Additionally, IL-13 can signal through a third receptor,
IL-13Rα2. IL-4 and IL-13-treated macrophages, although similar, exhibit different
gene signature profiles. In case of M2b macrophages, FcYR represses IL-12, one
of the hallmark cytokines for M1 state, and induces the production of IL-10 and
promotes a Th2 response (11, 12). The M2c inducers, IL-10 and glucocorticoids
signal through entirely different pathways. For example, macrophages metabolize
glucocorticoids that are secreted by the adrenal glands. These hormones bind to
the glucocorticoid receptor alpha (GCR) and results in its nuclear transcription,
where it either alone or by interacting with other transcription factors regulate the

7

expression of genes like, complement component 1 subunit A (C1QA), TSC22
domain family, member 3 (DSIPI), MRC1, thrombospondin 1 (THBS1), IL-10,
IL1R2, and CD163 (13). IL-10 on the other hand, signals through the STAT3
pathway and regulate the expression of several genes like, selected Fc receptors,
the chemoattractants CXCL13 and CXCL4, the recognition receptors formyl
peptide receptor 1 (FPR1), TLR1, TLR8, MARCO (14).
Of note, macrophage polarization is not an absolutely ON/OFF
phenomenon. For example, both the M1 and M2 types express Arg1, albeit in
different amounts. Another such pervasive misconception is about IL-10, a robust
anti-inflammatory cytokine. Although known as a marker for M2 polarized
macrophages, IL-10 is also secreted by M1 type cells. Surprisingly, macrophages
stimulated with immune complexes and that are signaling through Fc receptors
produce significant amount of IL-10. This may be a result of negative feedback
regulation to avoid excess inflammatory response. Another major concern is that
most of the studies on macrophages done in vitro use simple polarization
techniques. This clearly does not mimic the complex overlapping and pleiotropic
signals that a macrophage is exposed to in a tissue where M1 and M2 signals
cannot possibly exist alone. Also, the polarization technique varies among different
laboratories and hence there is a lot of inconsistency in the markers used for each
subtype. However, some of the classical markers used to identify either M1 or M2
polarized macrophages is listed in Fig. 1.6 and 1.7.
The above-mentioned M1/M2 classification of macrophages is oversimplified and vague. Especially, under conditions of non-resolving inflammation,
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like cancer, chronic infection or autoimmune disorders, macrophages exhibit much
more complex molecular profile and gene signatures of M2 as well as M1 type
macrophages. In the above cases, there is an increased output of monocytes from
the bone marrow to maintain sustained recruitment to the site of chronic
inflammation. Also, a non-resolving inflammation like cancer takes years to
decades to develop, allowing the monocytes/macrophages a lot of time to adapt
to the wide array of signals they receive. Once inside the tumor, they are exposed
to inflammatory as well as immunosuppressive factors, as a result of which they
show a mixed phenotype resembling more of M2 macrophages, but also express
some genes characteristic of the M1 type cells.
1.1.4. Functions of macrophages in normal physiology and clinical
conditions
Macrophages are indispensable for normal developmental processes. On
the other hand, they are also causally related to several clinical conditions, like
autoimmunity, rheumatoid arthritis, atherosclerosis, cancer to name a few. Few of
these aspects of are discussed briefly below:
Development: In absence of macrophages, several developmental defects
have been reported. For example, Csf1 null mice, which lacks macrophages,
develops osteopetrosis due to loss of osteoclasts. The cavities in bones where
hematopoiesis occurs are not formed in these mice. However, the mice survive till
adulthood due to extramedullary hematopoiesis in spleen and liver. Macrophages
are also important for angiogenesis, proper tissue architecture and patterning in
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kidney, pancreas, mammary gland, brain as well as stem cell niche maintenance
and deciding their fate (15).
Phagocytosis: The primary function of macrophages is phagocytosis. For
example, during erythropoiesis, macrophages surround the maturing erythroblasts
and engulf the extruded erythrocyte nuclei (16). Macrophages also phagocytose
cells not expressing CD47 and hence are critical for deciding erythropoietic egress
from bone marrow (17). They also maintain hematopoietic steady state by clearing
neutrophils in spleen and liver (18). Macrophages are also central to clearing
apoptotic cells arising as part of daily turnover in our body or apoptotic debris
occurring during infection or injury. The importance of removal of apoptotic cells
by macrophages is discussed later in the relevant sections.
Metabolic homeostasis: Macrophages are important for maintenance of
systemic metabolic homeostasis. For example, in healthy lean individuals,
macrophages are alternatively activated (express Arg-1, CD206) and comprise 1015% of white adipose tissue, which acts as a long-term storage of nutrients. This
is important for imparting insulin sensitivity in the white adipose tissue. However,
in obesity, the white adipose tissue is under stress and releases macrophage
chemoattractants like CCL2, CCL5 and CCL8 and macrophage content increases
upto 45-60%. These macrophages are inflammatory in nature and contribute to
insulin resistance in obesity (19-23). Further, high fat feeding causes inflammatory
macrophage infiltration into the insulin producing islets and augments β-cell
dysfunction (24, 25). Macrophages also phagocytose aged erythrocytes and
contribute to iron recycling (26).
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Thermogenesis: Brown adipose tissue or brown fat generates heat and
maintains our body temperature. Alternative activation of macrophages by IL-4 and
IL-13 induce the production of catecholamines in macrophages that contribute to
thermogenesis in brown fat.
Infections: In case of pathogenic infection or inflammation, circulating
monocytes are rapidly recruited to the site of injury where they polarize to
classically activated M1 type. These cells secrete pro-inflammatory and cytotoxic
cytokines, anti-microbial mediators like ROS/NOS and mediate killing of infected
cells. They also directly or indirectly alert the adaptive immune responses for
eradicating the invading pathogen. Post injury, macrophages adopt a reparative
phenotype where they phagocytose and clean up the apoptotic debris that arose
due to infection or injury and plays a vital role in tissue remodeling, regeneration
and wound healing process by secreting growth factors, angiogenic molecules,
and matrix metalloproteinases. However, in cases where the repair process is
impaired, it results in aberrant healing and fibrosis (scarring).
Inflammatory diseases: Macrophages are also causally associated with
several chronic sterile inflammation related diseases, like rheumatoid arthritis
(RA), inflammatory bowel disease (IBD), asthma, atherosclerosis and fibrosis. For
example, in RA, IBD and multiple sclerosis, macrophages secrete proinflammatory cytokines like IL-12, IL-18, IL-23, TNF-α and contribute to disease
pathogenesis and severity. On the other hand, allergic asthma, which arises due
to airway obstruction and inflammation and lung remodeling, is characterized by
the abundance of macrophages that secrete Th2 like cytokines and molecules that
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degrade the tissue and remodel the airway. Macrophages also secrete molecules
that result in the recruitment of eosinophils, basophils and Th2 type T cells that
worsen the disease.
1.2. Neuropilins: A brief introduction
Neuropilins

(NRPs)

are

multifunctional,

transmembrane

surface

glycoproteins that are expressed in all vertebrates and are highly conserved across
species. They were originally identified for their role in axonal guidance. NRPs are
well known for their function as co-receptors for Vascular Endothelial Growth
Factor (VEGF) members and Class III Semaphorins by interacting with VEGF
receptors and Plexins respectively. However, work over the past decade have
identified additional role of NRPs in a wide array of physiological processes, like
development, angiogenesis, immunity as well as clinical conditions like cancer.
The two isoforms, NRP1 and NRP2 are often over-expressed in different cancers
and their expression correlates with poor clinical outcome. NRPs are known to aid
cancer progression by promoting cell survival under therapeutic stress, inducing
tumor associated angiogenesis and therapy resistance. They are also expressed
in a variety of immune cells, like, macrophages, dendritic cells, and different T cell
subsets where they take part in the development, migration and immune
responses under physiological as well as pathological conditions. NRPs are also
expressed in bone compartment, namely osteoclast and osteoblast where they
regulate bone homeostasis. Of the two isoforms, NRP1 is well characterized in
different T cell subsets and to some extent in myeloid cells (dendritic cells and
macrophages). NRP2, on the other hand, is poorly characterized in the immune
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cell subpopulations, and details of its ligands and pathways governing its functions
not well understood.
1.2.1. Genomic organization, protein structure and splice variants of
Neuropilins
There are two isoforms of NRPs, NRP1 and NRP2. They are encoded by
distinct genes located on different chromosomes, 10p12 for NRP1 and 2q34 for
NRP2. The two isoforms arose because of gene duplication and share homology
in their structure and overlapping sets of ligands and functions. Each gene contains
17 exons and 16 exons and similarity in exon-intron junctions (27). The general
domain structure of the NRPs comprises of an N-terminal extracellular region, a
single pass transmembrane domain followed by a short C-terminal cytosolic part
(43-44 amino acids). The extracellular portion comprises of two CUB (complement
binding factors C1r/C1s, Uegf, Bone Morphogenetic protein 1)(a1/a2) domain, two
Factor V/VIII coagulation factor homology (b1/b2) domain, a b-c linker, followed by
a MAM (homologous to meprin protease, A5 antigen, receptor tyrosine
phosphatase µ and κ). The CUB domain interacts with Semaphorin group of
ligands, the b1/b2 domain is important for binding anionic phospholipids and thus
mediate cell-cell adhesion. This is also the site for interaction with VEGF ligands.
The MAM domain is required for homo or heterodimerization with other receptors.
Several splice variants have been identified for each of NRP1 and NRP2. Both
NRP1 and NRP2 can exist as membrane bound or soluble splice forms. The latter
often act as decoy molecules and antagonize the function of the full-length
receptors. For instance, two such splice forms,

12sNRP1

and

11sNRP1

arise due
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to pre-mRNA splicing at intron 12 and 11 respectively (27).
decoy receptor for VEGF165. When

12sNRP1

12sNRP1

acts as a

was overexpressed in rat prostate

carcinoma cells, this resulted in tumors with increased number of hemorrhaged
and damaged blood vessels and higher number of apoptotic tumor cells (28). Two
additional soluble splice forms have been reported for NRP1, namely, sIIINRP1
and sIVNRP1 and their expression detected in normal condition as well as tumor
tissues. Both these isoforms act as a ligand trap and regulated breast cancer cell
migration (29). Another splice variant for NRP1 is reported; it lacks a stretch of 7
amino acids, two residues downstream of the O-glycosylation site and hence
undergoes less glycosylation. When overexpressed in prostate cancer cells, it
reduced tumor cell proliferation and migration and hence slowed tumor growth
(30).
Two membrane bound splice variants are known for NRP2, namely NRP2a
and NRP2b. They differ at the last 100 amino acids in the cytoplasmic tail. NRP2a
is 44% homologous to NRP1 and may exhibit redundant functions. The
extracellular domain of NRP2a and NRP2b are identical, but share only 11%
homology in their transmembrane and cytosolic domains, indicating activation of
divergent downstream signaling cascades and functions. Indeed, a recent study
reported opposite function of these two splice variants in non-small cell lung
carcinoma. NRP2b showed pro-metastatic role whereas NRP2a antagonized
tumor progression and metastatic burden (31). In humans, two splice variants for
NRP2a have been identified, namely NRP2a(17) and NRP2a(22). The former
arises as a result of insertion of insertion of 17 amino acids after position 809,
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located between the MAM and transmembrane domains. On the other hand,
NRP2a(22) has an insertion of additional 5 amino acids within the 17 amino acid
stretch as in NRP2a(17) as a result of alternate splicing. Similarly, NRP2b can also
exist as two splice forms, NRP2b(0) and NRP2b(5) that is generated by alternate
splicing between exon 15 and 16b and insertion of 0 or 5 amino acids after residue
808. NRP2b(0) is more abundantly expressed than NRP2b(5) (27). Of note,
NRP2a and NRP2b have divergent C terminus, indicating they probably can
activate distinct signaling pathways and exert non-redundant functions. Therefore,
to successfully target NRPs, it is crucial to clearly understand why the different
isoforms or splice variants are expressed, sometime one preferentially over
another, under different conditions and the differences in their cellular signaling.
In mice, NRP2 undergoes alternative splicing and gives rise to four splice variants;
these differ in the insertion of 0, 5, 17 or 22 amino acids after residue 809. The fact
that these differential insertions occur in the b-c linker and transmembrane domain,
it may alter the ability of the splice variants to homo or heterodimerize with other
surface receptors. Hence the splice forms may potentially regulate distinct
downstream cellular signaling pathways (27).
A soluble isoform for NRP2 is known, 9sNRP2 (62.5 kDa). Alternate splicing
results in the inclusion of an intron in the b2 domain of the mRNA and an in frame
stop codon results in the termination of the translation of the protein. Hence this
soluble isoform has the a1/a2 domain, the b1 domain but only a part of the b2
domain, but not the last 48 amino acids of the b2 domain, the b-c linker, the
transmembrane domain and the cytosolic tail (27). Intriguingly, 9sNRP2 acts as a
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ligand trap and sequesters VEGFC, impairing the oncogenic VEGFC/NRP2
signaling axis and growth of prostatospheres in vitro (32).
1.2.2. Post translational modifications of NRPs
Both NRP1 and NRP2 undergo various post translational modifications with
different functional consequences. NRP1 is often modified by the covalent addition
of Glycosaminoglycan (GAG) to a conserved Serine residue (Ser 612) in the b-c
linker region (33). Structurally, GAGs are a repeating disaccharide unit containing
N-acetylglucosamine (GlcNac) or N-acetylgalactoseamine (GalNac) and a uronic
acid or galactose. GAGs can be either Heparan sulfate (HS-GAG) or Chondroitin
sulfate (CS-GAG), keratin sulfate or hyaluronic acid. In several human tumor cell
lines, NRP1 exists as N-glycosylated as well as CS-GAG modified fractions.
Surprisingly, the latter negatively regulated tumor cell invasion (34). CS GAG
NRP1 is predominantly expressed in the vascular smooth muscle (SMC) cells. In
HUVEC cells, NRP1 expressed equivalent amount of CS GAG and HS GAG. GAG
modification on NRP1 enhances its binding to VEGF, however, CS-GAG NRP1
may act as a decoy receptor under certain circumstances. On the other hand, HSGAG NRP1 may bind multiple NRP1 molecules and promote NRP1 clustering.
Such a cluster can bind VEGFR2 in presence of VEGF and stabilize the complex,
prevent internalization of VEGFR2, resulting in enhanced signaling (33). In
contrast, there are no reports for such modification on NRP2. In DCs, NRP2
undergoes post translational modification by the addition of polysialic acid (PSA)
chains to mucin type O-linked glycans between the b2 and c domains(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,

16

36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36)(35,
36)(35, 36)(35, 36)(35, 36)(35, 36)(35, 36. NRP2 polysialylation regulates CCL21
driven trafficking of DCs to the secondary lymphoid organs and modulates
interactions between DCs and T lymphocytes (37). NRP1 has also been recently
reported to undergo polysialylation at a level 50% of that of NRP2, although the
exact biological implication of this remains unknown (38).
1.2.3. Ligands for the NRPs
NRP1 and NRP2 are most well known for their role as co-receptors to VEGF
family members and Class III Semaphorins. Semaphorins comprise a large family
of proteins and can be sub-categorized into seven classes. They bind with Plexins
on the cell surface and activate cellular signaling to affect different aspects of
developmental biology, immune responses, as well as clinical disorders. Class III
Semaphorins are secreted from cells and can interact with either NRP1 or NRP2
at the a1/a2/b1 domain. Together with Plexin A1 or A2, they form a holoreceptor
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complex. NRP1 and NRP2 exhibit some selectivity in binding to the Semaphorins.
For instance, the major ligand for NRP1 is Sema3A, although it can also bind
Sema3F, albeit with lower affinity. NRP2, on the other hand, binds mainly Sema3C
and Sema3F, but not Sema3A. NRPs also bind VEGF family members with
differential specificities. For example, NRP1 binds VEGFA, classically VEGFA165
(39).

NRP2 preferentially binds with proteolytically cleaved and activated VEGFC,

although it can also bind other VEGFA isoforms. Structural studies have delved
into explaining how NRPs exhibit selectivity in binding different VEGF isoforms. It
has been shown that a surface groove in the b1 domain binds with linear epitopes
containing a C-terminal arginine, present in the VEGFA isoforms and
proteolytically cleaved VEGFC. However, the interactions can be fine-tuned by
additional side chain interactions in the b1 domain region.
NRPs are also known to bind several other ligands, where they mainly act
as co-receptors to enhance the signal. For example, NRPs can bind with
Transforming Growth Factor beta 1 (TGF-β1) and signal through the canonical
Smad2/3 pathway to trigger anti-apoptotic and anti-proliferative pathways. They
also bind to c-Met and platelet derived growth factor (PDGF) and contribute to
cancer pathogenesis. It is now well established that miRNAs circulate either in
encapsulated form or bound to protein Argonaute-2 (AGO2) and travel to distant
sites where they crosstalk with target cells. A recent study showed that NRP1 binds
AGO2/miRNA complexes and facilitates their cellular internalization process (40).
miRNAs have now been proven to be causally associated with several clinical
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disorders, including cancer. miRNA/NRP1 interaction may have impact in different
pathological conditions.
1.2.4. Phenotypes of genetically engineered mouse models for NRPs
The crucial roles of NRP1 and NRP2 in developmental biology began to
emerge from different genetically engineered mouse models. NRP1 depletion is
embryonically lethal at E10.5-E13.5. The embryos die of severe cardiac and
vascular defects (41-43). Transgenic mice with NRP1 overexpression also die in
utero at E12.5 owing to extensive hemorrhage and had developmental defects in
the nervous system (44). In contrast, NRP2 knock out mice are viable and proceed
to adulthood.

However, they have smaller lymphatic vessels and proper

development of cranial nerves, spinal sensory axons is impaired (45-47). NRP2
also plays an important role in bone homeostasis. This was evident from the
significantly lower bone mass of NRP2 knock out mice. The bone loss was
attributed to reduced number of osteoblasts and increased number of osteoclasts
in absence of NRP2 (48). Simultaneous depletion of NRP1 and NRP2 is embryonic
lethal at E8.5; the embryos die due to severe vascular defects (49).
1.2.5. Role of NRPs in macrophages
Both NRP1 and NRP2 expression have been reported in macrophages
under various conditions (50). NRP1 is expressed on tissue resident
macrophages, like alveolar, bronchial, intravascular, decidual as well as
microglia/macrophages in the brain. For example, TIE2+ yolk sac derived
microglia/macrophages

that

express

NRP1

are

important

during

brain

vascularization. These macrophages are present near the endothelial cells and
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promote vessel fusion. However, NRP1 has been shown to be dispensable for
normal vessel growth in brain (51-53). Recently, there have been a lot of focus on
tumor infiltrating macrophages (TAMs). As discussed later, TAMs comprise a
unique population of myeloid derived cells in the tumor core and their infiltration
correlates with disease progression and clinical outcome in many cancers. TAMs
have been causally associated with various aspects of cancer, like cancer cell
survival, EMT, migration and invasion, angiogenesis and suppression of immune
response against the malignant cells (54-57). Recently, it has been shown that
recruitment of TAMs to the hypoxic core of the tumor is crucial for their attainment
of pro-tumorigenic properties. Once recruited to the tumor site, NRP1 regulates
the migration of TAMs to the hypoxic core and its ablation arrests the TAMs in the
peripheral normoxic region of the tumor, activates anti-tumor immune response
and reduces tumor burden (58, 59). NRP1 is also expressed in glioma associated
macrophages (GAM) and promotes their tumorigenic activities. Indeed, depletion
of NRP1 in GAMs reduced the burden of glioma tumors (60). An immunoregulatory
role for NRP1 has been documented in several other studies as well.
NRP2 on the other hand, is not well characterized in the myeloid cell
compartment. Previous literature as well as work in the current dissertation show
that NRP2 is not expressed at a detectable level in the monocytes, but its
expression is induced in inflammatory M1 as well as alternatively activated M2
macrophages. NRP2 is also detected in tissue macrophages, including alveolar,
bronchial, peritoneal as well as intravascular macrophages in mice (50). A recent
study reported that polysialylation is progressively lost in monocytes as the cells
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migrate towards pulmonary and peritoneal sites of inflammation. Interestingly,
peritoneal macrophages do not express polysia themselves, however NRP2 is
modified post-translationally by polysialylation when maintained in culture. Further,
removal of polysia increased the phagocytosis of bacteria in macrophages.
However, it is still not clear if this observation could be attributed to polysialylated
NRP2 (61). It is possible that macrophages lose polysia during bacterial infection
to enhance phagocytosis, following which it is re-expressed and probably plays a
part in the interaction with T cells. Polysialylated NRP2 has also been reported in
microglia, where they mainly remain confined in the golgi compartment. Following
LPS stimulation, it gets quickly mobilized to the cell surface and is eventually lost.
Interestingly, polysialylated NRP2 was detected in the cell culture supernatant,
indicating metalloproteinase mediated cleavage of the protein. Exogenous addition
of polysia blunted the production of pro-inflammatory cytokines in microglia in
response to LPS challenge. This indicated a possible role for polysialylated NRP2
in negative feedback regulation of inflammatory response in macrophages (62,
63). However, the main concern in this finding is since the addition of exogenous
polysia abrogated the production of inflammatory cytokines in microglia in
response to LPS, this effect does not necessarily depend on the polysia carrier.
Also, it is not clearly known why polysialylated NRP2 is mobilized to the cell surface
following LPS challenge.
Expression pattern of NRP2 in TAMs is not well characterized, nor is its
function in cancer associated macrophages known. Two previous studies have
reported NRP2 expressing macrophages in patients with lung cancer as well in
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mouse mammary tumors (50, 64). However, no data exists till date that correlates
NRP2 expression in TAM with disease progression or clinical outcome and patient
survival. We have detected NRP2 expression in TAMs in pancreatic cancer.
Expression of NRP2 in TAMs in pancreatic cancer and its functions and
implications in tumor progression will be discussed in more detail in the relevant
sections.
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Fig 1.1. Neuropilin (NRP) domain structure and splice variants. The general
domain structure of NRP1 and NRP2 is shown. There is an N-terminal extracellular
domain for ligand binding, followed by a single pass transmembrane domain and
a short cytosolic tail. The extracellular domain comprises of two CUB, two b1/b2
and one MAM domain. The sites for binding different ligands are indicated. Both
NRP1 and NRP2 can exist as multiple splice variants. Soluble isoforms (sNRP1
and sNRP2) contain truncated extracellular domain but lack the transmembrane
and cytosolic regions and can act as decoy receptors to blunt NRP function. NRP2
can exist as two splice forms, NRP2a and NRP2b, which share only 11% homology
in their C terminus, therefore, being capable of regulating different signaling
pathways. The percentage of sequence homology in the different extracellular and
cytosolic domains of NRP1 and NRP2 as well as between NRP2a and NRP2b are
indicated. The C termini of both NRP1 and NRP2a contain a PDZ binding motif
(SEA) that can act as docking site for interacting partners. Red arrowheads
indicate insertion at residue 808 in NRP2 of five amino acids GENFK giving rise to
different splice variants of NRP2a and NRP2b.The percentage amino acid
homologies between the domains of full length NRP1 and NRP2 isoforms and
between the NRP1 and NRP2a/NRP2b isoforms are indicated. The figure has
been adapted from Roy et al. “Multifaceted Role of Neuropilins in the Immune
System: Potential Targets for Immunotherapy”. Front Immunol. 2017.
doi: 10.3389/fimmu.2017.01228 with permission.
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Fig. 1.2. Origin of monocytes in the bone marrow. Hematopoietic stem cells
(HSC) in the bone marrow continuously giving rise to monocytes through
sequential generation of Granulocyte-Myeloid Progenitor (GMP), MonocyteDendritic Cell Precursor (MDP) and Common Myeloid Progenitor (cMOP)
intermediates. Monocytes exit bone marrow to enter circulation. The two classes
of monocyte subsets are shown: classical monocytes and non-classical
monocytes; in the steady state, the two subsets form a developmental continuum,
but are functionally distinct. This figure has been adapted from Ginhoux et al.
“Monocytes and macrophages: developmental pathways and tissue homeostasis.”
Nat Rev Immunol. 2014. doi: 10.1038/nri3671 with permission.
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Fig. 1.3. Human monocyte subsets and their functions. Three different human
monocyte subsets are indicated: classical (CD14+++CD16-), intermediate
(CD14++CD16+) and non-classical (CD14+CD16++). In the steady state, the
different subsets comprise a developmental continuum, although the classical type
can switch to the intermediate and non-classical types in circulation. Classical
monocytes display efficient antimicrobial capability due to their enhanced
phagocytic activity, and secrete ROS/NOS upon LPS stimulus, whereas
intermediate and non-classical MCs secrete inflammatory cytokines, TNFα and IL1β. During inflammation, classical and intermediate subsets infiltrate target tissue,
mature to M1Mϕ and present self-antigen via MHC-I/II to prime naïve T cells. In
steady state, non-classical monocytes patrol the endothelium and become M2Mϕ.
They express CD206, IL-10 and are involved in tissue remodeling, wound healing,
immunosuppression and are pro-tumorigenic. During the resolution phase of
inflammation, M1 Mϕ can repolarize to M2Mϕ. This figure has been adapted from
Yang et al. “Monocyte and macrophage differentiation: circulation inflammatory
monocyte as biomarker for inflammatory diseases.” Biomarker Research. 2014.
doi.org/10.1186/2050-7771-2-1 with permission.
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Fig.1.4. Mouse monocyte subsets and their functions. Different monocyte
subsets in mouse are indicated: classical (Ly6c+) and non-classical (Ly6c-). Ly6C+
monocytes leave the bone marrow in a CC-chemokine receptor 2 (CCR2)dependent manner. In the steady state, both the subtypes form a developmental
continuum, and Ly6C+cells can differentiate into Ly6C- type. Ly6C- MCs patrol the
endothelium are recruited into normal tissue to become tissue resident Mϕ/DCs
where they clear apoptotic debris and perform other housekeeping functions.
Ly6C+MCs rapidly respond to inflammation or pathogen invasion, become M1Mϕ
and exhibit antimicrobial capability, enhanced phagocytosis and secrete ROS,
TNFα, and IL-1β, present antigens and activate T cells; they are anti-tumorigenic.
Ly6C- MCs are recruited to tissue and differentiate into M2Mϕ, which secrete antiinflammatory cytokine and contribute to tissue repair and are reparative and
immunosuppressive in nature and are protumorigenic. During the resolution phase
of inflammation or injury, M1 type can re-polarize to M2 type macrophages. This
figure has been adapted from Yang et al. “Monocyte and macrophage
differentiation: circulation inflammatory monocyte as biomarker for inflammatory
diseases.” Biomarker Research. 2014. doi.org/10.1186/2050-7771-2-1 with
permission.
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Fig.1.5. Stimuli for M1/M2 type polarization of macrophages and the
pathways associated. A. M1-M2 macrophage model, in which M1 is generated
following exposure to interferon-gamma (IFN-g) + lipopolysaccharide (LPS) or
tumor necrosis factor (TNF); M1 macrophages are characterized by secretion of
IL-12, IL-1, IL-23, TNF, IL-6 and MHC-II and low levels of IL-10 and are antimicrobial, cytotoxic and anti-tumoral. M2 type is further subdivided to M2a (IL4/IL-13 induced), M2b (immune complex+ Toll-like receptor (TLR) ligands
induced), and M2c (IL-10 and glucocorticoids induced). (B) The key signaling
pathways and downstream mediators behind the M1 and M2 stimuli in
macrophages are highlighted. The diagram includes granulocyte macrophage
colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor
(M-CSF) as M1 and M2 stimuli respectively, in addition to other cytokines
mentioned. This figure has been adapted from Martinez et al. “The M1 and M2
paradigm of macrophage activation: time for reassessment.” F1000Prime Rep.
2014. doi: 10.12703/P6-13 with permission.
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Fig.1.6. Marker panel for M2 macrophages. This figure has been adapted from
Murray et al. “Macrophage Polarization.” Annual Review of Physiology. 2016.
DOI:10.1146/annurev-physiol-022516-034339 with permission.
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Fig.1.7. Marker panel for M1 macrophages. This figure has been adapted from
Murray et al. “Macrophage Polarization.” Annual Review of Physiology. 2016.
DOI:10.1146/annurev-physiol-022516-034339 with permission.
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Fig.1.8. Physiological roles of macrophages. Macrophage heterogeneity arises
from their different origins (either yolk sac or bone marrow derived) and their ability
to detect and rapidly adopt to complex signals in the tissue microenvironment
(shown on the left). The vast range of physiological roles undertaken by
macrophages, e.g. erythropoiesis, metabolic homeostasis (insulin resistance),
iron recycling, development, tissue regeneration and thermogenesis (shown on the
right). Macrophages respond to external stimuli through “sensor systems” in the
form of (a) cell surface and intracellular pattern recognition receptors for detecting
invading pathogens and damage-associated molecular patterns; (b) receptors for
recognizing and engulfing apoptotic cells; (c) receptors that promote M1/M2-like
activation; (d) receptors for neurotransmitters (e) cell surface receptors that
regulate macrophage activation, e.g. the inhibitory receptors SIRP1-α and
CD200R. Integrins (f) mediate interaction with macrophages and ECM.
Macrophages produce numerous molecules that contribute to tissue remodelling
and inflammation and mediate clearance of apoptotic bodies, cell debris.
Macrophages rely heavily on efficient phagocytosis and endocytosis for
maintenance of homeostasis as well as other functions. This figure has been
adapted from Gordon et al. “Physiological roles of macrophages.” Pflügers Archiv
- European Journal of Physiology. 2017 with permission.
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Fig.1.9. Role of NRP2 in macrophages. NRP2 is expressed in microglia, tissue
resident (M2) and inflammatory M1 type macrophages as well as TAMs. In
peritoneal macrophages, NRP2 is involved in phagocytosis. In microglia, NRP2 is
polysialylated and remains confined in the golgi compartment. Following LPS
challenge, it rapidly translocates to the cell surface and is shed from the cells. The
role of NRP2 in TAMs is not reported. This figure has been adapted from Roy et
al. “Multifaceted Role of Neuropilins in the Immune System: Potential Targets for
Immunotherapy”. Front Immunol. 2017. doi: 10.3389/fimmu.2017.01228 with
permission.
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2.1. Tumor Associated Macrophages: An overview
The tumor microenvironment (TME) is now considered a complex
ecosystem, comprising not only of cancer cells, but also other cell types, like
immune cell infiltrates, stromal cells, endothelial cells and fibroblasts. It is now well
established that this ecology of cells evolves with and engages in a complex cross
talk with one another, thereby providing support to the growing tumor. Suppression
of antitumor adaptive immune response and non-resolving tumor-promoting
inflammation have now become known as hallmarks of cancer. Of the
inflammatory immune cell infiltrates, macrophages are the most abundant in the
ecological niche of cancer and orchestrate the non-resolving cancer related
inflammation (CRI). There is now substantial evidence to suggest that tumor
associated macrophages (TAMs) engage in dynamic interplay with cancer cells,
and other immune and non-immune cells in the TME, adopt a pro-tumoral
phenotype, both in the primary and metastatic sites and most often correlate with
poor clinical outcome. Therefore, understanding the ontogeny of TAMs, and the
molecular pathways that govern their differentiation and functional phenotypes will
emerge as an important prong in developing effective therapeutic strategies in
combination with chemotherapy and other immunotherapies in the future.
2.1.1. Origins of TAMs and their recruitment to the TME
In neoplastic tissues, cues from malignant cells or other cells of the TME
that govern the TAM differentiation and functional phenotypes are diverse in nature
and vary between tumors, or even various parts of the same tumor. Therefore,
there are varied TAM populations within a single tumor. Of note, most of the time
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TAMs do not fit into the oversimplified M1/M2 classification mentioned earlier and
exhibit complex molecular signatures. However, despite the varied intra-tumoral
and intertumoral phenotypes of TAMs, they are in general polarized towards an
immunosuppressed type in all cancers. As mentioned earlier, macrophages can
originate from either yolk-sac derived or bone marrow derived precursors.
However, the precise ontogeny of TAMs is still not entirely clear. Work over the
past few decades indicate that TAMs can arise either from circulating blood
monocytes, monocytic myeloid derived suppressor cells (M-MDSCs) that get
recruited to the TME or from local resident tissue macrophages of embryonic origin
(65). For example, in mouse gliomas, TAMs can originate from either blood
monocytes or tissue resident microglial cells (66). Using genetically engineered
mouse models, there have been attempts to assess the relative contribution of
TAMs arising from these various sources in tumor progression. Many recent
studies have documented that most TAM sub-populations in the TME arise from
the Ly6C+ circulating blood monocytes that invade the growing tumor in response
to recruitment cues from the TME, at least in grafted tumors (67), primary mouse
mammary tumors (68) and in lung metastases (57). Indeed, in mouse glioma, the
Ly6C+ circulating monocytes that differentiated to TAMs were causally associated
with increased rate of tumor incidence and shorter disease-free survival.
Interestingly, there was no significant contribution of TAMs that arose from the
resident microglial cells (66). Cortez-Retamozo et al. proposed that circulating
monocytes that give rise to TAMs originate from extramedullary hematopoiesis that
allows a rapidly mobilizable reservoir of TAMs for the tumor. However, recent
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lineage tracing studies have shown that bone marrow is the primary source of
monocytes that differentiate to TAMs, with minimal contribution from the spleen
(69).In addition, there are conflicting studies to suggest that TAMs arise from the
non-classical subset of circulating monocytes (70). Hence, it is possible that the
origin of TAMs depends on the tumor type and the tumor microenvironment.
Additionally, their origin may also dictate their functions in the tumor (71). Some of
these aspects have been discussed in more details elsewhere (72).
The tumor bed secretes a wide array of cytokines and chemokines that act
as a gradient for recruiting circulating monocytes and differentiate them towards
TAMs. Among these, CD62L, CX3CL1, CCL2, VEGF-A, CSF-1 are widely
implicated in TAM recruitment to the TME. For instance, in solid tumors, the
inflamed endothelium secretes molecules like CD34, podocalyxin, endomucin,
nepmucin, MAdCAM-1, endoglycan, GlyCAM-1, Spg2000 etc., which act as
ligands for CD62L expressed on circulating monocytes to recruit them to the TME.
Also, tumor cells produce CX3CL1, CCL2 and VEGF-A which bind to and act
through their cognate receptors, CX3CR1, CCR2 and VEGFR1 respectively to
promote monocyte migration to the TME (73). Additionally, CCL2/3/4/5/22,
CXCL8, Endothelin, PDGF have also been showed to promote monocyte
recruitment (74).
2.1.2. Pro-tumoral role of TAMs
Tumor infiltrating macrophages assist in tumor progression in many ways.
It is now well accepted that in addition to mutations acquired in the tumor cells, a
persistent inflammatory micro-environment can provide necessary support to
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cancer initiation (75). For example, chronic inflammation caused by Helicobacter
pylori in the stomach, Crohn’s disease, chronic pancreatitis have all been causally
associated with cancer initiation (76-78). Macrophages significantly contribute to
this process by producing molecules like IL-6, TNF-α, IFN-Y (78, 79). For example,
genetically depleting STAT3 in macrophages results in chronic inflammation in the
colon and subsequent invasive adenocarcinoma (80). This persistent inflammation
supports a mutagenic microenvironment for the tumor cells to acquire additional
mutations (78). Macrophages also produce reactive oxygen and nitrogen species
which further add to the genetic instability of the cancer cells. The mutated cells
recruit more inflammatory cells in a vicious cycle which further facilitates tumor
formation (57, 75, 76).
During the proliferation phase of the tumor, one of the most well-known and
well-characterized functions of macrophages is regulation of the ‘angiogenic
switch’. Macrophage secreted factors induce endothelial cells to produce VEGFA
resulting in the angiogenic switch (81, 82). Further, TIE2+ macrophages
physically associate with endothelial cells of blood vessels through ANG2 and
blockade of this association reduced angiogenesis in several tumor models (83,
84). Intriguingly, recent reports indicate macrophages can transdifferentiate to
lymphatic endothelial cell precursors and contribute to lymphangiogenesis (85).
Metastatic cancers, before spreading to distant sites, first colonize the draining
lymph nodes. Thus, by inducing lymphangiogenesis, macrophages facilitate
cancer cell metastasis. Another important criterion for cancer cell metastasis is
acquirement of EMT phenotype (86). With the advancement of cancer, tumor cells
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suppress the epithelial markers like E-Cadherin and upregulate mesenchymal
markers like Snail and Slug. Macrophages can induce EMT in cancer cells in
multiple cancers, including pancreatic, lung, hepatocellular and breast cancers
(87-89). Macrophages also release a variety of molecules like Osteonectin, MMPs,
cathepsin proteases that help remodel the surrounding extra cellular matrix and
facilitate cancer cell invasion and migration (90, 91). TIE2+ macrophages can
further facilitate tumor cell intravasation into blood vessels (92). Recently. an
anatomical structure comprising tumor cell, macrophages and endothelial cells in
histological sections of primary human breast cancers has been reported. These
“Tumor microenvironment for metastasis (TMEM)” structures are predictive of
metastasis. Macrophages and tumor cells engage in a paracrine interaction and
get aligned along blood vessels in ‘lock step’ fashion with the former eventually
facilitating the escape of the latter into circulation (92-94).
One of the most principal factors contributing to tumor advancement and
therapy failure is suppression of the adaptive immune response against the
malignant cells in the TME. Once the recruited monocytes enter the TME, tumor
cell derived factors efficiently re-educate them towards an immunosuppressive
TAM phenotype. The latter, in addition to the myriad functions described earlier,
potentially suppress helper T effector cell activation against the tumor by secreting
elevated levels of immunosuppressive molecules like TGF-β and IL-10 and skew
them towards Th2 phenotype. These molecules not only blunt helper and cytotoxic
T cell response against the tumor, but also induce the development of Tregs
(56, 95, 96). Also, in the TME, TAMs undergo metabolic reprograming. They
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produce Arginase-1 and other metabolites via the indoleamine 2,3-dioxygenase
(IDO) pathway which results in the starvation of T cells and their inactivation. LArginine is metabolized by inducible Nitric Oxide Synthase (iNOS) or Arginase-1,
depending upon the M1 or M2 state of macrophages (95). TAMs secrete Arginase1 and hence consumes L-Arginine from the TME to produce urea and L-ornithine
(97, 98). Non-availability of L-Arginine restricts T cell activation (99). The Th2 cells,
eosinophils and basophils in the TME also produce ample amount of IL-4, IL-10,
IL-13 which elicit TAM polarization of macrophages (100-102). Tumor cells
themselves secrete molecules like M-CSF and TGF-β to cause a phenotypic shift
in the infiltrating macrophages (103). Most importantly, intratumoral macrophages
are known to express immune checkpoint inhibitor molecules like PDL-1, PDL2 and ligands for CTLA-4 in various cancers. Upon binding with their cognate
ligands, these molecules potentially restrict T cell receptor (TCR) and B cell
receptor (BCR) signaling and restricts their activation and proliferation (56).
Enhanced expression of these checkpoint inhibitors on TAMs is one of the key
factors why most of the therapies fail in the clinic or show poor benefit. Another
important function of TAMs is to remove cellular debris to maintain growth
permissive environment for cancer cells. In the TME, apoptotic index is usually
high, either due to nutrient limitation or rapid proliferation of cancer cells. TAMs
phagocytose the cellular debris and facilitate their clearance. This process of
efferocytosis skews the macrophages more towards TAMs and establishes further
immunosuppression in the microenvironment (104). This aspect will be discussed
in more details in the relevant section.
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Finally, macrophages are essential for the formation of pre-metastatic niche
where disseminated cancer cells seed and colonize. Once tumor cells arrive at the
target tissue, they form micro-clots with associated platelets and get arrested in
tissue vessels (105). Tumor cells then secrete CCL2 and recruit circulating
monocytes via CCR2 (56, 106, 107). These recruited monocytes, called
metastasis associated macrophages (MAM) facilitate extravasation of cancer cells
by increasing vascular permeability.
2.1.3. Approaches to target TAMs
Immunotherapy has gained a lot of focus in the treatment of several cancers
lately. With increasing amount of evidences establishing a crucial role for TAMs in
tumor progression, metastasis and recurrence post therapy, several macrophage
centered strategies to target TAMs are currently being explored. The approaches
mostly aim at either inhibiting the recruitment of macrophages and thus dampening
their protumorigenic activities, or re-educate TAMs and activate them towards an
inflammatory phenotype that can trigger cytotoxic responses towards cancer cells
or activate T cells. A few of the various strategies employed are listed below:
Inhibiting the CSF-1/CSF-1R axis: CSF-1 is one of the most crucial
molecules for myeloid cell differentiation. The ligand is overexpressed by
many cancer cells, as a means to recruit and differentiate TAMs (56, 108)
and their expression correlates with poor prognosis (109, 110). A number
of small molecule inhibitors or antibody antagonists have been tested in
multiple preclinical models (111-114). For instance, emactuzumab
(RG7155), a humanized monoclonal antibody against CSF-1R decreased
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TAM densities and increased CD8+ T cells in the tumor (114). It showed
similar results in patients with several solid tumors enrolled in a phase I
clinical trial, as part of the same study. Another similar inhibitor, Pexidartinib
(PLX3397) induced regression in patients with tenosynovial giant cell
tumors (115), but did not increase 6-month progression free survival in a
phase II clinical trial with patients diagnosed with recurrent glioblastoma
(116). In addition to this, few other CSF-1R inhibitors, namely, BZL945,
GW2580 have shown positive results in mouse preclinical models, either
alone or when used in combination with gemcitabine or paclitaxel based
chemotherapy or other inhibitors (111, 117-119).
Re-educating TAMs towards an activated phenotype: Many of the
studies aimed at depleting monocyte/macrophage recruitment into the
tumor bed resulted in failure and eventual disease relapse. This is primarily
because macrophages are crucial for eliciting antitumor adaptive
responses. One of the most important strategies currently being explored is
to re-educate the immunosuppressed TAMs and activate them towards an
inflammatory M1 phenotype and prime them for triggering cytotoxicity or
recruiting and activating cytotoxic T cells. IFN-γ has been tested in
advanced ovarian cancer patients for its ability to induce macrophage driven
cytotoxicity (120, 121). One of the most important molecules in this regard
is CD40 agonist. This when administered, resulted in a shift towards M1
type macrophages, upregulated their antigen presentation ability and
activated T cell responses (122). Based on these findings, a fully humanized
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CD40 agonist, CP-870,893, was tested in a phase I trial in combination with
chemotherapy to treat advanced stage pancreatic cancer patients. The
combination therapy showed partial responses in 4 out of 22 patients and
correlated with improved survival (123). Another strategy that is currently
under clinical evaluation is ibrutinib, in combination with gemcitabine-nabpaclitaxel in advanced stage pancreatic cancer patients. This drug prevents
the crosstalk between M2-like TAMs and B cells via the PI3Kγ-BTK pathway
and re-polarized TAMs towards M1 type and triggered T cell responses
(124).
Blocking recruitment of monocytes/macrophages: Cancer cells secrete
a wide variety of cytokines to attract and recruit circulating monocyte and
polarize them towards TAMs. Hence, many strategies have attempted to
block

the

recruitment

of

monocytes/macrophages

to

the

tumor

microenvironment. Among these, treatment with anti-CCL2 antibodies in
combination with chemotherapy, reduced tumor growth and metastasis in
several tumor models (125-128). CCL2 antibodies have also been tested in
several Phase I and Phase II clinical trials (129-131), with variable results.
Another chemokine, CCL5, when targeted with antibodies (Maraviroc), also
associated with clinical response in a small cohort of patients with advanced
stage colorectal cancer (132). Other strategies like, bisphosphonates
(which induce apoptosis in bone macrophages, osteoclasts and tissue
macrophages) and trabectedin (which deplete MDSCs and also TAM
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population to some extent) have also yielded positive responses in bone
metastatic cancers, like breast and prostate cancers (133, 134)
Different strategies to target TAMs and the different clinical trials that are
either completed or ongoing, have been discussed in more details elsewhere (65).
Several studies over the past few years have attempted at investigating the
biomarker potential of TAMs in several cancers. In most cases, either CD68, a pan
macrophage marker or CD163 (a M2 type marker), CD204 (macrophage
scavenger receptor A) or CD206 (induced by IL-4) have been used to identify
tumor infiltrating macrophages. A high degree of TAM infiltration correlated with
tumor grade, more advanced stage of the disease and poor clinical outcome in
most of the cancers studied, including breast, bladder and pancreatic cancers. In
stark contrast, a negative correlation between TAM infiltration and disease stage
was observed in gastric cancers (135). Further, in some cancers, like non-smallcell-lung-cancer and colorectal cancer, a high degree of TAM infiltration correlated
with

a

favorable

patient

prognosis

(136,

137).

Interestingly,

chemotherapy/radiotherapy can significantly alter the TAM phenotype, as a result
affect the overall clinical outcome and the potential of TAMs as a predictive
biomarker. In many preclinical models using either chemotherapy or radiotherapy,
M2-like macrophages localized in the perivascular regions of the tumor and
promoted disease relapse post therapy. This can be attributed to extensive tissue
damage due to therapy which results in the recruitment of myeloid cells and
triggering of repair mechanisms by immunosuppressive macrophages (111, 138).
For instance, in patients with Hodgkin’s Lymphoma and follicular lymphoma who
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underwent chemotherapy, a high degree of CD68 + TAMs correlated with
decreased survival compared to patients who did not receive chemotherapy (139,
140). However, in follicular lymphoma patients undergoing R-CHOP regimen,
increased CD163+ TAM infiltration was associated with favorable outcome (141).
This indicated that TAM function largely depends on the type of treatment used
and they can either hamper or bolster anti-tumor immune response. Similarly, in
case of radiotherapy, it augments macrophage infiltration into irradiated tissues.
TAMs then either promote tissue repair mechanisms and thereby contribute to
disease recurrence by adopting an immunosuppressive phenotype or activate antitumor immune response in the host and decreasing metastatic burden (103, 142,
143). For example, post radiotherapy, there is an increased expression of CSF-1
and hence increased macrophage infiltration in a preclinical xenograft mouse
model of human intracranial glioblastoma. However, combination therapy with
radiation and Pexidartinib (CSF-1R antagonist) potentiated the therapeutic
benefits of radiotherapy. One of the clever ploys deployed by cancer cells is to
overexpress ‘don’t eat me’ signals like CD47, to avoid phagocytosis by
macrophages or other antigen presenting cells. As expected, antibody targeting
CD47 resulted in antibody dependent cellular phagocytosis (ADCP) and yielded
beneficial results in several preclinical mouse studies and have entered clinical
trials. Moreover, targeting CD47 which is expressed by cancer stem cells at large,
enabled the phagocytosis and removal of the latter by macrophages. Further,
targeting CD47 in combination with chemotherapy showed beneficial results in
patient derived xenograft models (144). Also, blocking CD47 in combination with
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PDL1 blockade resulted in enhanced antitumor responses (145). However, tumor
cell phagocytosis is a contentious topic. Increased phagocytosis of tumor cells by
macrophages although beneficial at first, however, it skews the TAMs more
towards protumorigenic type. The latter associates with recurrence and metastasis
by creating an immunosuppressive microenvironment (104). Further, conventional
anti-angiogenic therapies mostly fail because of increased infiltration of myeloid
cells. Hypoxia resulting from vasculature destruction by anti-angiogenic drugs
induces enhanced infiltration of macrophages that can then trigger angiogenic
responses. Moreover, macrophages often overexpress immune checkpoint
inhibitor molecules, like PDL-1, PDL-2, ligands for CTLA-4 among others. These
are often further upregulated on macrophages in response to hypoxia (146).
Antibody mediated targeting of CTLA-4 resulted in the removal of Tregs by the
FcγR+ macrophages (147, 148). Therefore, synergistically targeting TAMs with
anti-checkpoint inhibitor antibodies may be clinically beneficial and are currently
undergoing early clinical assessment. Overall, these suggest that even though
macrophage centered therapeutic strategies are currently being explored, they will
probably yield best results when used in combination with other standard of care
therapies or to complement other immunotherapies.
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Fig. 2.1. Origin of tumor associated macrophages. Blood monocytes and
monocyte derived suppressor cells (MDSCs) get recruited to the tumor tissue in
response to a wide array of chemokines and cytokines released from the tumor.
Once they infiltrate the tumor tissue, the monocytes and MDSCs differentiate to
TAMs following exposure to tumor microenvironment derived factors. In some
cancers, tissue resident macrophages can proliferate in situ and give rise to TAMs.
This figure has been adapted from Mantovani et al. “Tumour-associated
macrophages as treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi:
10.1038/nrclinonc.2016.217. with permission.
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Fig. 2.2. TAMs promote immune suppression in the tumor
microenvironment. TAMs engage in cross-talk with other immune cell types in
the microenvironment to suppress anti-tumor immune response. TAMs secrete
immunosuppressive cytokines like IL-10, TGF-β which promote Treg cell formation
and inhibit dendritic cell maturation. Metabolic reprogramming of TAMs result in
metabolic starvation of T cells and inhibit their activation and effector functions.
They also upregulate checkpoint inhibitor molecules like PDL-2 to further inhibit T
cell activation. This figure has been adapted from Mantovani et al. “Tumourassociated macrophages as treatment targets in oncology.” Nat Rev Clin Oncol.
2017. doi: 10.1038/nrclinonc.2016.217. with permission.
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Fig. 2.3. TAMs promote tumor cell intravasation. TAMs engage in a bidirectional cross-talk with tumor cells and promote tumor cell invasion. TAMs
produce TGF-β that induce EMT in cancer cells and facilitate their migration and
matrix remodeling and adhesion to matrix proteins. CSF-1 from tumor cells and
EGF from cancer cells potentially results in their ‘lock-step’ conformation and the
two cell types migrate together along the collagen fibers towards blood vessels.
The cancer cells then pile up on the blood vessels and the macrophages help them
intravasate through a structure known as ““Tumor Microenvironment of
Metastasis” (TMEN). This figure has been adapted from Noy et al. “TumorAssociated Macrophages: From Mechanisms to Therapy.” Immunity. 2014.
doi.org/10.1016/j.immuni.2014.09.021. with permission.
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Fig. 2.4. TAMs promote tumor metastasis. Once the tumor cells are arrested in
the blood vessels of target seeding organs, macrophages facilitate their
extravasation into the tissue by increasing the vascular permeability. Also, TAMs
promote survival of the tumor cells in the new metastatic site and suppress immune
cell activation. This figure has been adapted from Noy et al. “Tumor-Associated
Macrophages:
From
Mechanisms
to
Therapy.”
Immunity.
2014.
doi.org/10.1016/j.immuni.2014.09.021. with permission.
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Fig. 2.5. Brief summary of different clinical trials to target TAMs. This figure
has been adapted from Mantovani et al. “Tumour-associated macrophages as
treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi:
10.1038/nrclinonc.2016.217. with permission.
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Fig. 2.6. TAMs are double-edged swords in cancer therapies. TAMs can either
increase or dampen the therapeutic efficacy for anti-cancer treatments. Some
conventional therapies (like doxorubicin, gemcitabine) can either promote the
formation of antigen presenting cells or skew TAMs towards inflammatory M1 type.
On the other hand, cytotoxic therapies or radiation therapies cause cell death and
tissue damage which recruit fresh myeloid cells. The latter trigger a misdirected
tissue repair response, re-vascularization, protection of cancer stem cell niche and
suppression of adaptive immune response. This figure has been adapted from
Mantovani et al. “Tumour-associated macrophages as treatment targets in
oncology.” Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2016.217. with
permission.
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Fig. 2.7. TAMs after chemotherapy as predictor for patient outcome. TAMs
can either foster or dampen therapeutic efficacy of anti-cancer treatments and
hence can act as predictor for clinical outcome following therapy. This figure has
been adapted from Mantovani et al. “Tumour-associated macrophages as
treatment targets in oncology.” Nat Rev Clin Oncol. 2017. doi:
10.1038/nrclinonc.2016.217. with permission.
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Fig. 2.8. Different approaches to target TAMs. Various approaches are being
tried to either promote the cytotoxicity of TAMs by re-programing them to M1-type,
activation of adaptive responses or inhibit their recruitment, survival or
immunosuppression caused by them. This figure has been adapted from
Mantovani et al. “Tumour-associated macrophages as treatment targets in
oncology.” Nat Rev Clin Oncol. 2017. doi: 10.1038/nrclinonc.2016.217. with
permission.
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2.2. A brief overview of Pancreatic Cancer
2.2.1. Epidemiology
Pancreatic Cancer is one of the most lethal type of cancers and accounts
for 3% of all cancers and 7% of all cancer related deaths in the United States. The
American Cancer Society predicts 53,670 people will be diagnosed with pancreatic
cancer in 2017. The mortality rate due to the disease is estimated at 43,090 in the
United States alone in 2017 (2017 Cancer Facts and Figures of American Cancer
Society). It is the 3rd leading cause of cancer related deaths in the US. By 2020, it
is estimated to become the 2nd leading cause of cancer related deaths in the US,
surpassing

colorectal

cancer.

Early

stages

of

Pancreatic

Cancer

are

asymptomatic, however, for patients diagnosed with symptoms, the disease has
already metastasized where less than 15% cases are suitable for surgical
resection (149). Hence, chemotherapy presents the standard and only line of care
for most of the patients, but gemcitabine provides only modest regression of the
cancer.

Almost

all

the

patients

undergoing

therapy

rapidly

develop

chemoresistance. Pancreatic cancer is one of the few cancers for which the 5year survival rate has not improved significantly in the last 40years with 74% of
patients dying within the first year of diagnosis and only 9% of the patients surviving
more than 5 years. Despite extensive research, we are still desperately searching
for the ‘magic bullet’ that can cure pancreatic cancer. There are several risk factors
that have been associated with the disease. For example, obesity and inactivity,
use of tobacco, exposure to certain chemicals, Type 2 diabetes, chronic
pancreatitis, Cirrhosis of the liver, diets rich in fat have all been causally associated
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with pancreatic cancer. In addition, genetic alterations or familial predisposition
can also cause pancreatic cancer. For example, hereditary breast and ovarian
cancer syndrome caused by BRCA1/2 gene mutation, familial atypical multiple
mole melanoma (FAMMM) syndrome caused by mutations in the p16/CDKN2A
gene, hereditary non-polyposis colorectal cancer (HNPCC) caused by a defect in
MLH1 or MSH2 gene, familial pancreatitis caused by mutations in PRSS1 gene,
Peutz-Jeghers syndrome, caused by defects in the STK11 gene, Von HippelLindau syndrome, caused by mutations in the VHL gene can all increase the risk
of exocrine pancreatic cancer. (Detailed information regarding the causes, risk
factors and prevention of pancreatic cancer is available in the official webpage of
American Cancer Society). Pancreatic cancer stage and grade is measured using
the standard TNM system, where T stands for the primary tumor size, N means
whether the cancer has spread to nearby lymph nodes and finally M, indicating if
the disease has metastasized to distant organs (more detailed information about
the

TNM

grading

can

be

found

on

the

webpage

https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosisstaging/staging.html).
2.2.2. Pathology
The pancreas is a unique organ comprising of both exocrine and endocrine
glands. The exocrine gland secretes digestive enzymes like chymotrypsinogen,
trypsinogen amylase and pancreatic lipase. The endocrine gland, more commonly
known as the Islets of Langerhans, produce 3 types of hormones into the blood
stream, namely, glucagon, insulin and somatostatin. Pancreatic cancer can

70

broadly be of two main types, exocrine neoplasia and endocrine neoplasia, as
described below in details:
Exocrine cancer is most common type of pancreatic malignancy. About 95%
of pancreatic tumors are adenocarcinomas (pancreatic ductal adenocarcinoma,
PDAC). PDAC appears as a white yellow mass with the surrounding normal
pancreatic tissue showing signs of atrophy, fibrosis and dilated ducts (150). The
neoplasms can either present as well differentiated glands (carcinoma) or poorly
differentiated sarcomatoid carcinomas (151). PDAC evolves from either of three
types of pre-neoplastic lesions, namely, microscopic pancreatic intraepithelial
neoplasia (PanIN), macroscopic cysts, namely, the intraductal papillary mucinous
neoplasm (IPMN) and mucinous cystic neoplasm.
The most well characterized and by far the most common precursor lesions
for PDAC development are PanINs. Based on their cytological and architectural
irregularities, PanINs were categorized as: PanIN-1A (flat lesion) and PanIN-1B
(micropapillary type) that show low-grade dysplasia; PanIN-2 lesions that develop
features like, additional loss of cell polarity, nuclear crowding, cell enlargement,
and hyperchromasia with frequent papillary formation; PanIN-3 is the most
advanced lesions clinically and exhibit severe nuclear atypia, luminal necrosis, and
epithelial cell budding into the ductal lumen (152-154). However, recently, this
three-tier classification has been replaced by a revised two-tier low grade (PanIN1 and PanIN-2) and high grade (PaniN-3) classification system. As per this system,
the high-grade lesions have the most potential to generate PDAC (155). Indeed,
low grade lesions are common in adult normal pancreas or patients suffering from
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chronic pancreatitis. But PanIN-3 lesions are exclusively detected in invasive
PDAC (154).
IPMNs are less ordinary form of precursor lesion for PDAC. They arise in
the main pancreatic duct or its major branches and are characterized by papillary
like elongation of ductal epithelium and production of mucin (151, 152). Although
they present better prognosis, there have been multiple incidences where IPMNs
advanced to malignancy. Previously they were classified as villous dark cell type,
papillary clear cell type, and compact cell type, in combination of mucin expression
profiles. Later, based on morphology and mucin expression profiles, they were reclassified into gastric type (=papillary clear cell type), intestinal type (=villous dark
cel type), pancreatobiliary type, and oncocytic type (=compact cell type,
=intraductal oncocytic papillary neoplasm (IOPN) (156, 157). Benign, borderline,
and malignant lesions are detected in gastric and intestinal types, however,
progression of IPMNs into carcinoma usually occurs from the intestinal type (158).
The pancreatobiliary type and oncocytic type are mostly malignant lesions (156,
157). Mucinous cystic neoplasms (MCNs) are rare and slow growing preneoplastic lesions. They are found only in women, and are characterized by the
development of epithelial cysts that are lined by mucin producing cuboidal or
columnar cells and remain surrounded by ovarian stroma. Given their larger size,
MCNs are easily distinguished from PanINs. Further, they can be categorized as
either adenoma, borderline or malignant non-invasive or invasive neoplasia (152).
Several other pancreatic cancers, relatively less common, of exocrine origin are
known, for example, adenosquamous carcinomas, squamous cell carcinomas,
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signet ring cell carcinomas, undifferentiated carcinomas, and undifferentiated
carcinomas

with

giant

cells

(https://www.cancer.org/cancer/pancreatic-

cancer/about/what-is-pancreatic-cancer.html).
Acinar cell carcinoma is a rare exocrine pancreatic neoplasia and accounts
for less than 2% of exocrine pancreatic cancers. The malignant cells produce
elevated levels of pancreatic enzymes like lipases and appear granular under the
microscope. This is because they contain excess amount of zymogen in their
cytosol. In ACC, the malignant cells can be arranged in two fashions: acinar, where
the cells form a thin lumen with basal nuclei and moderate amount of eosinophilic
cytosol in the apical portion of the cells, or solid, where the cells are arranged as
sheets or nests with no apparent lumen. Basally palisaded nuclei can be detected
at the interface of solid nests of malignant cells and stroma (152). Adenosquamous
carcinoma, another rare variety, forms glands as adenocarcinoma but cells
undergo squamous differentiation with disease progression. Colloid carcinoma is
another form of exocrine pancreatic cancer where nests of cancer cells appear to
be floating in extracellular mucin. This form of the disease is comparatively less
aggressive. Hepatoid carcinoma is a very rare disease where the cancer cells
appear like liver cells. Mucinous cystic neoplasm is more commonly found in
women, where malignant cysts containing mucin forms at the tail of the pancreas
and can become invasive over time. Pancreatoblastomas, more commonly known
as pancreatic cancer of infancy, is found in children. The cancer cells look like
nests of squamoid cells floating in a pool of more uniform looking cells, but can
undergo acinar and neuroendocrine differentiation. Serous Cystadenomas is a
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benign cystic tumor that can be surgically removed. Signet Ring cell carcinoma,
another rare variety of pancreatic cancer, is characterized by the presence of large
mucin globule in the cells that pushes the nucleus to the side of the cell, giving it a
signet ring like appearance. Solid-Pseudopapillary Neoplasms are found in women
in their 30’s. Some parts of the tumors can be solid or produce finger like
projections. Although less harmless, it can metastasize if not removed.
Undifferentiated carcinomas are extremely aggressive in nature and the malignant
cells do not resemble any cell type in the body. Undifferentiated Carcinoma with
Osteoclast-like Giant Cells is another extremely rare type of exocrine pancreatic
cancer where the individual malignant cells become gigantic and resemble
osteoclasts in the bone (http://pathology.jhu.edu/pc/BasicTypes2.php?area=ba).
Pancreatic endocrine tumor (PNET) is more commonly known as Islet cell
tumor. 1 in every 100,000 people is diagnosed with this rare type of disease and
accounts for less than 2% of all pancreatic tumors (159). It is less aggressive than
pancreatic exocrine tumors and grows more slowly. Although the exact molecular
mechanism of PNET is not clearly determined, people with four types of inherited
disorders, namely, Multiple Endocrine Neoplasia Type I (caused by a mutation in
MEN1 gene on chromosome 11q13), von Hippel-Lindau disease (arises due to
mutation in VHL gene on chromosome 3), von Recklinhausen’s disease (caused
by NF1 gene on chromosome 17) and tuberous sclerosis complex (caused by
mutation in TSC1 and TSC2 genes on chromosome 8) have been reported to have
higher incidence of PNET. Intriguingly, PNET encompasses a broad range of
neoplasms of the pancreatic endocrine cells and can either be insulinomas (insulin
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secreting tumors), gastrinomas (gastrin secreting tumor), glucagonomas
(glucagon secreting tumors), VIPomas (vasoactive intestinal polypeptide secreting
tumor), somatostatinomas (somatostatinoma secreting tumor) and GRFomas
(growth hormone releasing factor, GRF secreting tumor). PNET can also be nonfunctional, meaning these tumors do not produce any hormone and therefore hard
to detect at early stages of development and are only diagnosed when the disease
has advanced into late stages (https://www.pancan.org/facing-pancreaticcancer/learn/types-of-pancreatic-cancer/endocrine-pancreatic-neuroendocrinetumors/).
2.2.3. Role of the Tumor Micro-environment in PDAC: current therapies and
challenges
A key distinguishing feature of PDAC is the strong desmoplastic stroma that
constitutes the bulk of the tumor. The robust desmoplastic reaction comprises of
cancer associated fibroblasts, pericytes, endothelial cells, various immune cell
infiltrates, pancreatic stellate cells and several cytokines and growth factors that
remain in a complex extra cellular matrix (ECM) and contribute to disease
pathogenesis and clinical outcome. The complex stroma in PDAC can be
separated into the following compartments: the tumor cells, the hematopoietic
compartment, the mesenchymal compartment and the ECM. The pancreatic tumor
cells secrete cytokines and chemokines to recruit the immune cells and arrest them
in a dysfunctional stage. For example, the tumor cells secrete G-MCSF to induce
the generation of MDSCs. They also express inhibitory ligands like PDL-1, TGF-β,
IL-10 and IDO that can directly suppress the activity of CD8 T cells. The stroma
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acts as a physical barrier and restricts successful delivery of therapeutic drugs. For
example, in the PDAC TME, there is extensive secretion from tumor cells and
deposition of the glycosaminoglycan hyaluronan or hyaluronic acid (HA) (160). HA
is negatively charged and therefore can imbibe large amount of water, expand and
exert stress on the collagen fibers. The latter contract under the tensile stress,
increase the interstitial fluid pressure (IFP) which ultimately results in vascular
collapse and hence the hypoperfusion (161) and limited access of drugs to the
tumor interior. Indeed, treatment with pegylated hyalurinidase (PEGPH20)
degraded HA, decreased IFP and improved drug delivery by increasing
intratumoral vessel patency (161, 162). Administration of PEGPH20 in combination
with gemcitabine decreased the metastatic burden and increased the objective
response rate (161). A recent phase III clinical trial in combination with gemcitabine
improved survival in metastatic PDAC patients (163). Other potential targets
include cancer associated collagen, decorin, fibronectin, versican, and connective
tissue growth factor (CTGF), all of which have been reported to correlate with
PDAC progression (164). A monoclonal antibody against CTGF in combination
with gemcitabine is currently used in clinical investigation in PDAC patients
(NCT01181245). The pancreatic stellate cells (PSC) also play a significant role in
stromal resistance in PDAC. Pancreatic tumor cells stimulate the PSCs become
activated to myofibroblasts and secrete ECM components and promote
fibrogenesis (165). Olive et al. showed that inhibition of Sonic Hedgehog pathway
(Shh) can deplete the stroma and improve drug delivery by increasing vascularity
(166). However, it was accompanied with rapid development of therapy resistance
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and more aggressive disease features. Additionally, a phase I and phase II clinical
trial launched by Infinity Pharmaceuticals was stopped owing to poor clinical
performance of the drug.
Intriguingly, the significance of the hematopoietic compartment in PDAC
can be understood from the fact that they constitute 50% of the total cells in the
PDAC tissue. As in the case of most tumors, in PDAC, the infiltrating macrophages
(TAMs), MDSCs, and T cells engage in complex paracrine signaling that eventually
results in suppression of T cell response and generation of Tregs and MDSCs. In
human PDAC, the frequency of MDSCs in circulation correlates with the stage of
the disease (167). Frequency of Granulocyte MDSC (Gr-MDSC) correlates with
more advanced stage of the disease (168). Depletion of MDSC in autochthonous
PDAC model resulted in activation and infiltration of T cells (169). However,
depletion of Gr-MDSC increased the population of monocytic MDSC (Mo-MDSC).
Additionally, a recent phase I study aimed at depleting Gr-MDSCs did not work in
patients (170). This creates an immune privileged TME that aids and abets the
tumor progression. Tregs comprise another significant factor for therapy failure.
They accumulate as early as in pre-invasive lesions, thereby dampening T cell
response from the earliest stages of disease progression (169) and abundantly
present in the blood, lymph nodes and primary lesion in PDAC patients (171, 172)
and correlated with poor survival (173). Currently, several strategies are being
tested to target Tregs (174). For example, two approved antibodies against the
immune checkpoint inhibitor CTLA-4, namely Ipilimumab and Tremelimumab are
currently being tested in several clinical trials in PDAC. Although Ipilimumab failed
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to show significant benefit in a phase II clinical trial of locally advanced or
metastatic disease, it has shown promise when used in combination with GVAX,
a G-MCSF gene transfected vaccine aimed at activating immune cell response
(175). Currently several other clinical trials are ongoing where patients are being
treated with a combination of Ipilimumab and GVAX or Ipilimumab and
gemcitabinehydrochloride
(https://clinicaltrials.gov/ct2/show/study/NCT01896869,https://clinicaltrials.gov/ct2
/show/NCT01473940). Another potential immunotherapeutic method is genetically
modifying autologous T cells and adoptively transfer them back to the patients to
equip them to mount immune response against the tumor associated antigens
(TAA). This is achieved by using modified T cell receptor (TCR) or chimeric antigen
receptors (CAR). Several CAR based preclinical studies performed in mice yielded
promising results with tumor regression and increased disease free survival (176178).
Among the myeloid cells, dendritic cells (DC) are the most potent antigen
presenting cells (APC) that can potentially present antigen to activate adaptive T
cell response (koski 2008 immunol rev). However, like most cancers, in pancreatic
cancer DC function is compromised by secretion of factors that interfere with DC
recruitment, activation and survival (179). In pancreatic cancer, DCs are mainly
located at the tumor edge and their recruitment to the microenvironment
compromised. Fewer DC in circulation correlated with poor outcome in PDAC and
increased number of circulator DCs correlated with better survival in both
resectable and non-resectable tumor (180-182). Therefore, strategies to activate
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DC can in turn result in alerting the adaptive immune response against the tumor
cells. In PDAC patients treated with gemcitabine or cisplatin, DC functions were
restored and showed synergistic effect with chemotherapeutic drugs (183, 184).
TAMs are the major constituent of pancreatic tumor stroma. Macrophages
can secrete inflammatory cytokines and molecules to promote acinar-ductal
metaplasia, a dedifferentiated state that can potentially become malignant (185).
Not only are macrophages abundantly present in the preinvasive lesions (169), but
they also are a rich source of cytokines, chemokines, proteases, angiogenic
molecules and growth factors that can remodel the ECM, induce EMT in cancer
cells and facilitate metastasis as well as suppress anti-tumor T cell responses. Like
most solid tumors, CD163+ or CD204+ macrophages are associated with shorter
survival in PDAC, whereas increased infiltration of M1-type macrophages is a
predictor of longer survival in patients (173). Distinct aspects of TAM in PDAC are
discussed in detail in the following sections.
2.2.4. Role of macrophages in the progression of Pancreatic Cancer
As mentioned earlier, the hallmark of Pancreatic Cancer is its rich
desmoplastic microenvironment, which is some cases can account for up to 80%
of the tumor mass. The stroma comprises tumor infiltrating immune cells including
macrophages, Tregs, endothelial cells, myofibroblasts and extracellular matrix
components (186). Infiltrating immune cells are one of the major concerns for
development of therapy resistance in Pancreatic Cancer. Macrophages are the
most abundantly found immune cell type in the pancreatic cancer TME and

79

contribute to various aspects of pancreatic cancer progression, therapy resistance
and disease relapse, as described below in details:
Macrophages and prognosis in pancreatic cancer: It is now well established
that TAMs promote tumor progression by inducing tumor associated angiogenesis,
facilitating EMT and invasion, increasing the stemness of cancer stem cells and
suppressing the anti-tumor immune response. CD163+ TAMs were detected in
primary lesions of pancreatic cancer, compared to adjacent normal tissues and
chronic pancreatitis and positively correlated with tumors in the tail and body of the
pancreas (187). Further, elevated TAM infiltration could be causally associated
with lymph node metastasis, neural invasion of the tumor, therapy resistance and
poor survival in pancreatic cancer (188, 189). However, it is important to note that
macrophage phenotype can be stage dependent and evolves with advancement
of the disease. For example, in the initial stages of PDAC, macrophages are more
M1-type but get skewed more towards M2-like TAMs with progression of cancer
(96).
Factors important for the recruitment and polarization of macrophages in
pancreatic cancer: Tumor cell derived chemokines, cytokines and other growth
factors recruit circulating monocytes and polarize them towards pro-tumoral TAMs
as the monocytes infiltrate the TME. One of the most potent chemokines in this
regard is C-C chemokine ligand 2 (CCL2) that acts via its receptor CCR2 (68, 107).
Several cytokines, like macrophage colony stimulating factor (M-CSF) and
endothelial monocyte-activating polypeptide II (EMAPII) have been shown to
recruit monocytes to tumor site. However, M-CSF is not frequently expressed by
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pancreatic cancer cells (190). The latter on the other hand, express significantly
higher level of granulocyte macrophage (GM-CSF) that can potentially generate
MDSCs (191). Additionally, pancreatic cancer cell derived GM-CSF is sufficient for
the development of CD11b+ TAMs and suppression of immune response against
the tumor (191). Once inside the TME, tumor cell and other stromal cell derived
factors hijack the monocytes and re-educate them towards TAM phenotype. In
Pancreatic cancer, several factors have been identified in this context. For
example, Heparanase, which cleaves heparan sulfate glycosaminoglycans, can
potentially augment STAT3 signaling in TAMs and contribute to their protumorigenic activity (192).
Role of macrophages in various aspects of pancreatic cancer pathogenesis:
As in other types of cancers, TAMs in pancreatic cancer have been causally
associated with various aspects of the disease, such as angiogenic and hypoxic
responses, silencing of the adaptive immune response against cancer cells, EMT
and cancer invasion, stem cell survival and metastasis. TAMs are known to induce
angiogenesis by releasing well characterized panel of pro-angiogenic molecules,
such as, VEGFA, TNF-α, basic fibroblast growth factor (bFGF) and thymidine
phosphorylase (TP). Inside the TME, TAMs are known as the most potent source
of VEGFA. They also secrete other molecules and enzymes, like, MMP-2, MMP7, MMP-9, MMP-12, COX-2, CCL2, CXCL12, CXCL8, CXCL13 and CCL5, all of
which can act as angiogenesis modulators. However, pancreatic cancer is
strikingly less dependent on angiogenesis, showing substantially lesser number of
microvessels compared to normal pancreas and hence is hypovascular (193). In
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contrast, there are reports which have correlated the expression of VEGFA with
high vessel density in pancreatic cancer, increased risk for metastasis and poor
disease outcome. Further, TAMs can express TIE-2 and localize in the hypoxic
region of the tumor in response to Angiopoietin-2 (Ang-2) secreted from the
hypoxic vascular cells and contribute to angiogenic switch (194). M-CSF secreted
into the TME can also upregulate the expression of TIE-2 on TAMs (195). TAMs
have been shown to promote the self-renewal and tumorigenic and metastatic
propensity of CSCs in various cancers (196). In PDAC, pharmacologically
targeting CSF-1R or CCR2 and thereby inhibiting TAM recruitment significantly
reduced the number of pancreatic cells expressing the CSC marker ALDH (197).
EMT is a hallmark feature of cancer cells prior to metastasis. Pancreatic
cancer cell lines like, Panc-1 and BXPC3 when cultured in the presence of TAMs,
upregulate mesenchymal markers and suppress the expression of E-Cadherin.
Cytokines like IL-10, macrophage migration inhibitory factor (MIF) and CCL-18
have been reported to contribute to EMT (198). It is thus likely that these molecules
secreted from TAMs act in concert to promote EMT in pancreatic cancer. It is wellknown that TAMs secrete molecules and enzymes to remodel the matrix for cancer
cell invasion and migration. In PDAC, TAMs produce macrophage inhibitory
protein-3 alpha (MIP-3α) that can regulate cancer cell invasion through the
production of MMP-9. Another important function of TAMs is facilitating
lymphangiogenesis, a crucial factor for metastasis. Studies have shown strong
correlation

between

infiltration
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and
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lymphangiogenesis (199) and poor prognosis resulting from lymph node
metastasis.
One of the main challenges for treating PDAC is the desmoplastic reaction
associated with it. PDAC stroma is essentially immunosuppressive in nature.
TAMs, which are abundantly present in the PDAC TME, constitute one of the key
factors responsible for suppression of adaptive immune response against the
cancer cells. As mentioned earlier, TAMs successfully suppress immune activation
in the TME by inducing the formation of Tregs and secreting immunosuppressive
cytokines like, IL-10, TGF-β which potentially blunt the activation and function of
helper and cytotoxic T cells and arresting them in an immature stage. TAMs can
also secrete factors like IL-4, IL-13, IL-1β and G-MSCF which can potentially
generate MDSCs and further cause immunosuppression (200). Of note, TAMs,
Tregs, MDSCs all express several immune checkpoint inhibitor molecules like
PDL-1, CTLA-4 etc. It is thus likely that all these immunosuppressive immune cells
work synergistically in PDAC TME and contribute to disease progression and
therapy resistance.
2.2.5. Probable Strategies for Targeting TAMs in Pancreatic Cancer
TAMs are indispensable for cancer progression. Hence, extensive research
is currently ongoing to develop potential therapies and target intratumoral TAMs.
In the TME, the life span of a macrophage can be divided into three stages:
mobilization from bone marrow and recruitment to target tissue, transformation
depending on local cues derived from the microenvironment and pro-tumoral
activities. Therefore, anti-macrophage therapies attempt at targeting either the
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recruitment step, survival of TAMs or re-educating and re-polarizing them towards
anti-tumor type. For example, CCL-2/CCR2 axis is important for the recruitment of
circulating monocytes to tumor site in PDAC and blocking this axis inhibits the
mobilization of bone marrow monocytes and their subsequent recruitment to tumor
site and has shown promising results in several clinical trials in various neoplasms.
PF-04136309, a small molecule inhibitor for CCR2 (developed by Pfizer) depleted
CCR2+ CD14+ monocytes and macrophages from primary pancreatic cancer and
pre-metastastic liver. This also activated anti-tumor immune response and
reduced tumor growth and metastasis in mice (201).
M-CSF and CSF-1R signaling axis is very important for macrophage
functioning. Targeting this axis has yielded promising results in various cancers
(202). Despite the fact that PDAC TME produces more G-MCSF compared to MCSF, several reports have documented the benefit of targeting CSF-1R axis in
reducing CSCs and improving therapeutic response in vivo (197). Also targeting
this axis depletes the CD206+ TAMs and re-polarize the remaining macrophages
towards an activated phenotype (203). Another attractive approach of targeting
TAMs is to re-educate them towards an inflammatory and activated M1-like
phenotype, which will then support the activation of anti-tumor adaptive immune
response. One of the prominent studies in this regard was done by administering
CD40 agonist antibody. CD40 is a cell surface receptor expressed in various APCs
like monocytes, macrophages, DCs. Its ligand CD40L is expressed on activated T
cells. Binding of the ligand with CD40 results in the proliferation and activation of
CD4+ and CD8+ T cells (204). Preclinical studies using CD40 agonist induced
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infiltration of CD40+ macrophages into the tumor and induced elevated levels of
M1-type markers in intratumoral macrophages (MHC class II, CD86) and mounted
robust anti-tumor response (122). Further, CD40 agonists (CP-870, 893) in
combination with gemcitabine significantly increased treatment efficacy in a small
cohort of 22 patients with surgically incurable pancreatic cancer (123). Using
RECIST criteria, 4 patients showed partial response, 11 patients with stable
disease with PET demonstrating 25% reduction in FDG uptake in the primary
tumor. 1 patient with partial response also showed complete regression of 7.6cm
liver mass and 47% regression in second liver metastasis. Also, the level of
inflammatory cytokines increased in the patients.
There are several other reports that have attempted at targeting TAM
survival in the TME using mouse models and have observed moderate to
promising results. However, anti-TAM therapy in pancreatic cancer is still in its
infancy. One important caveat is that most of the therapeutic strategies proposed
in the current section have been validated in mouse tumor models. Also, many
therapies that have shown promising results in other cancers have not yet been
validated in PDAC. Hence, more extensive research is required to successfully
target TAMs in PDAC in the future.
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Fig. 2.9. Anatomy of the pancreas. a: Gross anatomy of the pancreas. b: The
exocrine pancreas. c: A single acinus. d: A pancreatic islet embedded in exocrine
tissue. The pancreas consists of separate functional units for performing two major
functions: secretion of digestive juices and glucose metabolism. The acinar cells
that produce the digestive enzymes form the bulk of the pancreatic tissue and are
organized into grape-like clusters. The ducts produce mucus and bicarbonate to
the enzyme mixture and terminate in main and accessory pancreatic ducts and
empty into the duodenum. The endocrine pancreas secretes hormones into the
bloodstream. The α- and β-cells produce glucagon and insulin, respectively.
Pancreatic polypeptide and somatostatin are produced in the PP and δ-cells and
regulate the secretory properties of other pancreatic cells. This figure has been
adapted from Bardeesy et al. “Pancreatic cancer biology and genetics.” Nat Rev
Cancer 2002. doi:10.1038/nrc949 with permission.

86

87

Fig. 2.10. Progression of PanIN lesions to Pancreatic Ductal
Adenocarcinoma. Pancreatic Cancer progresses sequentially through the
formation of PanIN lesions (low grade to high grade) to invasive carcinoma,
acquiring mutations in stages. The hallmark mutations occur in the genes K-RAS
and the tumor suppressors CDKN2, TP53, SMAD4/DPC4 and BRCA2. The figure
has
been
adapted
from
http://2010.igem.org/Team:ESBSStrasbourg/proteolux/application/cancer.
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Fig. 2.11. Different components of the desmoplasia associated with PDAC.
PDAC TME is comprised of cancer associated fibroblasts, TAMs, T regs, other
immune cells, endothelial cells, and matrix proteins and contribute to the dense
desmoplasia that is the hallmark feature of PDAC. Cancer associated fibroblasts
deposit matrix which creates solid stress and compresses the vasculature for
limited diffusion into the tumor. TAMs, Tregs are mainly responsible for suppression
of the immune responses against the tumor cells. The figure has been adapted
from Carr et al. “Pancreatic cancer microenvironment, to target or not to target?”.
Embo Mol Med 2016. doi: 10.15252/emmm.201505948 with permission.
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Fig. 2.13. Therapeutic agents and strategies to target TAMs at different
stages of pancreatic cancer pathogenesis. The figure has been adapted from
Cui et al. “Targeting tumor-associated macrophages to combat pancreatic
cancer.” Oncotarget 2016. doi: 10.18632/oncotarget.9383 with permission.
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3.1. Efferocytosis: A Brief Overview
Efferocytosis is a strictly orchestrated process where phagocytes, such as
macrophages recognize and engulf apoptotic cells and remove them from the
system in an immunologically silent manner. Programmed cell death, such as
apoptosis is an indispensable process, starting from early developmental stages
and lasting over an organism’s lifetime, for the maintenance of physiological
homeostasis. In adult humans, one million cells undergo apoptosis per second as
part of the regular turnover process (205, 206). However, under normal
homeostatic conditions, we rarely observe any apoptotic cell. This is because the
apoptotic cellular debris is as efficiently removed through the process of
efferocytosis as it is generated, to avoid inappropriately evoking the adaptive
immune responses. If apoptotic cells are not engulfed, they leak out their cellular
contents as secondary necrosis and this result in aberrant immune responses by
exposure to self-antigens and a break in tolerance. Indeed, in absence of
clearance of apoptotic cells, lethal developmental defects, autoimmune disorders
or even cancers can occur. Also, components leaked out as secondary necrosis
can be recognized by IgG autoantibodies which in turn can activate the
inflammatory immune response. All these events thereby underscore the
importance of efferocytosis in maintaining normal human physiology.
In the tissues, the task of recognizing, engulfing and clearing the apoptotic
cells have been endowed upon professional phagocytes, like macrophages as well
as nonprofessional phagocytes, such as epithelial cells or fibroblasts. Tissue
Resident Macrophages are the most well characterized cell population that
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efficiently clear dying cells in different tissues. However, in the absence of
professional phagocytes, nonprofessional phagocytes can fill up the niche. For
example, in the mammary gland or the intestinal epithelium, where macrophages
are scarce, the tissue epithelial cells and fibroblasts play a leading role in clearing
the apoptotic cellular debris. In addition to the alveolar macrophages, bronchial
epithelial cells can also clear the cellular debris resulting from airway epithelial cells
undergoing apoptosis (207).
3.1.1. Stages of efferocytosis
The process of efferocytosis occurs in 4 stages:
1. Release of ‘find me’ signals from dying cells to recruit phagocytes to
the site of cellular corpses: In most of the cases, phagocytes are not
proximal to the site of cell death. Therefore, to recruit phagocytes to the
location of cell death, the dying cells express a variety of ‘find me’ molecules
that act as chemotactic signals for the phagocytes e.g. ATP, Sphingosine1-Phosphate (S1P), Lysophosphatidylcholine (LPC), CX3CL1 and a wide
variety of other molecules. ATP released from dying cells in a caspase
dependent manner via the activation of pannexin-1 channels is recognized
by purinergic receptors, like P2Y2 on phagocytes (208). Fractalkine or
CX3CL1 released from dying cells bind to CX3CR1 expressed on
phagocytes and mediates their migration to site of cell death (209).
2. Phagocyte recognition of apoptotic cells and activation of ‘eat me’
molecules on the dying cells: Once the phagocytes reach the site of cell
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death, the apoptotic cells upregulate various molecules that serve as ‘eat
me’ signals to the former. Also, these molecules help the phagocytes to
distinguish between apoptotic cells from neighboring healthy cells. Among
others, Phosphatidyl Serine (PtdSer) is arguably the most well-known ‘eat
me’ molecule expressed on the surface of apoptotic cells. This is then
recognized by several molecules like, T-cell immunoglobulin mucin receptor
4 (TIM4), brain-specific angiogenesis inhibitor 1 (BAI1), and stabilin-2 as
well as several bridging molecules, like milk fat globule-EGF factor 8 (MFGE8) and Gas6. These then engage integrin αvβ3, αvβ5, or Tryo3-Axl-Mer
(TAM) receptors on the surface of the phagocytes to begin the uptake
process. There are several other molecules like ICAM3, Calreticulin,
Oxidized LDL-like moieties and glycosylated surface proteins that have
been reported to further enhance this process by acting as ‘eat me’
molecules. Of note, healthy cells express several ‘don’t eat me’ molecules
on their surface, like CD47 which is recognized by cognate receptor SIRPα
on phagocyte, that impairs phagocytosis of living cells even in the presence
of externalized PtdSer (210). Indeed, constitutive expression of CD47 is a
clever ploy used by cancer cells to avoid being phagocytosed (17).
Administration of neutralizing antibodies against CD47 has shown
promising results in mouse tumor models (211) and extensive research is
ongoing to develop effective neutralizing antibodies against CD47 to treat
lethal malignancies. CD31 and CD300a are two additional ‘don’t eat me’
molecules, albeit less well characterized in comparison with CD47.
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3. Uptake of the apoptotic corpse: Once the phagocyte captures the dying
cell, the next step in the process of efferocytosis is internalization of the
apoptotic cell by the phagocyte. This process is similar to macropinocytosis
and requires active membrane ruffling. Once the ‘eat me’ molecules engage
the cognate receptors on the phagocyte, there occurs extensive
cytoskeleton rearrangement in the latter to facilitate the uptake process.
This is mediated by the Rho family of small GTPases like RhoA, ROCK,
Rac and Cdc42. RhoA negatively regulates efferocytosis and its depletion
enhances the uptake process (210). Its effect is mainly mediated by
increasing the kinase activity of ROCK, which in turn phosphorylates Myosin
Light Chain and increases the contractility of the cell (212), thereby
inhibiting the formation of pseudopods and phagocytic cup formation.
However, RhoA activation at later stages may aid the digestion process by
enhancing phagosome acidification (213). Different pathways have been
proposed so far, that can regulate the uptake process. All pathways
ultimately lead to the evolutionarily conserved Rac1. GTP-bound active
Rac1 promotes Arp2/3 activation and cytoskeleton rearrangement through
Scar/WAVE pathway for phagocytic cup formation (214, 215).
4. Processing, degradation and clearance of engulfed cell: Once the
apoptotic cell is inside the phagocyte, the latter begins the process termed
as phagosome maturation that eventually leads to degradation of the cargo.
In fact, recent studies indicate the events downstream of uptake, that is
proper digestion and clearance affects the phagocyte’s ability to engulf
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additional targets (216-218). For efficient clearance, phagosomes
containing the cellular corpse undergoes acidification and ultimately fuse
with the lysosomes (219, 220). The process of efferosome (phagosome
containing apoptotic cell debris) maturation and degradation of apoptotic
cells in professional phagocytes proceeds very rapidly, thus making it
technically challenging for researchers to investigate the process. The
maturation of early phagosomes to mature late phagosomes and eventual
fusion with the lysosomes is similar as in classical endocytosis. First,
Dynamin, a GTPase is recruited to the phagocyte-apoptotic cell interface.
This then interacts with Vps34 on the nascent phagosome, and recruits
GDP-bound GTPase Rab5. Rab5 is then activated by GEFs like Gapex-5
(221) which then promotes Vps34 activation and generation of PtdIns(3)P
on the surface of the phagosome. Next, Mon1 and its partner Ccz-1 form a
complex and act as Rab5 effector and recruit Rab7 and its activation
(222)an event that is crucial for phagosome maturation. Indeed, in Mon1
depletion conditions, phagosomes were arrested at Rab5+ stage and failed
to transit to Rab7+ late phagosomes. Next, the HOPS complex gets
activated and the phagosome fuses with the lysosome. Inside the mature
phagolysosomes, the apoptotic cells are then degraded by the acidic
proteases and nucleases.
Recently, another pathway has been proposed that can contribute
significantly to the overall degradation and clearance process. This
pathway, named LC3-associated autophagy (LAP) is at the interface of
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autophagy and phagocytosis. LAP gets activated once a phagocyte
internalizes a cargo using surface receptors, like Toll like receptors 1/2 (TLR
1/2), TLR4, TLR 2/6, FcR, and TIM4 (recognizes PtdSer on apoptotic cells)
and play a vital role in regulating the immune response. Interestingly, it has
been reported that bacterial viability is needed to initiate LAP, however this
is not the case for zymosan bioparticles or efferocytosis of apoptotic cells.
Despite sharing several common molecular players, there are certain
fundamental differences between canonical autophagy and LAP. For
example, the latter recruits LC3 to the phagosomes as early as within 510minutes of phagocytosis whereas in canonical autophagy, LC3
recruitment can take up to several hours. In brief, following engulfment, the
Class III PI3K complex, comprising of Beclin 1, VPS34, UVRAG and
Rubicon are recruited to the phagosome (here LAPosome) containing the
apoptotic debris. The PI(3)P generated by VPS34 is important for the
recruitment of the downstream LAP components (such as, ATG5, ATG12,
ATG16L, and ATG7). PI(3)P and Rubicon stabilize NOX2, the predominant
NADPH oxidase in phagocytes, for the production of ROS at the
phagosome. Both PI(3)P and ROS help recruit LC3 to the LAPosome
surface which then fuses with the lysosome for degradation of the cargo
(223, 224).
3.1.2. What happens to the efferocyte: Efferocytosis a fate-determining event
for macrophages?
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As mentioned earlier, inappropriate inflammation or aberrant activation of
the immune response needs to be kept in check for the maintenance of
physiological homeostasis. Hence, the hallmark feature of efferocytosis is the lack
of immunogenic response. Several clinical conditions have been identified where
defective clearance of dying cells contribute to the pathogenesis. Indeed, defects
in the efferocytosis receptors like, MerTK, CD36 or MFG-E8, give rise to
autoimmunity in mice and humans, especially systemic lupus erythematosus
(SLE) (225).
The effects of efferocytosis can vary depending on the type of the
efferocyte. For example, the rate of digestion of engulfed apoptotic cells is much
slower in DCs than in macrophages (226), thereby allowing the dying cell derived
antigens to associate with the MHC molecules for presentation to the adaptive
immune system. Further, DCs have been reported to exhibit selectivity in their
ability to engulf and digest cellular corpses. CD8a+ and CD103+ DCs that express
the transcription factor Batf3 are much more efferocytic than CD11b+ DCs that are
dependant on the transcription factor IRF4 (227). Also, the more efferocytic DCs
(CD8+ and CD103+) can then migrate to the lymph nodes where they can crosspresent the antigens to the cytotoxic T cells for their cross-priming. Apoptotic cell
derived immunogens can also escape the efferosomes and associate with MHC1
molecules for cross-presentation. Presence of elevated levels of TLR3/7 in the
endosomes can facilitate this process and subsequent activation of CD8+ T cells.
The effect of efferocytosis on non-professional phagocytes like, epithelial cells or
stromal cells is not clearly understood and needs further investigation. In case of
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macrophages, efferocytosis reprograms phagocytes to an anti-inflammatory
phenotype. Following engulfment of apoptotic cells, phagocytes suppress the
production of inflammatory cytokines like, IL-12, TNF-α and IL-1 and upregulate
the production of immunosuppressive cytokines like, TGF-β and IL-10 (225). Both
TGF-β and IL-10 are potent in dampening effector helper T cell response by
stimulating regulatory T cells and T helper 2 cells. Also, in case of any inflammatory
condition, like microbial infection, the infiltrating inflammatory cells (such as
neutrophils) are cleared through efferocytosis by macrophages during the
resolution phase. In macrophages with impaired LAP, phagosome acidification
does not occur resulting in defective degradation of apoptotic debris. These LAP
deficient macrophages produce considerable amounts of inflammatory cytokines
like IL-6 and IL-1β, but not anti-inflammatory cytokines like IL-10. The exact
molecular mechanism that couples the two processes of efferocytosis and immune
suppression is not clearly understood and is under extensive investigation.
However, recent studies have identified several nuclear receptor (NR) family
members for their role in the regulation of inflammatory response during
efferocytosis. For example, depletion of LXR-α/β in macrophages fail to produce
TGF-β and IL-10 but secrete copious amount of IL-1β and IL-12 (228). However,
the molecules that trigger these nuclear receptors or bridge the various stages of
efferocytosis with gene regulation is still not clearly known.
Finally, the efferocytic macrophages must also be removed from to
establish tissue homeostasis. Three possibilities have been proposed: either the
efferocytic macrophages exit the body through mucosa or emigrate to the blood or
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lymph or they undergo programmed cell death and are removed locally by tissue
resident macrophages (225). Contrary to the idea that macrophages lack the
imigratory property to lymphatics in comparison with DCs, it was documented that
following efferocytosis, CD11Bhigh macrophages convert to CD11Blow satiated
phagocytes with enhanced pro-resolving properties and display propensity to
migrate from the site of inflammation to the lymphoid organs (229). This is crucial
for the return of homeostasis in the tissue. However, the satiated macrophages
can also release chemoattractants to recruit new monocytes for continued
clearance of cellular debris.
3.1.3. Efferocytosis in different conditons
The impact of effecrocytosis has been studied under different conditions. A few
are discussed in detail below.
Efferocytosis in microbial clearance: Efferocytosis plays a vital role in microbial
clearance (230). Many of the pathogens that infect cells deploy mechanisms to
hijack the cellular machinery in order to persist inside the host cell. The infected
cell activates the apoptosis pathway to get rid of the pathogen. Cytotoxic T cells
can also extrinsically induce apoptosis in the infected cell by secreting perforins or
granzymes or via the Fas/FasL pathway. The apoptotic cell with its load of
infectious particles is next engulfed by macrophages through efferocytosis. This
can potentially have two possible outcomes: either the pathogen will be destroyed
along with the engulfed dying cell or the pathogen can use the process of
efferocytosis as a “Trojan Horse” mechanism to disperse into and infect new host
cells. For example, during the infection of Leishmaniasis major, infected
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neutrophils undergo apoptosis. These dying neutrophils with their intracellular load
of pathogen are then efferocytosed by macrophages and this is a crucial step for
establishment of the disease. Strikingly, infection of macrophages with
Mycobacterium tuberculosis usually induces necrosis to allow dispersion to new
cells (231). However, it does induce apoptosis in some of the infected
macrophages. These apoptotic macrophages are next efferocytosed by uninfected
macrophages that then destroy the pathogen along with the dying cell corpse using
phagolysosomal fusion machinery (232). What is intriguing, in many cases the
infection with bacterial pathogen circumvents the phagolysosomal fusion and
degradation. This can be attributed to the ability of many pathogens to arrest
phagosome maturation and prevent phagolysosomal fusion. For example,
Mycobacterium tuberculosis have several bioactive lipids on their surface that
interfere with the recruitment of endosome and lysosome and hence phagosome
maturation (233, 234). However, when the apoptotic cell containing the pathogen
is efferocytosed by uninfected macrophages, it results in clearance of the
pathogen. This may be possible because the pathogen, when infected along with
the dying cell, remains in the efferosome and hence may not have access to the
host cell efferocytosis machinery. Also, despite the fact that many of the molecular
components are similar in the processes of classical phagocytosis and
efferocytosis, a different subset of effector molecules are involved in efferosome
maturation than a phagosome (219, 220). For example, canonical Rab5 GEF,
Rabex5 is involved in phagosome maturation but not in efferosome maturation.
Instead, Gapex5 may potentially act as Rab5 GEF during maturation of

103

efferosomes. Hence, it is possible that the pathogen is not equipped with
remodeling or interfering with these family of proteins and hence efferosome
maturation proceeds resulting in the eventual pathogen clearance. Of note,
molecular players associated with autophagy are also known to be involved in
efferocytosis mediated pathogen clearance (223). As mentioned earlier,
efferocytosis of apoptotic cells induce the secretion of anti-inflammatory molecules
and cytokines in macrophages. However, when a macrophage ingests an
apoptotic cell infected with pathogen, two possible conflicting signals are expected:
pathogen associated molecular patterns (PAMPs) that drive inflammatory
signaling pathways, and apoptotic cell that triggers the anti-inflammatory
responses. Currently, the unique signal elicited by a macrophage following
efferocytosis of pathogen-infected cell is still not clearly understood.
Efferocytosis in atherosclerosis: Atherosclerosis is a clinical condition where
plaques form inside arteries due to deposition of fatty materials, like, cholesterol,
fatty substances, cellular waste products, calcium and fibrin. As plaques continue
to accumulate, it narrows the artery wall, gradually slowing down blood flow and
decreasing oxygen availability to cells. Atherosclerosis can result in clinical
conditions like a heart attack, angina, stroke and gangrene. Macrophages play
crucial role in all stages of atherosclerosis (235). They are recruited to clean up
the plaque and their ability of efferocytosis correlates with disease stage and
plaque stability. The conventional M1/M2 phenotype of macrophages depends on
the stage of the lesion in atherosclerosis and is dynamic and complex, and
probably undergoes conversion depending on a variety of factors (236). As the
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fatty materials get deposited on the artery wall, it recruits circulating monocytes
and differentiate them to macrophages. The latter engulf the lipoproteins and store
the lipids in droplets, becoming foam cells in the process. The foam cells secrete
inflammatory cytokines and finally undergo apoptosis. They are then cleared by
efferocytosis by freshly recruited macrophages, which results in resolution of
inflammation in the early lesions and thus reduction in lesion cellularity and size.
However, in the more advanced lesions, the process of apoptosis exceeds
efferocytosis and hence clearance of apoptotic macrophages is impaired. This
results in the accumulation of apoptotic macrophages and subsequent secondary
necrosis. Gradually a necrotic core builds up which leads to further inflammation
and formation of vulnerable plaque and acute thrombosis.
3.1.4. Efferocytosis in cancer: TAMs paving a pro-metastatic niche?
The exact role of phagocytosis of cancer cells by phagocytes is a
contentious topic. As mentioned earlier, cancer cells upregulate the expression of
‘don’t eat me’ signals e.g. CD47 to escape being phagocytosed. Treatment with
neutralizing antibodies against CD47 have shown promising results in various
mouse tumor models and extensive research is currently ongoing to develop anti
CD47 therapies for clinical trials. Recently, Gordon et al. has shown that TAMs
express PD-1, a well-known checkpoint inhibitor for T cell activation and its
expression negatively regulates the ability of the macrophages to phagocytose
cancer cells. Blockade of PD-1-PDL-1 increased the phagocytic ability of TAMs
and resulted in reduced tumor burden and increased survival in mice (237).
However, efferocytosis of dying cancer cells can act as a double-edged sword.
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The non-immunogenic properties of efferocytosis that prevails under normal
homeostasis conditions can be mimicked by malignant cells to create an
environment of immunosuppression in the TME. For example, in their recent
elegant study, Stanford et al. reported an immunosuppressive role of cancer cell
phagocytosis (104). Within the TME, apoptosis of cancer cells is a common
feature, arising because of nutrient limitation and rapid proliferation of malignant
cells. These dying tumor cells are then efficiently phagocytosed and cleared by the
TAMs. Interestingly, using mouse model for postpartum breast cancer (ppBC),
Stanford et al. showed efferocytosis of dying tumor cells increased the production
of Th-2 like cytokines (IL-4, IL-10, IL-13, TGF-β) in TAMs and increased the risk of
metastasis by 10-fold. Additionally, tumor associated tissue repair processes,
expansion

of

regulatory

T

cell

population

(Treg)

and

production

of

immunosuppressive cytokines by phagocytes were all dependent on efferocytosis
induced TGF-β signaling. Further, pharmacologically blocking efferocytosis of
dying cancer cells significantly reduced the risk for metastasis in ppBC. Of note,
evasion of phagocytosis by upregulation of ‘don’t eat me’ signals is a hallmark of
cancer cells and several studies have indicated towards a therapeutically
beneficial effect of enhancing cancer cell clearance by phagocytes. Additionally,
although treatment with cytotoxic therapies in cases provide partial response,
eventually result in relapse of the disease with more aggressive features. These
cases are characterized by an initial activation of the immune cells followed by
their subsequent impairment to mount a robust antitumor immune response.
Stanford et al. showed in their elegant study that this could be attributed to
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efferocytosis

mediated

enhanced

pro-tumorigenic

polarization

of

TAMs.

Administration of cytotoxic therapy resulted in significant death of tumor cells in the
TME. Intriguingly, the TAMs that phagocytosed these dying tumor cells became
more pro-tumoral and showed increased tissue healing, production of Th-2 like
immunosuppressive cytokines and more Treg induction in the TME, as well
significantly increased risk for distant metastasis. Indeed, treatment with a
combination of chemotherapy and efferocytosis blocker not only reduced the risk
for therapy-enhanced metastasis but also limited the number of TAMs and
immunosuppression in the TME. This study raised the attractive possibility that
inducing cell death using chemotherapeutic agents as well as inhibiting their
clearance by phagocytes can activate the adaptive immune response against the
tumor and can emerge as potential therapy in the future.
In addition to this, depletion of the efferocytosis receptor, MERTK,
dampened tumor growth and metastasis in syngeneic breast, melanoma and colon
cancer models (238). Bone marrow transplantation of MERTK-/- cells into lethally
irradiated MMTV-PyVMT mice slowed tumor progression. Additionally, MERTK-/CD11b+ macrophages isolated from MERTK-/- tumors produced significantly
higher amount of IL-6 and IL-12p40, hallmarks of immune activation. In line with
this, there was increased infiltration of cytotoxic CD8 cells into the tumor.
The expression of PtdSer, the well-known ‘eat me’ signal is deregulated in
cancer. In the TME, PtdSer is expressed by tumor cells, immature vasculature as
well as tumor cell derived exosomes. Tumor associated dendritic cells that engulf
PtdSer expressing tumor cells remain arrested in an impaired functional state,
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incapable of expressing the costimulatory molecules required for optimum antigen
presentation to the T cells. Following chemotherapy or radiotherapy, the apoptotic
index in the TME is increased which correlates with increased PtdSer expression.
This eventually results in further immunosuppression. Moreover, the cognate
receptors and other bridging molecules expressed on TAMs interact with PtdSer
on tumor cells and hinder tumor recovery by creating an immunosuppressive local
environment. All these studies indicated that molecules associated with
efferocytosis of dying tumor cells probably act as critical immune checkpoint
inhibitors and targeting these molecules can work akin PDL-1 and CTLA-4. Indeed,
pre-clinical studies showed that administration of PtdSer blocker resulted in
immune activation in the TME, marked by increase in M1 macrophages, reduction
in the number of MDSCs and infiltration of cytotoxic T cells (239). Currently
Bavituximab, a PtdSer targeting antibody is being tested in multiple clinical trials,
either as monotherapy or in combination with other therapies and has so far shown
signs of activity (240).
These studies taken together, raise an important question, if cancer cells
are targeted using chemotherapy or radiotherapy, and the phagocytosis of the
apoptotic cells are blocked pharmacologically by immunomodulating TAMs, will
the defective efferocytosis activate anti-tumor immune response in the host?
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Fig. 3.1. Find me and Eat me signals during efferocytosis. Interaction between
different molecules that mediate recognition and uptake of apoptotic cells. The
figure has been adapted from Hochreiter-Hufford et al. “Clearing the Dead:
Apoptotic Cell Sensing, Recognition, Engulfment, and Digestion.” Cold Spring
Harbor Perspectives in Biology. 2013. doi: 10.1101/cshperspect.a008748
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Fig.3.2. Phagosomal maturation during efferocytosis. During efferocytosis,
Dynamin is first recruited to the apoptotic cell/phagocyte interface. Dynamin then
interacts with Vps34, resulting in Rab5 recruitment and activation. Activated Rab5
further activates Vps34, resulting in the formation of PI(3)P on the phagosome
surface. In the next step, Mon1-CCz complex recruits Rab7 recruitment to the
phagosome. Finally, the HOPS complex is recruited, Rab7 is activated and
eventually the phagosome containing the apoptotic cell fuses with with the
lysosome for degradation of the cargo. The figure has been adapted from
Hochreiter-Hufford et al. “Clearing the Dead: Apoptotic Cell Sensing, Recognition,
Engulfment, and Digestion.” Cold Spring Harbor Perspectives in Biology. 2013.
doi: 10.1101/cshperspect.a008748
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Fig.3.3. LC3 associated autophagy (LAP) during efferocytosis. Following
engulfment of apoptotic cell corpse, the Class III PI3K complex, comprising of
Beclin 1, VPS34, UVRAG and Rubicon are recruited to the LAPosome containing
the apoptotic debris. The PI(3)P generated by VPS34 recruits the downstream LAP
components (such as, ATG5, ATG12, ATG16L, and ATG7). PI(3)P and Rubicon
stabilize NOX2 for the production of ROS at the phagosome. Finally, PI(3)P and
ROS help recruit LC3 to the LAPosome surface which then fuses with the
lysosome for degradation of the cargo. LAP mediated efferocytosis results in
decreased production of IL-12, TNF-α, IL-1β and IL-6 and enhanced secretion of
IL-10 and TGF-β, thereby dampening the inflammatory immune activation. The
figure has been adapted from Green et al. “The clearance of dying cells: table for
two.” Cell Death Differ 2016 doi: 10.1038/cdd.2015.172 with permission.

113

114

Fig.3.4. Efferocytosis in cancer. Efferocytosis of apoptotic cells by TAMs in TME
resulting in increased pro-tumorigenic polarization of TAMs. Enhanced production
of immunosuppressive cytokines stimulates regulatory T cells and dampens
effector T helper and cytotoxic T cell response against tumor, resulting in increased
risk for relapse post therapy and distant metastasis. This figure is adapted from
Stanford et al. “Efferocytosis produces a prometastatic landscape during
postpartum mammary gland involution.” JCI 2014 doi:10.1172/JCI76375 with
permission.
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Concluding remarks and dissertation hypothesis
Macrophages comprise a heterogenous population of innate immune cells
and are highly plastic in nature. They are endowed with diverse functions, ranging
from maintenance of homeostasis by phagocytosing and clearing apoptotic debris
in tissues, metabolic homeostasis, development of organs, angiogenesis to
combating inflammations or pathogenic infections. They can also bridge the innate
and adaptive arms of the immune system by their ability to prime naïve T cells.
Depending on the milieu of cytokines and chemokines they are exposed to in the
tissue microenvironment, macrophages can exist as classically activated or M1
type or alternatively activated or M2 type. M1 type macrophages are cytotoxic and
release pro-inflammatory cytokines to eliminate infected or injured cells. However,
post infection or injury, M1 type cells polarize towards a reparative M2 type, that
secrete angiogenic growth factors, tissue remodeling matrix metalloproteases and
other immunosuppressive cytokines for suppressing T cell responses, that
augment the wound healing and tissue repair processes. Intriguingly,
macrophages comprise a substantial population of many solid tumors, including
breast, prostate, and pancreatic cancers. In most of the cancers studied so far, the
intratumoral infiltration of macrophages correlate with disease stage and severity
and is causally associated with poor clinical outcome. Tumor associated
macrophages (TAMs) comprise a complex population of cells. Although their gene
expression profiles are characteristic of the M2 type, they also express several M1
type genes. Extensive studies over the past few years have shown that TAMs are
indispensable for tumor progression. They have been associated with several
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stages of neoplastic development, like, attainment of epithelial to mesenchymal
transformation (EMT), survival and proliferation of cancer cells, maintenance of
cancer stem cell niche, tumor associated angiogenesis and lymphangiogenesis,
suppression of anti-tumor immune responses and distant metastases. Research
is currently ongoing to discover strategies to re-educate TAMs towards a
classically activated M1 type. Several clinical trials targeting various aspects of
TAMs either alone or in combination with other therapies have been reported (54,
56, 65).
Neuropilins (NRPs) are non-tyrosine kinase, cell surface glycoproteins that
are widely characterized for their roles in development, migration and
angiogenesis. Two isoforms are known till date, NRP1 and NRP2. They are
endowed with unique as well as redundant functions. NRPs have been implicated
in several neoplasms where they are often overexpressed and correlate with
cancer cell survival under stress, proliferation, metastasis and poor patient
survival. Research over the past few years have focused on the role and function
of NRPs in different immune cell compartments. For example, NRP1 is a marker
for mouse regulatory T cells and is associated with immunosuppression. It is also
expressed in macrophages and is important for their protumoral activities (241). In
contrast, NRP2 is less characterized in the immune subsets. Although previous
studies detected NRP2 expression in macrophages, its function and the molecular
pathways that govern these functions are still not clearly known. Our lab has
previously reported a novel role for NRP2 in regulating endocytic maturation in
cancer cells. NRP2 positively regulates the maturation of early to late endosomes.
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This is important for cancer cells that heavily rely on endocytic machinery for their
oncogenic activities (242). The primary role of macrophages is phagocytosis. This
function is indispensable for clearance of pathogens, pathogen infected cells as
well as for maintenance of physiological homeostasis. Following internalization of
cargo, nascent phagosomes in macrophages mature to late phagosome and
phagolysosome, recruiting and fusing with the classical endocytic compartments
and gradually becoming more and more acidic in the process (219-222). Since the
processes of endosomal and phagosomal maturation are similar, and involve
several common downstream effectors, we hypothesize that NRP2 regulates
phagosome maturation in macrophages; hence NRP2 depletion will affect
pathogen clearance in macrophages. Our study aims to fully understand the role
of NRP2 in macrophage biology and how this may affect macrophage function in
normal physiology as well as clinical settings.
One of the essential functions of TAMs in the TME is efferocytosis of
apoptotic cancer cells. In the TME, the apoptotic index is high owing to either
nutrient limited growth condition or rapid proliferation of cancer cells or any
therapeutic stress. The dying cell corpses need to be removed as efficiently as
they are generated and impairment of their clearance results in the leakage of
cellular contents into the surrounding milieu as secondary necrosis. This can
potentially activate anti-tumor immune responses. Intriguingly, efferocytosis of
dying tumor cells makes TAMs more tumorigenic and immunosuppressive, and
significantly increases the risk for metastasis. Blockade of efferocytosis can
potentially reduce the risk for metastatic cancer and disease recurrence (104). We
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hypothesize that NRP2 in TAMs regulates clearance of apoptotic tumor cells and
maintains an immunosuppressive environment in the TME; hence NRP2 ablation
in macrophages will slow down tumor progression and activate anti-tumor immune
response. The goal of this study is to understand the role of NRP2 in macrophages
and how this NRP2 driven function may affect TAMs and tumor progression.
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most lethal types of
cancers with high incidence and low survival rates. One of the hallmarks of PDAC
is the dense desmoplastic reaction that acts as a physical barrier to therapeutics.
TAMs are abundantly present in PDAC and have been causally associated with
distinct stages of disease progression, metastasis, therapy resistance and
correlate with poor outcome (243-245). Despite the exciting potential of a targeted
immunotherapy for treating PDAC, it is a clinical reality that tumors relapse, often
with more aggressive features. Our goal is to identify the function of NRP2 in TAMs
and how targeting this axis may affect PDAC progression. Collectively, the
outcome of the study will address the requirement for developing strategies to
target NRP2 in TAMs either alone or as combination therapy in the effective
treatment of PDAC.
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Chapter II
Materials and Methods:
2.1 Antibodies used
NRP2 (CST 3366 for mouse, R&D AF2215 for human), CD8 (CST 98941), CD4
(ab183685), CD68 (ebioscience 14-0681-82), F4/80 (ebioscience 14-4801-82),
CD31 (ab28364), α-SMA (ab5694, kind gift from Dr. Maneesh Jain, University of
Nebraska Medical Center), Granzyme B (ab4059), Rab5 (ab13253), Rab7
(ab50533), Rho GDI (Santa Cruz Biotechnology sc373724), β-actin (Cell Signaling
Technology, 4970), Hsc 70 (Santa Cruz Biotechlogy, sc 7298), α,β tubulin (Cell
signaling technology 2148).
2.2 Cell culture and generation of human PBMC and murine bone marrow
derived macrophages:
Monocytes isolated from the peripheral blood of healthy human donors were
obtained from the elutriation core facility at the University of Nebraska Medical
Center. Cells obtained were >97% pure. PBMCs were then cultured at 37ºC with
5% CO2 in RPMI 1640 containing 10% fetal bovine serum, 2mM glutamine, 100
µg/mL streptomycin and 100U/mL penicillin for the indicated time points. M1
macrophages were obtained by maintaining PBMCs in culture for 6 days with 100
ng/mL G-MCSF; fresh media containing G-MCSF was added to the cells every
alternate day. On day 7, cells were stimulated with 1 µg/mL LPS and 10 ng/mL
human recombinant IFN-Y for 24 hours. M2 macrophages were obtained by
similarly maintaining PBMCs in culture for 6days with 100 µg/mL human
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recombinant M-CSF and activated with IL-4, IL-10, IL-13 (10 ng/mL each) for 24
hours on day 7.
For generation of murine macrophages, mice were first euthanized by CO2
asphyxiation, and the animal surface sprayed with 70% ethanol. tibia and femur
were harvested from mice, cleaned of all muscle and connective tissue. Intact
bones were then transferred to tissue culture dish containing Dulbecco’s
Phosphate Buffered Saline (PBS) on ice. Bone marrow was flushed from both the
ends of the bone shafts with ice cold PBS using a 25-gauge needle and 30cc
needle, and collected into 50mL falcon tubes on ice. Cells were centrifuged at
2000rpm for 10minutes. The cell pellet was resuspended in RPMI and filtered
through a 70µm Nylon mesh filter to remove muscle and connective tissue. Cells
were centrifuged again and 1mL Erythrocyte Lysis Buffer added to the pellet for
lysing the red blood cells and allowed to stand for 1minute at room temperature.
To neutralize, 1omL of RPMI media was added, homogenized by pipetting
thoroughly with a 10mL pipette and centrifuged again at 2000 rpm for 10minutes.
The cell pellet was resuspended α-MEM media containing 10% fetal bovine serum,
2mM glutamine, 100 µg/mL streptomycin and 100U/mL penicillin and the number
of cells counted using a hemocytometer. Trypan Blue staining was performed to
analyze the cell viability. Based on the experiment, the required number of cells
were plated in either tissue culture dishes, two well chambers, or 6-well plates and
cultured at 37ºC with 5% CO2 in the above-mentioned media for the indicated
periods of time. For the generation of M1 macrophages, 50 ng/mL murine
recombinant G-MCSF was added into the culture for 7days; on day 2, the non-
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macrophage lineage cells were removed by replacing the supernatant with fresh
media containing G-MCSF. Repeated boosts of G-MCSF was added to the cells
every alternate day. Finally, on day7, the old media was replaced with new media
containing 1µg/mL LPS and 10ng/mL murine recombinant IFN-Y and kept for 24
hours. M2 macrophages were obtained by similarly adding murine M-CSF into the
culture for 7days. Cells were activated by the addition of 10ng/mL IL-4 for 24 hours.
For some experiments, to knock out NRP2, 4-HydroxyTamoxifen (1mM stock in
methanol) was added into the culture media at a concentration of 0.3 µM every
alternate day for 3-5days.
For isolation of peritoneal macrophages, mice were euthanized as mentioned
earlier and sprayed with 70% ethanol and mounted on a Styrofoam block. The
outer skin of the peritoneum was cut using scissors and forceps and gently pulled
back to reveal the inner lining of the peritoneum. Using a 27gauge needle, 5mL ice
cold PBS was injected into the peritoneal cavity carefully so that no organs were
punctured. The peritoneum was gently massaged for 5mins to dislodge any
attached cells into the cavity. Using a 25gauge needle, as much fluid was collected
from the cavity as possible. Care was taken so that no fat or connective tissue or
blood contamination occurred. The fluid containing peritoneal macrophages were
collected into 15mL falcon tubes on ice. They were centrifuged at 2000rpm for
10mins, resuspended in complete α-MEM media mentioned earlier. The cell
number was counted using a hemocytometer and plated for experiments.
Peritoneal macrophages were maintained in M-CSF containing media for 3 days,
following which they were subjected to different assays. (Z)-4-HydroxyTamoxifen
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was added into the cell culture medium (dose as mentioned earlier in this section)
for 3 consecutive days to knock out NRP2.
Panc-1 cells were purchased from ATCC. UN-KC-6141 and KPC cells were
generated by Dr. Surinder K. Batra, University of Nebraska Medical Center and
were a kind gift to us from his laboratory. All these cell lines were maintained in
Dulbecco's Modified Eagle's Medium (DMEM) media containing 10% fetal bovine
serum, 2mM glutamine, 100 µg/mL streptomycin and 100U/mL penicillin at 37ºC
with 5% CO2. For generation of conditioned media, cells were plated in 75mm 2
tissue culture flasks and allowed to grow till 75% confluency. The complete media
was then removed and cells washed twice with PBS without Calcium or
Magnesium and replaced with only DMEM for 48hours. The conditioned media
was then collected, centrifuged at 100rpm for 5minutes, strained through 0.22µm
filter and kept at -80ºC until use.
Jurkat cells were purchased from ATCC and cultured in RPMI-1640 medium
containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L
glucose, and 1500 mg/L sodium bicarbonate, 10% FBS, 100 µg/mL streptomycin
and 100U/mL penicillin at 37ºC and 5% CO2.
2.3 Generation of human and murine Tumors Associated Macrophages
(TAMs) ex vivo:
To generate tumor associated macrophages ex vivo, PBMCs and BMDMs were
treated with conditioned media (50% v/v) collected from pancreatic cancer cell line
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Panc-1 (ATCC) and UN-KC-6141 or KPC cell lines respectively for the indicated
periods of time.
2.4 Generation of mouse model:
The NRP2flox/flox mouse was developed by Peter Mombaerts, Max Planck
Research Unit for Neurogenetics. The Nrp2 targeted mutation was generated in
129P2/OlaHsd derived E14 ES cells and has a loxP-tauGFP-pA+-FNF cassette
inserted into the first intron and a corresponding loxP site inserted upstream of the
start codon. The FRT-flanked neomycin resistance sequence (FNF) was excised
by crossing to mice with the Tg(ACTB-flp)4917Dym transgene insertion, which was
generated in a mixed B6;SJL background, yielding the Nrp2tm1.1Mom targeted
mutation on a mixed background that is predominantly 129P2 and C57BL/6. These
mice were bred to pure C57BL/6 background and were a kind gift to us from our
collaborator, Dr. Michael Muders, Germany. The FVB- Tg(Csf1r-Mer-iCreMer)1Jwp/J mice (developed by Dr. Jeffrey W Pollard, Albert Einstein College of
Medicine) were purchased from Jackson Laboratories. These Tg(Csf1r-Mer-iCreMer)1Jwp transgenic mice express a Cre recombinase/mutant murine estrogen
receptor double-fusion protein under the direction of the mouse Csf1r, colony
stimulating factor 1 receptor, promoter. Tamoxifen-inducible cre activity is detected
in bone-marrow-derived macrophages and yolk sac macrophages. When these
Tg(Csf1r-Mer-iCre-Mer)1Jwp mice are bred with mice containing a loxP-flanked
sequence of interest, tamoxifen-inducible, Cre-mediated recombination will result
in deletion of the flanked sequences in Csf1r-expressing cells; making them useful
for studying inflammation, metastasis and tracking myeloid lineage cells.
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The MerCreMer double fusion protein consists of Cre recombinase flanked on
each end with a mutated murine estrogen receptor (mer) ligand binding domain
(amino acids 281-599, G525R); which does not bind its natural ligand (17'estradiol) at physiological concentrations but will bind the synthetic estrogen
receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser
sensitivity, ICI 182780. Restricted to the cytoplasm, MerCreMer can only gain
access to the nuclear compartment after exposure to tamoxifen. A transgenic
construct containing tandem copies of icre/Esr1*, or Mer-icre-Mer, under the
control of the mouse Csf1r, colony stimulating factor 1 receptor, promoter, was
injected into fertilized FVB/N mouse eggs. Founder line 1 was subsequently
established. Upon arrival at The Jackson Laboratory, the mice were crossed to
FVB/NJ at least once to establish the colony. For our experimental purpose, the
FVB-Tg(Csf1r-Mer-iCre-Mer)1Jwp/J (henceforth called CSF1R-Cre) mouse was
first bred with C57BL/6 mice for one generation (n1). Cre + mice from this n1
generation

was

then

NRP2flox/floxCSF1R-Cre

crossed
compound

with

NRP2flox/flox

mice.

Following

mice

to

generate

administration

of

intraperitoneal injection of Tamoxifen (75mg/kg body weight from 20mg/mL stock
in corn oil, every day for 5-7days) or (Z)-4-hydroxytamoxifen into cell culture
medium specifically and selectively knocks out NRP2 from myeloid cells
expressing CSF1R, like monocytes, macrophages and dendritic cells in an
inducible manner.

2.5 Mouse genotype analysis:
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Approximately, 0.5cm piece tails of 3-4 weeks old mice were snipped and digested
using the tail extraction buffer and thermostable protease from Kapa Hotstart
Genotyping kit (Kapa Biosystems). Each reaction mixture contained 88µL of PCR
grade water, 10µL of 10X KAPA Express extract buffer (final concentration 1X)
and 2µL (1U/µL) of KAPA Express enzyme. Lysis was performed for 15min at 75ºC
and then stopped at 95ºC for 5mins. The digested samples were centrifuged at
13000rpm for 5mins and supernatants were transferred to clean tubes without
disturbing the cell pellet. Following manufacturer’s protocol, the genomic DNA was
diluted 10-fold in 10 mM Tris-HCl (pH 8.0–8.5) and then used for PCR. Each PCR
reaction mix consisted of 0.5µM final concentration of each of forward and reverse
genotyping primers, 2X KAPA2G Fast (HotStart) Genotyping Mix with dye, 1µL of
crude DNA extract (diluted) and 10.25 µL of PCR grade water. KAPA2G Fast
Genotyping Mix (2X) is a ready-to-use master mix containing all components for
fast PCR, except primers and template. The 2X ReadyMix contains KAPA2G Fast
DNA Polymerase (with or without antibody-mediated HotStart), KAPA2G Buffer A,
dNTPs (0.2 mM each at 1X), MgCl2 (1.5 mM at 1X) and stabilizers. The ReadyMix
also contains two inert dyes, allowing for the analysis of PCR reaction products by
agarose gel electrophoresis without the need to add a DNA loading solution. After
PCR amplifications, the amplicons were run on a 2% agarose gel containing 3%
v/v Ethydium Bromide prepared in 1X TAE buffer, and visualized using BioDoc-It
Imaging system.
2.6 Nucleofection:
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siRNA transfection in PBMCs was performed using Human Monocyte
Nucleofection kit (Lonza, VPA-1007) following manufacturer’s protocol. 25nM
siNRP2 or Scrambled antisense RNA was used. Cells were analyzed or subjected
to any assay 48-72 hours after siRNA transfection.
2.7 Immunoblot Analyses:
Briefly, cells were washed with ice cold PBS followed by lysis with CHAPS lysis
buffer (150mM KCl, 50mM HEPES (pH 7.4), 0.1% CHAPS, 2mM EDTA, 20µg/mL
Leupeptin, 10µg/mL Aprotinin, 5mM DTT, 1mM PMSF and Halt protease and
phosphatase inhibitor cocktail) on ice. Cells were gently scraped using cell scraper
and sonicated on ice. Supernatant was separated by cold centrifugation (13000
rpm for 5 mins) and total protein was estimated using Bradford method (Biorad,
Hercules, CA). SDS sample buffer was added and the sampled were heated at
95ºC for 8mins. The whole cell extracts were next run on 4–20% Mini-PROTEAN®
TGX™ Gel (BioRad) and transferred to polyvinylidene difluoride (PVDF)
membrane (Life Technologies, Carlsbad, CA). Protein transfer was to PVDF
membrane was checked regularly by Ponceau stain. The membrane was then
blocked in either 5% non-fat dry milk or 5% Bovine Albumin Serum (BSA) in 1X
TBST (1X Tris Buffered Saline, 0.1% Tween-20) for atleast 1hour. The blocked
membrane was then incubated overnight in 1X PBS containing appropriate dilution
of primary antibodies overnight at 4ºC with continuous shaking at low speed. The
next day, membrane was washed with 1X TBST for 5min (x5) and then incubated
for 1hr in 1X TBST containing appropriate dilution of horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) with
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continuous shaking at low speed. The membranes were washed in 1X TBST for
5min (x5). The protein bands were detected using SuperSignal™ West Femto
Maximum Sensitivity Substrate. For successive immunoblots, membranes were
stripped in Stripping Buffer (Thermo Fisher Scientific) for 20mins, re-blocked in 1X
TBST containing either 5% BSA or 5% non-fat dry milk and probed as mentioned
before.
2.8 RNA isolation using Trizol:

Cells were harvested and washed twice with PBS. 1mL of TRI ReagentTM
(Invitrogen, CA) was added per 10million cells (if the cells were more and appeared
cloudy, more trizol was added accordingly). They were gently scraped using cell
scraper and collected in 2mL eppendorfs and kept for 5mins at room temperature.
300µL of Chloroform was added into each tube and mixed well by inverting the
tubes for 15-20seconds. The tubes were allowed to stand for 5mins at room
temperature following which they were centrifuged at 12000 rpm for 15mins at 4ºC.
The clear upper supernatant was extracted without disturbing the cellular layer and
collected into fresh eppendorfs. To this, we added 500µL isopropanol and 1µL of
Glycogen (RNA graded from Invitrogen) and samples were allowed to stand for
5mins at room temperature. The samples were then centrifuged at 12000rpm for
15min at 4ºC. The supernatant was decanted and 1mL of 75% ethanol was added,
mixed and spun at 7500rpm for 5mins at 4ºC. The supernatant was decanted and
tubes air-dried for 10mins. The pellet was resuspended in 25µL DEPC water. The
concentration and quality of the RNA was analyzed using Nanodrop
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Spectrophotometer. The RNA was either stored at -80ºC until use or processed
immediately for cDNA synthesis.

2.9 Quantitative Real-Time PCR (qRT-PCR):

Total RNA was extracted using TRIzol reagent as mentioned above. 1µg of RNA
was used to synthesize cDNA by Transcriptor First Strand Synthesis kit (Roche,
Indiapolis, IN, 04379012001). Quantitative real time PCR (qRT-PCR) was then
carried out using Power SYBRGreen master mix (Life Technologies, Grand Island,
NY, 4368706) as described using Applied Biosystems (ABI) 7500 Real Time PCR
machine. The acidic ribosomal phosphoprotein, 36B4 gene was used to normalize
and calculate the relative levels of mRNA expression of genes of interest, using
the 2-ΔΔCt methods and expressed as arbitrary units. The sample analysis was
performed in duplicates. Data is represented as ±SEM.

2.10 Continuous E.coli phagocytosis and clearance assay:
(i) continuous phagocytosis to demonstrate phagosome maturation defect: The
pHrodo™ Red E. coli BioParticles™ Conjugate suspension was prepared following
manufacturer’s protocol. The particles are non-fluorescent outside the cell, but
fluoresce red in the phagosomes. The intensity of red fluorescence increases with
increasing acidity of cellular compartment where the particles are localized. An
optimized dose of 65µg/mL bioparticles were used for phagocytosis.
For continuous phagocytosis assay, either human PBMC derived macrophages or
murine BMDM were grown in two welled chambers as described in 2.2. Human
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PBMC derived macrophages were subjected to nucleofection on day5 to knock
down NRP2 and the assay was performed on day7. Before the assay, cells were
washed twice with 1X DPBS. The fluorescent E.coli particles were then added at
a concentration of 65µg/mL and incubated at 37ºC for the indicated periods of time
to allow adequate particle internalization. Different time points were used
depending upon the objective of the experiment. Phagocytosis was arrested by
placing the cells on ice and washing vigorously 3-5 times with 1X DPBS to remove
the excess particles. Cells were then fixed with 4% paraformaldehyde at 4ºC for
20 minutes and washed with DPBS to remove the excess fixative. Nuclei were
stained using the nuclear dye Hoechst in PBS for 5 minutes, washed twice with 1X
PBS and analyzed by either Zeiss LSM 800 with Airyscan or Zeiss 710 Confocal
Laser Scanning Microscope at UNMC confocal core facility, and data were
analyzed and processed with the Zeiss Zen 2010 software. All confocal data were
quantified using ImageJ software and graphical illustrations made using GraphPad
Prism software as mentioned later.
(ii) E.coli uptake assay: Human macrophages or mouse BMDMs were grown in
two well chambers as mentioned in 2.10 (i). Before the assay, cells were washed
twice with 1X DPBS and added 65µg/mL red fluorescent E.coli particles for 1hr at
37ºC to allow the cells to phagocytose the particles. Uptake was arrested by adding
ice cold DPBS. Cells were thoroughly rinsed with DPBS to remove excess
bioparticles from the supernatant. Cells were next fixed with 4% PFA for 20mins
at 4ºC, washed thrice with DPBS to remove excess fixative and nuclei stained with
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Hoechst. Cells were then analyzed by confocal microscopy as described in 2.10
(i).
(iii) in vitro E.coli clearance assay: BMDMs or mouse peritoneal macrophages
were grown in two well chambers as described earlier. On day of the experiment,
cells were washed twice with 1X DPBS and added 500 µL of Opti-MEM media per
well. pHrodo red E.coli bioparticles were added at a concentration of 65 µg/mL for
15mins (pulse) to allow the cells to uptake the bioparticles. Immediately after
15mins, uptake was stopped by adding ice cold DPBS. Cells were washed
vigorously with DPBS (x3) to remove any E.coli particle that was not taken up or
loosely adhered to cell surface. Fresh complete α-MEM media was added and the
gradual maturation and clearance (breakdown) of the E.coli particles was
monitored at different time points (chase). At each time point, chambers were
taken out, cells vigorously washed with DPBS (x5) and fixed with 4% PFA for
20mins at 4ºC, nuclei stained with Hoechst and analysed using confocal
microscopy as described earlier.
Where mentioned, human macrophages grown for phagocytosis as described in
2.10 (i) were washed with 1X DPBS twice and added pHrodo red fluorescent
tagged E.coli bioparticles (30 µg/mL) and allowed the cells to phagocytose the
bioparticles for 45mins. Cells were then gently washed with DPBS to remove the
excess pHrodo red bioparticles from the media, added fresh DPBS into which
green fluorescent E.coli bioparticles were added (30 µg/mL) for another 45mins.
This allowed us to monitor phagosome maturation by chasing the maturation of
pHrodo E.coli bioparticles containing phagosomes as well as uptake of E.coli
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particles using the green bioparticles. At the end of the experiment, cells were
vigorously washed with ice cold DPBS to stop uptake and fixed with 4% PFA for
20mins at 4ºC. Cells were washed with DPBS (x3) to remove excess fixative,
nuclei stained with Hoechst and analyzed by Confocal microscopy as described in
2.10 (i).
2.11 In vitro Apoptotic Cell Clearance Assay:
For this assay, Jurkat cells were grown as mentioned in 2.2. Prior to the assay, the
cells were centrifuged at 1000rpm for 5mins, washed with 1X PBS (x2). They were
resuspended in only RPMI and incubated in 50µM Etoposide (Abcam) overnight
at 37ºC and 5% CO2 for 12hrs. This treatment routinely yielded 80-90% apoptotic
cells. The next day, cells were centrifuged at 2000 rpm for 10mins and the pellet
was washed twice with PBS. The cells were incubated with pHrodo™ Red,
succinimidyl ester (Thermo Scientific) following manufacturer’s instructions. This
dye enabled us to view the apoptotic cells in the phagosomes only after they are
internalized. Cells were centrifuged at 2000rpm for 10mins. The cell pellet was
washed twice with 1X DPBS and resuspended in Opti-MEM medium (Gibco).
Mouse BMDMs or peritoneal macrophages were plated in two well chambers and
grown in the presence of M-CSF as described earlier in 2.2. (Z)-4HydroxyTamoxifen was added to knock out NRP2 as described earlier. On the day
of the assay, the old medium was removed, cells were washed twice with 1X PBS
and added 500µL Opti-MEM medium per well. Apoptotic Jurkat cells were added
(1:5 macrophage : jurkat ratio) for either 15min or 30min (pulse) and allowed the
cells to uptake at 37ºC. Following this, uptake was stopped by adding ice cold
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DPBS; cells were vigorously washed with DPBS (x3) to remove any cell that was
not phagocytosed or remained loosely bound to the cell surface. Fresh complete
α-MEM media was added and the clearance of apoptotic cells were monitored over
time (chase). At each time point, cells were vigorously washed with DPBS (x5),
fixed with 4% PFA at 4ºC for 20mins and washed again with DPBS (x3) to remove
excess fixative. Nuclei were counterstained using Hoechst for 5mins and analysed
using confocal microscopy as mentioned earlier.
2.12 In vitro Zymosan Clearance Assay:
For this assay, BMDMs were grown in two well chambers as described earlier. On
the day of the experiment, cells were washed twice with 1X DPBS and added 500
µL of Opti-MEM media per well. pHrodo red zymosan particles were added at a
concentration of 65 µg/mL for 15mins (pulse) to allow the cells to uptake the
particles. Immediately after 15mins, uptake was stopped by adding ice cold DPBS.
Cells were washed vigorously with DPBS (x3) to remove any zymosan particle that
was not taken up or remained loosely adhered to cell surface. Fresh complete αMEM media was added and the gradual maturation and clearance (breakdown) of
the zymosan particles was monitored at different time points (chase). At each time
point, chambers were taken out, cells vigorously washed with DPBS (x5) and fixed
with 4% PFA for 20mins at 4ºC, nuclei stained with Hoechst and analysed using
confocal microscopy as described earlier.
2.13 Subcutaneous Tumor implantation:
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UN-KC-6141 cells were maintained in culture as described earlier. For
subcutaneous implantation, cells were allowed to grow until 50% confluency. The
night before implantation, the old medium was replaced with fresh complete
medium. The next day, the cells were washed with 1X DPBS, and then trypsin was
added to the cells for 2mins, neutralized by adding equal volume of media
containing FBS and centrifuged at 1000rpm for 5mins. Cells were washed twice
with DPBS and resuspended in DPBS and cell number and viability counted using
Trypan Blue. Cells with less than 90% viability were discarded. Cells were
centrifuged again and resuspended in HBSS. For implantation, 500,000 cells in
HBSS were mixed with equal volume of Matrigel (without growth factors) so that
the total volume was 100µL and kept on ice.
The right dorsal flanks of mice were gently shaved using Veet hair removal crème
and a spatula. Care was taken so as not to irritate or inflame the skin of the mice.
The cell mixture was slowly pulled up using a 1mL syringe and 22gauge needle
and kept on ice. The skin of the mouse around the dorsal right flank was gently
pinched using the index and middle finger and pulled away from the body of the
mouse, and the cells were slowly and carefully injected into the pocket created.
For our studies, mice were divided into two groups (n=3 or 5 in each group). To
deplete NRP2 from the macrophages, the test group was injected with Tamoxifen
intraperitoneally (75mg/kg body weight from a 20mg/mL stock in corn oil) everyday
till the end point of the experiment. The control group was injected with corn oil as
vehicle control. The tumor growth was manually monitored regularly using digital
slide calipers and weight of the mice recorded. Once the end point of the
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experiment was reached, mice were euthanized by CO2 asphyxiation following
IACUC protocol and tumors harvested. Harvested tumors were washed gently in
ice cold DPBS, transferred to new tubes containing DPBS and kept on ice. Tumors
were fixed in 10% formaldehyde overnight and transferred to 70% ethanol and
given to Tissue Science Facility at UNMC for paraffin embedding, sectioning (4
µm) and Hematoxylin and Eosin (H&E) staining. Sections were subjected to
staining for different proteins as described later.
2.14 Histology and Immunostaining:
Immunohistochemistry and immunofluorescence staining on histological sections
were performed using the following procedure: slides containing tissue sections
(4µm thick) were kept on heat block at 58ºC for 2hours. They were then rehydrated
in a sequential passage of solutions starting with Xylene for 20mins, 100% ethanol
for 15mins, 95%, 90%, 80%, 75%, 50% and 20% ethanol for 5mins each followed
by immersion in double distilled water for 10mins. For IHC only, slides were next
immersed in 3% Hydrogen Peroxide (H2O2) in methanol for 1hr at room
temperature followed by incubation in double distilled water for 5mins. Antigen
retrieval was performed using Dako antigen retrieval solution (either pH9 or pH6,
depending on the antigen of interest). The antigen unmasking solution was first
preheated at a high temperature in the microwave until boiling and then the slides
were immersed into it and boiled on a 98ºC water bath for 45mins. Following this,
the slides were gradually allowed to cool to room temperature for atleast 1hr and
then washed with 1X PBS thrice, 5mins each. Slides were then blocked with 5%
goat serum in 1XPBS containing 0.2% saponin at 4ºC for 1hr in a moist chamber.
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Then the tissue sections were covered with 1X PBS containing 0.2% saponin and
3% BSA and the required concentration of primary antibodies, and incubated
overnight in a moist chamber at 4ºC. The next morning, slides were washed in 1X
Tris Buffered Saline (TBS) solution for 5mins (x5). Secondary antibodies were then
diluted in in 1X PBS containing 0.2% saponin and 3% BSA at 1:200 concentration
for biotinylated antibodies (IHC) or 1:500 for fluorophore conjugated antibodies (IF)
and incubated for 1hr in dark in a moist chamber. For IHC staining, slides were
next washed with 1X TBS for 5min (x6) and then incubated with Avidin-Biotin
complex for 40mins at room temperature, following manufacturer’s instructions.
Slides were then rinsed with 1X TBS for 5mins (x3) and added diaminobenzidine
solution containing 0.3% H2O2 as a substrate for peroxidase (Dako) until the
desired staining intensity was developed. Slides were washed in double distilled
water and hematoxylin added for counter staining. The slides were then rinsed
under running tap water to remove excess counter staining, and the dehydrated
by gradual passage of slides from double distilled water to xylene in a reverse
order mentioned earlier for rehydration of slides. Slides were finally mounted with
Permount and covered with glass cover slips. Clear nail polish was used to seal
the sides of the cover slips. The whole slides were next digitally scanned at Tissue
Science Facility, UNMC. For IF, following incubation with secondary antibody,
slides were thoroughly washed with 1X TBS for 5mins (x5) and finally once with
distilled water and then mounted with Vectashield mounting media containing
DAPI

(Vector

Laboratories,

Burlingame,

CA).

For

monolayer

culture,

immunofluorescence staining was performed as described: briefly, cells were
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grown on poly-DL-lysine–coated coverslips (BD Biosciences) for indicated periods
of time before fixation and analysis by confocal microscopy. Cells were rinsed with
Dulbecco's Phosphate-Buffered Saline (DPBS; Invitrogen)(x3), followed by fixation
with ice cold 4% paraformaldehyde at 4ºC for 20 minutes. Cells were then washed
with DPBS (x3). Finally, cells were blocked using 1% BSA and 0.2% saponin in
PBS for 1hr at 4ºC in a moist chamber. The slides were then incubated overnight
in the same blocking buffer containing appropriate concentration of primary
antibodies at 4ºC in a moist chamber. The next day, the coverslips were carefully
washed in 1X PBS (x5) and added fluorescent conjugated antibodies (1:200) in 1X
PBS containing 1% BSA and 0.2% saponin for 2hrs at 4ºC in a moist chamber.
The coverslips were finally washed in 1X PBS (x5) and mounted on glass slides
with mounting media containing DAPI as mentioned above and sealed with clear
nail polish. Slides were viewed using either Zeiss LSM 800 with Airyscan or Zeiss
710 Confocal Laser Scanning Microscope at UNMC confocal core facility, and data
were analyzed and processed with the Zeiss Zen 2010 software. All confocal data
were quantified using ImageJ software and graphical illustrations made using
GraphPad Prism software as mentioned later.
The list of all the primary antibodies used have been listed earlier. For the purpose
of Immunofluorescence staining, the secondary antibodies conjugated with
fluorophores were purchased from Invitrogen Corporation, and DAPI from Vector
laboratories was used for counter staining the nuclei. For IHC, biotinylated
antibodies were purchased from Invitrogen. The ABC Peroxidase Standard
Staining Kit was purchased from Thermo Fisher Scientific.
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2.15: TUNEL staining

To assess the number of apoptotic or necrotic cells in the tumor tissues, TUNEL
staining was performed following manufacturers’ instructions (Roche In Situ Cell
Death Detection Kit, TMR red, catalogue number 12156792910).

2.16 Isolation of TAMs from subcutaneous mouse tumors:
TAMs were isolated as described elsewhere (246). Subcutaneous mouse tumors
were generated as mentioned above. The tumors from both control and test
animals were harvested and kept in ice cold RPMI media on ice. Each tumor was
cut into small pieces using scissors or scalpel and the digestion media was added
(RPMI media containing the following: 10U/mL Collagenase I, 400U/mL
Collagenase IV, 30U/mL DNAse I- all diluted in HBSS) and kept at 37ºC for
30mins. Following this, the tumor pieces were crushed with the plunger of a 10mL
syringe, 5mL RPMI media was added and homogenized well using a 10mL pipette.
The tumor suspension was filtered by passing through a 70µm nylon gauze and
the collected into fresh tubes. The suspension was centrifuged at 450g for 6min at
4ºC; the supernatant was discarded and the pellet was resuspended in 2mL
erythrocyte lysis buffer to remove the RBCs. The tubes were allowed to stand for
2mins at room temperature, neutralized by the addition of 12mL of RPMI media,
passed through a sterile 70µm nylon gauze and centrifuged again at 450g for
6mins at 4ºC and the supernatant discarded. The pellet was resuspended in
Lymphoprep solution at a concentration of 1-2X107 cells/mL and transferred to
fresh tubes. To this was added 6mL RPMI media very cautiously to obtain a two-
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phase gradient. The gradients were centrifuged at 800 x g for 30 min at room
temperature without acceleration or break. The interphase (enriched in myeloid
cells and lymphocytes as well as the upper layer containing the RPMI media were
collected into fresh tubes without disturbing the lymphoprep layer. The cells were
washed once with MACS buffer, centrifuged at 800g for 5mins at 4ºC and the
supernatant discarded. The cell pellet was finally resuspended in MACS buffer at
a concentration of 108 cell/mL. TAMs were isolated using CD11B magnetic beads
and LS columns (both from Miltenyi Biotech) following manufacturer’s instructions.
The CD11B+ myeloid cells were arrested in the columns and the non-labelled cells,
which were mainly the enriched T cells, were collected as flow-through in separate
tubes. The TAMs thus collected were centrifuged and Trizol was added and kept
in -80ºC for processing for RNA-Seq analysis.
2.17 Transcriptome analysis using RNA-Seq:
CD11b+ cells were isolated from subcutaneous PC tumors using magnetic beads
as mentioned in 2.15. RNA was isolated from the control and test group with n=3
animals contributing to each pool. This was done in order to obtain sufficient
amount of RNA. RNA-Seq service was obtained from Kelvin Chan and his team at
Seqmatic. Extracted RNA was QC with Agilent TapeStation RNA screentape. The
RIN value of the control sample was 9.1 and that of the test was 9.4. A paired end
read 2x75bp sequencing run of RNA libraries were performed using the Illumina
NextSeq 500 instrument. For analysis, raw reads were demultiplexed by barcode
and output into FASTQ format. Cutadapt was used to filter out adapter sequences
and low-quality bases. Filtered sequence reads were aligned to mouse reference
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genome mm10 using HISAT2 aligner. Reads mapping to exon regions as defined
by Ensembl gene annotations were counted using FeatureCounts. Data analysis
was performed with the help of Seqmatic, California and the Bioinformatics and
Systems Biology Core at UNMC. To address the limitation of number of samples,
we chose to identify differentially expressed genes using log2 fold metric instead
of p-value. Genes with a cutoff value log2 fold change1 were selected and those
with zero counts in both control and test samples or in either of them were
eliminated for stringency. The Ingenuity Pathway Knowledge Base (IPA) was used
to identify the enriched canonical pathways and cellular and molecular functions
among the differentially expressed genes in the two samples. In addition to the
IPA, the Database for Annotation, Visualization and Integrated Discovery (DAVID),
the Gene Ontology Project, Kegg Pathway and extensive literature curation was
performed to identify functional terms associated with the differentially expressed
genes. Among the enriched functional annotation clusters, we selected
representative clusters (as mentioned in the Results section) to analyze the effect
of NRP2 depletion on phagocytosis, macrophage phenotype and secretion of
chemokines and cytokines as well as interaction between macrophages and
leucocytes/lymphocytes.
2.18 Statistical Analyses:
All the graphical illustrations statistical tests were performed using Prism-6
software (GraphPad software, Inc., La Jolla, CA). All data reported in graphs are
expressed as mean ± standard error of mean (SEM) unless otherwise mentioned
and were compared using unpaired student T-test, p values were considered
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statistically significant when less than 0.05. All experiments were repeated at least
3times unless specified.
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Chapter III
NRP2 is expressed in M1 and M2 type macrophages and regulate
phagocytosis by modulating early to late phagosomal maturation.
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3. NRP2 is expressed in M1 and M2 type macrophages and regulate
phagocytosis by modulating early to late phagosome maturation.
3.A. Introduction
Macrophages are highly plastic and functionally diverse cells of the immune
system and undertake an array of functions, like maintenance of homeostasis by
phagocytosing and clearing apoptotic debris in tissues, metabolic homeostasis,
development of organs, angiogenesis to combating inflammations or microbial
infections. They can also bridge the innate and adaptive arms of the immune
system by their ability to prime naïve T cells. Briefly, macrophages can exist as
classically activated or M1 type or alternatively activated or M2 type. M1 type
macrophages are cytotoxic and release pro-inflammatory cytokines to eliminate
infected or injured cells. However, post infection or injury, M1 type cells polarize
towards a reparative M2 type, that secrete angiogenic growth factors, tissue
remodeling matrix metalloproteases and other immunosuppressive cytokines for
suppressing T cell responses, that augment the wound healing and tissue repair
processes (15, 54, 56, 247).
Neuropilins (NRPs) are non-tyrosine kinase, cell surface glycoproteins that
are widely characterized for their roles in development, migration and
angiogenesis. Two isoforms are known till date, NRP1 and NRP2. NRPs are often
overexpressed in several neoplasms and correlate with cancer cell survival under
stress, proliferation, metastasis and poor patient survival. Research over the past
few years have focused on the role and function of NRPs in different immune cell
compartments. In comparison to NRP1, NRP2 is less characterized in the immune
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subsets (241). Although previous studies detected NRP2 expression in
macrophages, its function and the molecular pathways that govern these functions
are still not clearly known. The primary role of macrophages is phagocytosis. This
function is indispensable for microbial clearance. Following internalization of
cargo, nascent phagosomes in macrophages mature to late phagosome and
phagolysosome, recruiting and fusing with the classical endocytic compartments
and gradually becoming more and more acidic in the process (219, 220). The
processes of endosomal and phagosomal maturation are similar in many aspects,
often recruiting identical effector molecules. Our previous report documented a
requirement for NRP2 in endosomal maturation in cancer cells (242). However, its
role in phagocytosis in macrophages is not well understood. Based on our previous
observation that NRP2 positively regulates endosomal maturation in cancer cells
and the similarity between endosomal and phagosomal maturation processes, we
hypothesized that NRP2 regulates phagocytosis in macrophages.
In this chapter, we report the expression pattern of NRP2 in human and
murine macrophages under M1 and M2 polarizing conditions. Using human
macrophages and bone marrow derived macrophages isolated from transgenic
mice generated in our lab, where NRP2 can be selectively depleted from the
myeloid cells, we observed NRP2 regulates phagosomal maturation in
macrophages and hence pathogen clearance in vitro. Further, NRP2 depletion
does not significantly affect the uptake of phagocytic cargo. In agreement with the
phagosomal maturation defect, we observed an increased accumulation of Rab5+
early phagosomes and a concomitant decrease in the number of Rab7+ late
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phagosomes in absence of NRP2. Overall, our study documents a novel role of
NRP2 in regulation of phagocytosis in macrophages.
3.B. Results
NRP2 is expressed in human and murine bone marrow derived M2 type
macrophages: NRP2 is not expressed by monocytes or bone marrow precursor
cells. To get M2 type macrophages, monocytes isolated using elutriation from the
peripheral blood of healthy human donors were differentiated using M-CSF for
7days, following which they were exposed to M2 polarizing cytokines, like IL-4, IL10 and IL-13 for 24hrs. A similar differentiation protocol was followed for
differentiating mouse bone marrow derived precursor cells. NRP2 is not detected
at protein level in either human monocytes or murine bone marrow derived
precursor cells, but an enhanced mRNA (not shown) and protein expression was
observed during the differentiation of the human monocytes to mature M2 type
macrophages (Fig. 3.1 A). Interestingly, there was no further increase in the
expression level of NRP2 following treatment with M2-polarizing cytokines, IL-4,
IL-10 or IL-13. Further, the data suggested a post translational modification of
NRP2 as the cells gradually differentiated to mature macrophages. Various post
translational modifications have been reported for NRP2. For example, it
undergoes polysialylation in microglia. The post translational modification of NRP2
in macrophages is beyond the scope of the current study.
A similar enhancement in the mRNA (not shown) and protein level of NRP2 was
observed during the differentiation of murine bone marrow derived precursor cells
to mature macrophages following treatment with mouse recombinant M-CSF for
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7days, and then exposure to M2-polarizing cytokines, like IL-4, IL-10 or IL-13 for
24hrs (Fig. 3.1 B).
NRP2 is expressed in human and murine bone marrow derived M1 type
macrophages: To generate inflammatory M1 type macrophages, monocytes
isolated from the peripheral blood of healthy human donors using elutriation was
differentiated using G-MCSF for 7days, following which the cells were treated with
a combination of LPS and IFN-Y for 24hrs. As mentioned in 3.B.1, NRP2 is not
detected at protein level in the human monocytes. However, an upregulation in the
expression of NRP2 mRNA (not shown) and protein was observed as the cells
differentiated towards M1 type macrophages. There was further enhancement in
the expression of NRP2 following stimulation of the cells with a combination of LPS
and IFN-Y (Fig. 3.2 A). Similarly, in murine bone marrow derived precursor cells,
NRP2 expression was not observed at a detectable level. However, an
enhancement in NRP2 protein level was observed as the precursor cells
differentiated to M1 type macrophages. Here also, following stimulation with a
combination of LPS and IFN-Y for 24hrs, further upregulation in the protein level of
NRP2 was observed (Fig. 3.2 B).
NRP2 regulates phagocytosis in human macrophages: Phagocytosis is one of
the key functions of macrophages and important for maintenance of physiological
homeostasis as well as microbial clearance during infections. Phagocytosis, a
special form of endocytosis, recruits similar downstream effector molecules and
the two pathways eventually converge onto each other. Because we previously
observed that NRP2 regulates endocytosis in cancer cells, therefore, we wanted
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to investigate whether NRP2 regulates phagocytosis in macrophages. To confirm
if NRP2 plays a role in phagocytosis in human macrophages, we differentiated
human PBMCs on M-CSF for 7days. NRP2 was depleted using siRNA approach.
We incubated the macrophages with pHrodo red and pH insensitive green E.coli
bioparticles at an optimized concentration of 65µg/mL for 1.5hrs. The pHrodo E.coli
bioparticles are non-fluorescent at neutral pH, however their fluorescence intensity
increases with an increase in acidity of the vesicle they are localized in. Following
engulfment, phagocytic cargo remains in nascent early phagosomes of higher pH,
which sequentially mature to late phagosomes, becoming more and more acidic
and finally fuse with the lysosomes. Therefore, a bright red fluorescence dot in the
cell indicates a mature phagocytic vesicle containing the E.coli, which has or is
going to be fused with lysosomes and thus can indicate an active phagocytic
process. On the other hand, the pH insensitive E.coli particle (green) uniformly
fluoresces irrespective of the pH of the phagosome or phagolysosome it is
delivered to. This experimental approach enabled us to test the ability of the
macrophages to mature the phagosomes (red) as well as their uptake efficiency
(green) in the presence and absence of NRP2. A schematic for the experimental
design is shown in Fig. 3.3 A. Quantification of the average total cell fluorescence
revealed a significant decrease in the intensity of red puncta in siNRP2 treated
macrophages. This indicated that as compared to control where phagosomes
containing E.coli bioparticles matured to acidic late phagosomes or fused with
lysosomes, in NRP2 depleted macrophages, the maturation of early phagosome
to more acidic less phagosome or the formation of phagolysosome was delayed.
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However, the uptake efficiency in mock and siNRP2 treated macrophages were
similar, as evident from the intensity of the green puncta (Fig. 3.3 B). Fig. 3.3 C
and D represent the quantification of the result and knockdown efficiency of NRP2
following electroporation with siNRP2. This data suggested that NRP2 regulates
phagosomal maturation in macrophages, without significantly affecting the uptake
process. NRP1 and NRP2 share structural homology and can have redundant
functions. To test if NRP1 regulates phagosomal maturation in macrophages,
phagocytosis assay was repeated using pHrodo E.coli bioparticles following NRP1
depletion. However, we did not observe any difference in the maturation of
phagosomes when NRP1 was knocked down in macrophages (Fig. 3.4 A). Fig.
3.4 B and C respectively show the graphical representation of the result and the
knockdown efficiency for NRP1. This indicates NRP2 uniquely regulates
phagocytosis in macrophages.
Because during any type of infection or injury, GM-CSF induced M1-type
macrophages are predominantly found in tissues and phagocytose pathogens, we
tested the role of NRP2 in phagocytosis in GM-CSF treated human macrophages.
For this, we repeated the phagocytosis assay using pHrodo E.coli bioparticles
following NRP2 depletion by siRNA approach. Our results indicated a similar
maturation delay in absence of NRP2 (Fig. 3.5 A). Fig. 3.5 B and C respectively
show the graphical representation and the knockdown efficiency of NRP2. Next,
to assess if NRP2 regulates the uptake of phagocytic cargo in GM-CSF treated
macrophages, phagocytosis assay was repeated using pH insensitive E.coli
bioparticles (red) following NRP2 depletion. We did not observe any significant
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change in the uptake efficiency of macrophages depleted of NRP2 (Fig. 3.6 A).
Fig. 3.6 B and C show the quantification of the phagocytic uptake and the
knockdown of NRP2 respectively. Overall, these data suggest that NRP2 regulates
phagocytosis in macrophages through modulation of phagosomal maturation.
NRP2 regulates phagocytosis in murine macrophages: We validated our
observations made in human macrophages using a transgenic mouse model that
we have developed in our lab. We have developed a compound mouse by crossing
NFP2fl/fl mice with Tg (Csf1r-Mer-iCre-Mer)1Jwp mice for selective and inducible
knockout of NRP2 in myeloid lineages following intraperitoneal administration of
Tamoxifen (75mg/kg body weight from 20mg/mL stock in corn oil) for 3-5days or
addition of (Z)-4-Hydroxytamoxifen to the cell culture medium at a concentration
of 0.3µM for 3-5days (Fig. 3.7 A). We optimized NRP2 knockout using different
concentrations of (Z)-4-HydroxyTamoxifen (Fig. 3.7 B). For future experiments,
0.3 µM concentration was used.
For

phagocytosis

assay,

bone marrow

derived

precursors

were

differentiated to M2 type macrophages with M-CSF for 7days. (Z)-4HydroxyTamoxifen was added to the cell culture medium at a concentration of
0.3µM every alternate day to knock out NRP2. Phagocytosis assay was performed
using pHrodo red E.coli bioparticles at an optimized concentration of 65µg/mL for
1.5hrs. As in case of human macrophages, NRP2 depleted murine BMDMs had
significantly less number of red visible puncta as compared to the control cells
where bright red phagocytic vesicles were observed (Fig. 3.8 A). Reduction in the
intensity of visible red fluorescence or number of bright red puncta indicated a

150

delay in the formation of acidic late phagosomes or phagolysosomes. Fig. 3.8 B
and C show the graphical representation of the result and knock out efficiency for
NRP2 respectively. NRP1 protein level remained unaffected following addition of
HydroxyTamoxifen (Fig. 3.8 C), indicating that NRP2 uniquely regulates
phagocytosis in macrophages.
Next, we wanted to test if NRP2 regulates uptake of phagocytic cargo in
mouse macrophages. For this, mouse bone marrow derived macrophages were
exposed to 65µg/mL pH insensitive E.coli bioparticles (red) for 1hr and uptake
efficiency monitored using confocal microscopy. We did not observe any significant
change in the uptake efficiency of macrophages following depletion of NRP2 (Fig.
3.9 A). Fig. 3.9 B and C show the graphical quantification of the result and the
depletion of NRP2 respectively.
Since maturation of nascent phagosomes is a prerequisite for efficient degradation
of engulfed cargo, next, we wanted to assess the effect of NRP2 depletion on
macrophages to clear bacterial load in vitro. For this, we conducted a phagocytic
pulse and chase experiment using pHrodo E.coli particles. A schematic diagram
explaining the experimental design is shown in Fig. 3.10 A. First, bone marrow
derived precursors were differentiated to M2 type macrophages as mentioned
earlier and NRP2 knocked out using (Z)-4-HydroxyTamoxifen. pHrodo red E.coli
bioparticles were added to the cells at a concentration of 65µg/mL for 15mins
(pulse). Excess bacteria that either not engulfed or remained loosely adherent
were removed by vigorous washing. Next, phagosomal maturation and
degradation and clearance of the bacteria from the cells was monitored at chase
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time points= 15mins, 45mins, 1.5hrs, 2hrs and 4hrs using confocal microscopy. In
the control macrophages, starting from 0min up to 2hrs chase and 4hrs, there was
a gradual increase in the intensity and number of red phagocytic vesicles indicating
their maturation and probably fusion with lysosomes. Interestingly, at 4hrs chase,
there was once again a decrease in the intensity of the visible red puncta,
suggesting degradation of the E.coli bioparticles (Fig. 3.10 B). Compared to the
control, NRP2 depleted macrophages had significantly less red intensity and less
number of visible red puncta upto 2hrs chase (Fig. 3.10 B). However, at 4hrs
chase, higher value of total cellular fluorescence in the NRP2 depleted cells in
comparison to the control macrophages indicated that phagosomes have probably
started maturing in the former, whereas the bioparticles are almost degraded at
that time in the control cells. This indicated that in control cells, phagosomes
containing E.coli bioparticles matured and fused with lysosomes and degraded the
phagocytic cargo, whereas in absence of NRP2, there was a delayed maturation
of phagosomes. Fig. 3.10 C and D respectively show the quantification of the
result and the knockout of NRP2. show the quantification of the result and the
knock out efficiency for NRP2 respectively. Overall, these results further highlight
the fact that NRP2 regulates phagocytic activity in macrophages. Cells infected
with bacteria try to degrade the pathogen by phagosomal maturation and their
subsequent lysosomal degradation. Based on our observations, it is thus
conceivable that NRP2 depletion will impair the ability of professional phagocytes
like macrophages to clear bacterial load following infection.
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Following uptake of E.coli bioparticles, TLR4 pathway is activated. One major
concern would be whether NRP2 selectively regulates TLR4 mediated phagosome
maturation and degradation or whether NRP2 can regulate phagosome maturation
or clearance of particles that recruit other pathways for their maturation and
clearance. To test this, we performed phagocytic pulse and chase experiment
using pHrodo red zymosan particles (that signal through TLR2 pathway) that are
are non-fluorescent at neutral pH, but start fluorescing in the phagosomes. For this
assay, murine BMDMs were cultured in the presence of M-CSF for 7days and
NRP2 depleted by the addition of 0.3µM (Z)-4-HydroxyTamoxifen into the culture.
Zymosan particles were added to the cells at a concentration of 65µg/mL for
15mins (pulse) following which the degradation was monitored at 6hrs, 10hrs,
14hrs and 18hrs (chase). A schematic diagram showing the experimental design
is provided in Fig. 3.11 A. After 15mins pulse, both the control and NRP2 depleted
macrophages showed similar number of zymosan containing phagosomes. At
6hrs, we observed a burst in the visible red fluorescence in both the control and
NRP2 depleted cells. This indicated the beginning of the maturation process.
However, at 10hrs, 14hrs and 18hrs, the control macrophages gradually matured
the phagosomes and efficiently degraded and cleared the zymosan particles, as
evident from the gradually decreasing intensity of visible red puncti structures of
the zymosan particles. Interestingly, NRP2 depleted macrophages significantly
delayed the degradation and clearance process. This was evident from the bright
red fluorescence and bigger size of the zymosan particles that persisted within the
cells, even at 18hrs, when the control cells had efficiently broken down individual
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particles (3.11 B). This data confirms our hypothesis that NRP2 regulates
phagocytic activity in macrophages and that its depletion significantly delays the
clearance bacteria and zymosan particles in vitro. Fig. 3.11 C and D respectively
show the graphical representation of the data and the knock out efficiency of
NRP2.
NRP2 inhibits early to late phagosome maturation in macrophages: Our
previous findings demonstrated that NRP2 regulates phagosomal maturation;
depletion of NRP2 either genetically or by siRNA approach resulted in delayed
maturation of E.coli containing phagosomes as well slowed down the clearance of
E.coli and zymosan bioparticles in macrophages. Nascent phagosome maturation
occurs in a step-wise manner through sequential recruitment of Rab5 to the early
phagosomes followed by Rab7 to the late phagosomes. To test the effect of NRP2
depletion on phagosome maturation, we next assessed the Rab5+ early
phagosomes and Rab7+ late phagosomes in NRP2 proficient and deficient cells.
In NRP2 depleted human macrophages, there was an increased accumulation of
Rab5+ early phagosomes and a concomitant decrease in the Rab7 + late
phagosomes (Fig. 3.12 A). Similar observations were made in mouse bone
marrow derived macrophages following NRP2 knock out (Fig. 3.13 A). Fig. 3.12
B and 3.13 B show the graphical representations for changes in early and late
phagosome maturation in human and mouse macrophages respectively. Fig. 3.12
C and 3.13 C respectively show that total cellular level of Rab5 and Rab7 remain
unaffected following NRP2 depletion in human and mouse macrophages
respectively. Knockdown or knockout for NRP2 is also shown in Fig. 3.12 C and
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3.13 C respectively. Overall, these data suggest that NRP2 regulates phagosome
maturation in macrophages. Depletion of NRP2 arrests maturing phagosomes in
the early stages and impairs their maturation to late phagososomes or
phagolysosomes.
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3.C. Summary and Discussion
Limited information is currently available about the function of NRP2 in
macrophages. Previous literature as well as our current data show NRP2 is not
expressed at a detectable level in freshly isolated human monocytes or bone
marrow derived precursor cells in mouse. Its expression is induced as the cells
differentiate towards mature macrophages, under M1 as well as M2 polarizing
conditions. This raises the important question what might be the potential function
of NRP2 in macrophages under normal physiological conditions (for example,
when macrophages predominantly exist as M-CSF induced M0/M2 type) or during
infections or inflammations (where GM-CSF is abundant, and macrophages mainly
polarize towards inflammatory M1 type) and whether it can be potentially targeted
for therapeutic purposes in the future. Our current study has answered some of
these questions. Earlier literature suggested that Neuropilins are required for
cellular locomotion. The directional migration of neuronal and endothelial cells is
regulated by Neuropilins and their co-receptors such as Plexins and VEGF
receptors. Interestingly, recent report also indicated the presence of a specific
polysialylated form of NRP2 in dendritic cells, which is required for their movement
to lymph nodes (36). Although NRP2 may potentially promote the migration,
studying other molecular pathways it can govern will be crucial for the
comprehensive understanding of its role in macrophages under normal as well as
pathological conditions.
We have previously reported a requirement for NRP2 in regulating
endocytic activities in cancer cells, where it favors the maturation of early to late
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endosome (242). Recognition of microbial pathogens and their phagocytosis is one
of the most important functions of macrophages for maintenance of homeostasis.
Following phagocytic engulfment, the internalized cargo initially remains in a
nascent phagosome which needs to acquire the microbicidal enzymes and acidify
its lumen for degradation of the cargo. For this maturation process, the
phagosomes need to undergo a tightly co-ordinated sequence of fusion and fission
with distinct compartments of the endocytic pathway (219, 220). Notably, the
phagocytosis and classical endocytosis pathways are similar in many aspects,
recruiting similar families of effector molecules for the maturation process. In their
report, Stamatos et al. reported a progressive loss of polysialylation in monocytes
and monocyte derived cells as they migrate to the pulmonary and peritoneal sites
of inflammation. Removal of polysia enhanced macrophage phagocytosis of
Klebsiella pneumoniae. However, it is not clear if this effect could be attributed to
NRP2 alone (61). In the current study, we reveal a novel role of NRP2 in regulating
phagocytosis in macrophages. NRP2 and NRP1 share structural homology and
may have redundant functions. Importantly, the regulation of phagocytic activity is
specific for NRP2 as NRP1 depletion did not influence the phagocytic activity of
macrophages. To further assess how NRP2 regulates the phagocytic activity of
macrophages, we tested whether NRP2 depletion leads to a defect in the uptake
of phagocytic cargo or delays the maturation of phagocytic vesicles after the cargo
has been engulfed. Our experiments with E.coli and zymosan particle conjugated
with pH sensitive as well as pH insensitive fluorescent dye showed that NRP2
depletion did not result in a significant decrease in the uptake of phagocytic cargo.
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However, it regulates the overall degradation and clearance of internalized cargo
by affecting the maturation of early phagosomes to late phagosomes or
phagolysosomes. We corroborated our observations in human peripheral blood
derived as well as mouse bone marrow derived macrophages. Therefore, NRP2
mediated phagosomal maturation is a global phenomenon in human as well as
mouse derived macrophages. A conclusive proof for the involvement of NRP2 in
regulating the maturation process of phagosomes came when we observed an
increase in Rab5+ early phagocytic vesicles with a concomitant decrease in Rab7+
late phagocytic vesicles, suggesting a defect during the exchange of Rab5 to Rab7
in phagosomes. Generation of Rab7+ phagosomes is crucial for phagosome
maturation, and is a prerequisite step for their fusion with lysosomes. Yet current
knowledge on the detailed steps of phagosome maturation is limited. It is believed
that the process begins with the recruitment of Dynamin (a large GTPase) which
then interacts with Vps34 (a PI3 Kinase) and helps recruit Rab5 to the phagosome
surface. Rab5, following its activation by Gapex-5 (Rab5 GEF), promotes Vps34
activation. Vps34 generates PtdIns(3)P on the phagosome surface where the
vacuolar fusion protein complex, Mon1A-Ccz1, is recruited. Mon1A-Ccz1 helps the
recruitment and activation of Rab7 in the membrane and also promotes the
recruitment of the homotypic fusion and vacuole protein sorting (HOPS) complex.
Rab7 then interacts with HOPS to facilitate the fusion of phagosome to lysosomes
(219-222)In. Since NRP2 depletion in macrophages resulted in more Rab5+ with
a simultaneous decrease in Rab7+ phagosomes, we concluded that the molecular
effectors downstream of Rab5 are regulated by the NRP2 axis. Further studies are
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warranted to identify and understand how NRP2 regulates the maturation defect
in macrophages.
It is important to understand the clinical implications of NRP2 regulated
phagocytosis in macrophages under different conditions. Since phagosome
maturation is prerequisite for successful pathogen killing, many microbes have
developed mechanisms to interfere with the phagosome maturation process. For
example, Mycobacterium tuberculosis arrests phagosome maturation by
preventing phagolysosomal fusion and the acquisition of lysosomal hydrolases
(248). Interestingly, besides its role in pathogen killing, a phagosome also serves
as a signaling platform for other related processes. The dynamics and molecular
changes that a phagosome undergoes during the maturation phase enable other
immune cells to respond to pathogen threat and maintain physiological
homeostasis. Acceleration in phagosome maturation enhances pathogen killing.
Whereas a delay in the maturation process preserves the antigenic peptides from
degradative enzymes in the acidic mature phagosomes or phagolysosomes and
favor presentation to T cells. This has been observed in case of macrophages and
dendritic cells; macrophages acidify their phagosomes faster than dendritic cells.
This enables the macrophages to rapidly degrade the internalized cargo whereas
slow maturation in dendritic cells preserves antigen epitopes for longer period of
time. Contrary to popular belief, it is now known that macrophages can also
potentially present antigens to T cells and activate the immune responses (249).
Additionally, MHC I complexes can be recruited to phagosomes through fusion of
phagosomes and endosomal recycling vesicles and become accessible to the
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antigenic peptides generated in the phagosomes (250). Next, they can be crosspresented to CD8+ T cells and activate robust immune reaction. Also,
macrophages may undergo apoptosis due to uncleared pathogen burden. Cellular
contents leaked out can then be taken up by dendritic cells, resulting in enhanced
T cell responses. This strategy is used for designing effective vaccines for various
pathogens. Based on our observations, NRP2 favors phagosome maturation and
hence aid in microbial clearance in macrophages. Although NRP2 depletion delays
phagosome maturation, it is too early to assume if it will favor antigen presentation
in macrophages and warrants further investigation. However, NRP2 may be useful
for development of better vaccines in the future.
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Fig. 3.1 Expression of NRP2 in M2 type macrophages. Immunoblot analyses
showing expression pattern of NRP2 in M2 type human and mouse bone marrow
derived macrophages. (A) Freshly isolated human monocytes were differentiated
to mature macrophages with M-CSF for 7days to generate resting or M2 type
macrophages. IL-4/10/13 was added on day7 for 24hrs to complete the M2 type
polarization. NRP2 was not detected in the monocytes but expression increased
as cells differentiated to mature macrophages. (B) Bone marrow cells isolated from
WT C57/BL6 mice were differentiated to resting or M2 type type macrophages
using M-CSF for 7days. Cells were exposed to IL-4/10/13 on day7 for 24hrs to
complete the M2 type polarization. NRP2 was not detected in freshly isolated the
bone marrow, but expression increased significantly during the differentiation to
macrophages.
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Fig. 3.2 Expression of NRP2 in M1 type macrophages. Immunoblot analyses
showing expression pattern of NRP2 in M1 type human and mouse bone marrow
derived macrophages. (A) Freshly isolated human monocytes were differentiated
to mature macrophages with GM-CSF for 7days to generate M1 type
macrophages. A combination of LPS+IFNγ was added on day7 for 24hrs to
complete the M1 type polarization. NRP2 was not detected in the monocytes but
expression increased as cells differentiated to mature macrophages. (B) Bone
marrow cells isolated from WT C57/BL6 mice were differentiated to M1 type
macrophages using GM-CSF for 7days. Cells were exposed to a combination of
LPS+ IFNγ on day7 for 24hrs to complete the M1 type polarization. NRP2 was not
detected in freshly isolated the bone marrow, but expression increased
significantly during the differentiation to macrophages.
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Fig. 3.3 NRP2 regulates phagosome maturation in macrophages without
affecting uptake in human macrophages. (A) Schematic diagram for
phagocytosis assay. (B) Phagocytosis assay for assessing the ability of M-CSF
treated human macrophages to uptake E.coli bioparticles and phagosome
maturation following NRP2 depletion by siRNA transfection. Cells were exposed
to pH insensitive (green) and pHrodo E.coli (red) bioparticles for 1.5hr and
analyzed microscopically. The first column shows the phagosome maturation (red
puncta) in the scr (upper) and siNRP2 treated (bottom) cells. The second column
shows the uptake efficiency (green puncta) in the scr (upper) and siNRP2 treated
(bottom) cells. The third column represents merged images to show that NRP2
primarily affects phagosome maturation, but not phagocytic uotake in
macrophages. Scale bars, 20µm. Single cell magnified within the boxed region to
show green or red E.coli particle. (C) Uptake efficiency was measured as green
cellular fluorescence whereas the intensity of red fluorescence was an indication
for phagosome maturation. Results were represented as bar graph, values as
mean ± SEM. Dapi was used for staining the nucleus in all the experiments.
Student t test was used for comparison between 2 groups of cells. *P < .05; **P <
.005; ***P < .0005. ns=not significant. (D) Immunoblot analysis shows knockdown
efficiency for NRP2 following electroporation.
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Fig. 3.4 NRP1 does not regulate phagosome maturation in macrophages. (A)
Phagocytosis assay to show NRP1 depletion does not have any effect on
phagosome maturation in macrophages. Human macrophages were cultured for
7days with M-CSF. Phagocytosis assay was conducted with pHrodo E.coli
bioparticles following NRP1 depletion by siRNA transfection. Phagosome
maturation was microscopically assessed from the intensity of red fluorescent
puncta. Insets show magnified image of cell containing bacteria. Scale bars 10µm.
Dapi was used for nuclear staining. (B) Phagosome maturation in the presence
and absence of NRP1 was quantified using Image J software and represented in
bar graph as mean ± SEM. Student t test was used for comparison between 2
groups of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western
blot shows knockdown of NRP1.
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Fig. 3.5 NRP2 regulates phagosome maturation in GM-CSF treated
macrophages. (A) Phagocytosis assay to assess the effect of NRP2 on
phagosome maturation in GM-CSF treated human macrophages. Human
monocytes were differentiated with GM-CSF for 7days and then exposed to
pHrodo E.coli bioparticles for 1.5hr. Cells were fixed and analyzed by confocal
microscopy. Phagosome maturation was scored from the intensity of red
fluorescent puncta. Individual cell is magnified in the inset. Scale bars 10µm. Dapi
was used for nuclear staining. (B) Bar graph showing quantification of phagosome
maturation in GM-CSF treated macrophages following NRP2 depletion. Values are
mean ± SEM. Student t test was used for comparison between 2 groups of cells.
*P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western blot shows
knockdown for NRP2.
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Fig. 3.6 NRP2 does not affect uptake of phagocytic cargo in GM-CSF treated
macrophages. (A) Phagocytosis assay to test the effect of NRP2 on phagocytic
uptake in GM-CSF treated human macrophages. Cells were exposed to pH
insensitive E.coli (red) for 1hr to allow the macrophages uptake the bacteria. Cells
were then fixed and analyzed by confocal microscopy. The intensity of red
fluorescent puncta was used as a measure for uptake efficiency of the cells.
Individual cells are magnified in the insets. Scale bars 10µm. (B) Uptake efficiency
of the macrophages was quantified using Image J software and represented as
bar graph. Values are mean ± SEM. Dapi was used for nuclear staining. Student
t test was used for comparison between 2 groups of cells. *P < .05; **P < .005;
***P < .0005. ns= non-significant. (C) Western Blot analysis showing knockdown
efficiency of NRP2 following siRNA transfection.
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Fig. 3.7 Scheme for transgenic mouse generation and knock out of NRP2
from macrophages. (A) CSF1R-iCre mouse is bred with NRP2f/f mouse to get
CSF1R-iCre;NRP2f/f mouse. NRP2 can be genetically knocked out from myeloid
cells following intraperitoneal administration of Tamoxifen or adding (Z)-4-Hydroxy
Tamoxifen into cell culture medium. (B) Western blot showing knock out of NRP2
from macrophages with different doses of Z)-4-Hydroxy Tamoxifen.
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Fig. 3.8 NRP2 regulates phagosome maturation in mouse macrophages. (A)
Bone marrow cells isolated from CSF1R-iCre;NRP2f/f were cultured for 7days with
M-CSF and NRP2 knocked out by adding (Z)-4-Hydroxy Tamoxifen to the culture
medium. Cells were challenged with 65 µg/mL of pHrodo E.coli bioparticles for
1.5hrs. Cells were fixed and phagosome maturation was analysed by confocal
microscopy. Dapi was used for nuclear staining. Inset shows magnified image of
individual cell. Scale bar, 10µm. (B) Phagosome maturation was quantified as total
cellular red fluorescence using Image J software and represented as bar graph.
Values are mean ± SEM. Student t test was used for comparison between 2 groups
of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant. (C) Western Blot
analysis showing depletion of NRP2.
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Fig. 3.9 NRP2 does not significantly affect the uptake of phagocytic cargo in
mouse macrophages. (A) Representative image for phagocytosis assay with
bone marrow derived macrophages isolated from NRP2fl/flCSF1R-iCre mice to
show the effect of NRP2 depletion on uptake phagocytic cargo. Cells were
challenged with pH insensitive E.coli bioparticles for 1hr and analyzed by Confocal
microscopy. Scale bars, 10µm. Magnified images within the inset show the
phagosomes containing E.coli bioparticle. Dapi was used for staining the nuclei.
(B) Quantification for uptake efficiency of macrophages (red puncta, measured as
total cellular fuorescence using Image J software) in the presence and absence of
NRP2, represented in bar graph as mean ± SEM. Student t test was used for
comparison between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns= nonsignificant. (C) Western Blot analysis showing depletion of NRP2.
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Fig. 3.10 Effect of NRP2 depletion on bacterial clearance in vitro by
macrophages. (A) Schematic diagram depicting bacterial clearance assay. (B)
Bone marrow cells isolated from NRP2fl/flCSF1R-iCre mice were differentiated to
macrophages for 7days using M-CSF. NRP2 was knocked out by the addition of
(Z)-4-Hydroxy Tamoxifen to the cell culture medium. Macrophages were
challenged with 65µg/mL pHrodo E.coli bioparticles for 15min (pulse time) and
then assessed for their ability to mature the phagosomes and degrade the bacteria.
Images were acquired at chase time = 0min, 15min, 45min, 90min, 120min and
240min using Confocal microscopy. Scale bars, 10 µm. Magnified images within
the inset show the phagosomes containing E.coli particles. Dapi was used for
nuclear staining. (C) Phagosome maturation and degradation of fluorescent
bioparticles was assessed as corrected total cell fluorescence using Image J
software. Cells were analyzed at times indicated at the graph abscissa and
represented in bar graphs as mean ± SEM. Student t test was used for comparison
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns= non-significant.
(D) Western blot for NRP2 depletion is shown.
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Fig. 3.11 NRP2 affects zymosan clearance in vitro by macrophages. (A)
Schematic diagram for zymosan clearance assay. (B) Bone marrow derived
macrophages isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7days with
M-CSF. Cells were challenged with pHrodo zymosan particles for 15mins (pulse
time) and then analyzed for phagosome maturation and degradation of zymosan
particles following knocking out NRP2. Images were acquired at chase time= 0hr,
6hr, 10hr, 14hr and 18hr. Scale bars, 10µm. Magnified images within the inset
show the phagosomes containing zymosan particles at each time point. Dapi was
used to detect the nucleus. (C) Phagosome maturation and degradation of
fluorescent zymosan particles was scored as corrected total cell fluorescence
using Image J software. Cells were analyzed at times indicated at the graph
abscissa and represented as bar graph. The values are mean ± SEM. Student t
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P
< .0005. ns= non-significant. (D) Western blot for NRP2 depletion is shown.
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Fig. 3.12 NRP2 inhibits phagosome maturation in human macrophages.
Depletion of NRP2 inhibits maturation of early to late phagosomes in
macrophages. (A) Immunostaining of early and late phagosomal maturation
markers in human macrophages following NRP2 depletion by siRNA transfection.
The upper panel represents early phagosome marker Rab5 (green). Scale bars
10µm. The lower panel shows representative images for the late phagosomal
marker Rab7 (green). Scale bars 20µm. Magnified images of individual cell is
shown in the inset for each condition. Dapi was used for staining the nucleus. (B)
Immunostaining data for Rab5 and Rab7 were quantified as cellular fluorescence
using Image J software and represented as bar graph. The upper panel shows
graphical representation of Rab5 in the presence and absence of NRP2. The lower
panel shows bar graph representing the change in Rab7 following NRP2 depletion.
All values are shown as mean ± SEM. Student t test was used for comparison
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. (C) Western Blot
analyses showing total cellular Rab5 and Rab7 and NRP2 depletion in whole cell
lysates from human macrophages following knockdown of NRP2.
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Fig. 3.13 NRP2 inhibits phagosome maturation in mouse macrophages. (A)
Immunostaining of early and late phagosomal maturation markers in mouse bone
marrow derived macrophages following NRP2 depletion by addition of (Z)-4Hydroxy Tamoxifen to cell culture media. The upper panel represents early
phagosome marker Rab5 (red). The lower panel shows representative images for
the late phagosomal marker Rab7 (red). Scale bars 10µm. The insets are
magnified image of individual cell for each condition. (E) Representative bar
graphs showing quantification of Rab5 and Rab7 using Image J software. The
upper panel is the bar graph for change in Rab5 following NRP2 depletion. The
lower panel is the graphical representation of change in Rab7 following NRP2
depletion. All values are shown as mean ± SEM. Dapi was used for staining the
nucleus in all the experiments. Student t test was used for comparison between 2
groups of cells. *P < .05; **P < .005; ***P < .0005. (C) Western Blot analyses¬¬
showing total cellular Rab5 and Rab7 in whole cell lysates from mouse
macrophages following knockdown of NRP2.
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Chapter IV

NRP2 is essential for clearance of dying cells and affects tumor
progression and anti-tumor immune responses
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4. NRP2 is essential for clearance of dying cells and affects tumor
progression and anti-tumor immune responses
4.A Background, Hypothesis and Objectives
Macrophages are important component of the immune system and
undertake a diverse array of functions like, clearance of cellular debris,
development, metabolic homeostasis, microbial clearance and angiogenesis.
Briefly, depending on the converging signals they are exposed to in the tissue
microenvironment, macrophages can exist in two states: exposure to danger
signals like bacteria or other infections skew them towards a classically activated
or M1 type; these cells are cytotoxic and produce pro-inflammatory cytokines,
ROS/NOS and robustly activate T cell responses. Post injury or infection, during
the resolution phase, macrophages are polarized to alternatively activated or M2
state where they produce angiogenic and tissue remodeling factors that augment
the wound healing process. Macrophages have been implicated in several clinical
conditions, like RA, diabetes, atherosclerosis and cancer. Macrophages comprise
a substantial population in the TME and have been causally associated with
distinct stages of disease progression, including EMT, angiogenesis, stem cell
niche maintenance, metastasis and therapy resistance. TAMs are complex cell
population; although gene expression profiles suggest TAMs closely represent the
conventional M2 type macrophages, they also express several genes
characteristic of the M1 type. NRPs have been implicated in TAMs. NRP1 is
expressed in TAMs and is important for their migration to the hypoxic core of the
tumor and their protumoral activities. Although NRP2 expression has been briefly
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reported in TAMs, knowledge about its function and the molecular pathways it
governs is lacking.
Despite several targeted immunotherapies currently being explored preclinically or in clinical trials, most cancers relapse, with more aggressive features.
One of the essential functions of TAMs in the TME is efferocytosis of apoptotic
cancer cells. The role of efferocytosis in cancer has remained elusive. However,
there are some evidences to indicate that the non-immunogenic properties of
efferocytosis that prevails under normal homeostasis conditions can be mimicked
by malignant cells to create an environment of immunosuppression in the TME. In
a tumor, the apoptotic index is high because of the rapid growth of cancer cells in
a

nutrient

limited

hostile

environment

or

because

of

treatment

with

chemotherapeutic drugs, and therefore mimic the environment of a non-resolving
wound. TAMs show increased efferocytosis, which also facilitates immune
tolerance by rendering the former more protumorigenic and increase the risk for
metastasis. A protumoral role of efferocytosis was also observed where tumor
progression was dampened following genetic depletion of the efferocytosis
receptor MerTK (Cook 2013). MerTK-/- CD11b+ cells isolated from the tumors
showed signs of immune activation. Intriguingly, intratumoral dendritic cells
engulfing tumor cells expressing the well-known ‘eat me’ signal, PtdSer remain
arrested in an immature state of differentiation, incapable of expressing the costimulatory molecules required for optimum T cell activation (Bondanza A JEM
2004), resulting in further immunosuppression in the TME. However, the molecules
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that couple the two pathways, viz. efferocytosis and immune modulation are still
not well known.
The goal of this study is to understand the role of NRP2 in TAMs and how
this may affect tumor progression. Pancreatic Ductal Adenocarcinoma (PDAC) is
one of the most lethal types of cancers with high incidence and low survival rates.
One of the hallmarks of PDAC is the dense desmoplastic reaction that acts as a
physical barrier to therapeutics. TAMs are abundantly present in PDAC and have
been causally associated with distinct stages of disease progression, metastasis,
therapy resistance and correlate with poor outcome. Despite extensive research,
therapeutic modalities are still not available to effectively treat PDAC. Our goal is
to identify the function of NRP2 in TAMs and how targeting this axis may affect
PDAC progression. Based on our previous reports and findings in Chapter 3, we
hypothesized that NRP2 regulates efferocytosis of apoptotic cells in TME and
maintains immune tolerance. In this chapter, we report that NRP2 is expressed in
macrophages in human and mouse PDAC. We also observed that NRP2 in
macrophages regulates efferocytosis and that its depletion significantly delays the
clearance of apoptotic cells in vitro. Further, we investigated the effect of NRP2
mediated apoptotic cell clearance on pancreatic cancer progression, using a
subcutaneous tumor model. NRP2 depletion resulted in a moderate decrease in
tumor progression. Interestingly, NRP2 does not have any role in TAM recruitment
into the tumors, however, NRP2 depletion significantly increased the intratumoral
infiltration of cytotoxic CD8+ T cells. This could be attributed to the delayed
clearance of apoptotic cancer cells in the TME and cross presentation to cytotoxic
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T lymphocytes. CD11b+ TAMs from the tumors were isolated and Next Generation
RNA-Sequencing analysis performed. Gene enrichment analysis showed
deregulation of several genes associated with phagosomal maturation, exocytosis
and recycling, immunosuppressive phenotype of TAMs as well as leucocyte
migration and activation processes. In brief, our data strongly support our
hypothesis that NRP2 regulates efferocytosis in macrophages and maintains
immune tolerance in TME. Further, NRP2 depletion results in delayed apoptotic
cell clearance and activates immune response against tumors and slows down
tumor progression. Overall, the study strongly suggests the importance for the
development of an adjuvant therapeutic strategy targeting the NRP2 axis in
macrophages and to reduce pancreatic cancer recurrence and metastasis.
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4.B Results
NRP2 is expressed in tumor associated macrophages (TAMs) in Pancreatic
Cancer.
We obtained pancreatic cancer tissue sections (from the Rapid Autopsy Program
at UNMC) from 10 PDAC patients who died with no history of treatment. We tested
the presence of NRP2 expressing TAMs by co-staining with anti NRP2 and CD68
(a pan macrophage marker) antibodies. We observed that most of the
macrophages in the tumor microenvironment were NRP2 positive (Fig. 4.1 A).
However, we also detected the presence of few NRP2 lo or NRP2- CD68+
macrophages in certain areas of 2 tissues. NRP2 expressing F4/80+ macrophages
were also detected in mouse pancreatic tumor tissue derived from KC mouse (Fig.
4.1 B). To generate TAMs in vitro, freshly isolated human monocytes or bone
marrow cells from WT mice were differentiated for 7days with CM from either
human PC Panc-1 or mouse PC UNKC-6141 and KPC cell lines respectively. In
both the conditions, NRP2 expression increased as the cells differentiated to TAMs
(Fig. 4.2 A-C). Overall, these results suggest that NRP2 is expressed by TAMs in
vivo as well in vitro.
NRP2 regulates phagosomal maturation in TAMs in vitro.
Our previous findings indicated that NRP2 regulates phagosomal maturation in
macrophages under M2 and M1 polarizing conditions, in human as well as in mice.
Next, we wanted to test if NRP2 regulates phagosomal maturation in TAMs. To
test this, we treated human monocytes with CM derived from Panc-1 cells for
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7days to differentiate them to TAMs in vitro. Phagocytosis assay was performed
with pH sensitive pHrodo E.coli particles and monitored under confocal
microscope. Compared to the control, NRP2 deficient macrophages showed
significantly lesser number of visible red puncta (Fig. 4.3 A). This suggests that
phagsosomes containing E.coli particles matured into either late phagosomes or
phagolysosomes and hence fluoresced bright red in the acidic vesicles. In contrast,
in NRP2 depleted macrophages, the phagosomes did not mature to acidic late
phagosomes or phagolysosomes and hence there was a significant decrease in
the visible fluorescence intensity of the bioparticles. Fig. 4.3 B and C show the
graphical representation of the result and the knockdown efficiency of NRP2 by
siRNA approach.
The assay was repeated using bone marrow derived macrophages isolated from
CSF-1R-iCRE;NRP2f/f mice. Cells were treated with CM derived from mouse
pancreatic cancer cell lines UNKC-6141 and KPC. (Z)-4-HydroxyTamoxifen was
added to cell culture medium to genetically delete NRP2 from the macrophages.
Phagosomal maturation was assessed using the pH dependant pHrodo E.coli
bioparticles. In the wild type cells, bright red puncta indicated phagosomal
maturation to acidic late phagosomes or phagolysosomes. There was a significant
reduction in the intensity as well number of bright red puncta in the NRP2 depleted
cells, indicating a delay in the maturation process (Fig. 4.3 D,G). Fig. 4.3 E,H and
F,I show the graphical representation of the results and the knock out efficiency of
NRP2.
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Overall, these results indicated that NRP2 regulates phagosomal maturation in
TAMs (human and mice) and that its depletion results in a significant delay in the
maturation process.
NRP2 in macrophages regulates efferocytosis of apoptotic cells.
Efferocytosis is a strictly orchestrated process where professional phagocytes,
such as macrophages recognize and engulf apoptotic cells and remove them from
the system in an immunologically silent manner. Maturation of nascent efferosome
containing apoptotic debris and subsequent degradation and clearance share
similarity with endosomal maturation and lysosomal fusion processes. Both the
pathways often hire similar family of effector molecules. Based on our previous
data that NRP2 regulates phagocytosis in macrophages, we wanted to investigate
its role in the clearance of dying cells by macrophages. To test this, a pulse and
chase experiment was performed where apoptosis was induced in Jurkat cells
using 50µM Etoposide and added to M-CSF treated mouse bone marrow derived
macrophages for 1hr (pulse). Non-engulfed or loosely bound cells were removed
by vigorous washing and the macrophages were then monitored for their ability to
degrade and clear the apoptotic cargo (chase). A schematic diagram showing the
experimental design is depicted in Fig. 4.4 A. Phagosomes containing engulfed
dead cells need to fuse with lysosomes to form phagolysosomes. During the
course of degradation, the latter gradually decrease in size and finally disappear.
Therefore, in the current experiment, ability of the macrophages to clear apoptotic
cells was assessed from the breakdown of the apoptotic cells and loss of
fluorescence (red). At 2hrs chase, there was significant increase in the red
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fluorescence in both the control (-H-Tam) as well as NRP2 KO cells (+H-Tam).
However, at 6hrs, there was a significant decrease in the red fluorescent intensity
and disappearance of apoptotic cells in the control macrophages, indicating the
apoptotic cells were broken down and degraded. In contrast, even after 12hrs,
NRP2 KO cells exhibited significant delay in the clearance of apoptotic cell cargo
(Fig. 4.4 B). This was apparent from larger size of the cargo and higher amount of
fluorescence that persisted in the cells even after 12hours. Fig. 4.4 C and D
respectively show the graphical representation of the result and the knock out
efficiency in macrophages.
The assay was repeated using peritoneal macrophages isolated from CSF-1RiCRE;NRP2f/f mice, and NRP2 knocked out by intraperitoneal administration of
Tamoxifen. Here also, in NRP2 deficient cells, there was a significant delay in the
degradation and clearance of apoptotic cells, compared to the NRP2 proficient
control macrophages (Fig. 4.5 A). Fig. 4.5 B and C respectively show the
graphical representation of the result and the knock out efficiency of NRP2 in
macrophages following Tamoxifen treatment.
Overall, these data suggest that NRP2 in macrophages regulates the clearance of
apoptotic cells and its depletion significantly increases the life time of the
efferosome (phagosome containing the apoptotic cargo) and delays their
clearance.
Efferocytosis of dying cancer cells in the TME is critical for the pro-tumoral
behavior of TAMs and contributes to cancer progression and metastasis, and
recurrence. Based on our previous data that NRP2 depletion affects the clearance
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of apoptotic cells, we further wanted to test if NRP2 regulates the clearance of
apopototic debris in TAMs. For this we repeated the efferocytosis pulse and chase
assay using bone marrow precursor cells isolated from the transgenic mouse
model (CSF-1R-iCre;NRP2f/f). Cells were differentiated to TAMs using CM from
the murine pancreatic cancer cell line UNKC-6141 for 7days.

(Z)-4-

HydroxyTamoxifen was added into the cell culture, every alternate day, for 7days,
to genetically knock out NRP2 from the macrophages. Prior to the assay, as
apoptosis was induced in Jurkat cells using Etoposide (as mentioned earlier).
Apoptotic Jurkat cells were added to the macrophages for 1hr in 1:10 ratio
(macrophage:Jurkat) and allowed the engulfment by macrophages. Following this,
non-engulfed or loosely bound cells were washed away and macrophages
monitored upto 12hrs for their ability to degrade and clear the apoptotic cells that
were engulfed. At the beginning of chase, there was no significant difference in the
intensity of red fluorescence in the control and NRP2 KO cells. At 2hr chase, the
intensity increased in the control and NRP2 KO macrophages, indicating the
efferosomes are maturing further and becoming acidic. However, at 6 and 12 hrs
of chase, there was a significant decrease in the intensity of red fluorescence as
well as size of the internalized apoptotic debris in the control macrophages. This
suggests efficient degradation and clearance of apoptotic cells in the control
macrophages. In contrast, the higher red fluorescent intensity and persistence of
bigger cellular debris in the NRP2 KO macrophages at the above-mentioned time
points indicated a delayed clearance of apoptotic cargo in the absence of NRP2
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(Fig. 4.6 A). Fig. 4.6 B and C show the graphical representation of the result and
genetic depletion of NRP2 in the macrophages respectively.
Overall, these results suggested that NRP2 regulates efferocytosis of apoptotic
cells in macrophages, during physiological homeostasis (M-CSF) as well as TAM
polarizing conditions (CM treatment). Further, NRP2 depletion in macrophages
significantly delayed the degradation and clearance of the apoptotic cells.
NRP2 in macrophages regulates tumor growth
(1) NRP2 regulates apoptotic cell clearance in TME and affects tumor growth:
Studies have shown that efferocytosis of apoptotic tumor cells by TAMs is an
important factor for maintenance of pro-tumorigenic activities of TAMs. Further,
blockade of efferocytosis relieves the tumor burden by activating anti-tumor
immune responses. However, the molecular effectors that couple the processes
of efferocytosis and immune silencing in phagocytes is still not clearly understood.
Based on our previous findings that NRP2 regulates efferocytosis of dying cells by
macrophages (Fig. 4.4-4.6), we sought to next test if NRP2 depletion in TAMs
affects tumor growth. For this, we used a subcutaneous pancreatic cancer
progression model. 2X106 UNKC-6141 murine pancreatic cancer cells were mixed
with Matrigel and subcutaneously implanted into the right flanks of animals. Once
tumors became palpable, animals were randomly divided into two groups (n=5
each): Control and test. In the test animals, tamoxifen was administered
intraperitoneally (75mg/kg body weight of the animals) to genetically deplete NRP2
from macrophages. Tumor growth was monitored for a period of 21days since day
of implantation. The overall design of the study is shown in Fig. 4.7. NRP2
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depletion in macrophages resulted in a decrease in tumor growth (Fig. 4.8 A,B).
The tumors were excised and weighed and tumor volume measured. The average
volume of the control tumors was 449.80 mm3 and that of test tumor was 215.15
mm3, indicating a 52.16% decrease in average tumor volume in the test group (Fig.
4.8 C). The average weight of the control and test tumors was 0.33 and 0.22 gm
respectively, suggesting a 33.33% decrease in the average weight of the test
tumors in comparison the control (Fig. 4.8 D). Importantly, weight of the mice did
not alter significantly following Tamoxifen administration (Fig. 4.8 F). Fig. 4.8 E
shows immunoblot for knock out efficiency of NRP2 from bone marrow
macrophages following Tamoxifen administration intraperitoneally in the control
and test animals. One concern was whether intraperitoneal administration of NRP2
could knock out NRP2 from macrophages inside the tumor. RNA-Seq analysis
(Fig. 4.11 H) revealed a knock-out of NRP2 from the TAMs isolated from the
tumors. Thus, it is conceivable that the effect on tumor progression and TME arises
as a consequence of myeloid specific NRP2 depletion.
Interestingly, histological analysis of the tumor sections revealed a significant
increase in the percentage of average necrotic area in the test tumors (32%)
compared to the control (19.2%) (Fig. 4.9 A and B). This could be attributable to
the impaired clearance of dying tumor cells by NRP2 deficient TAMs. Given that
NRP2 has a known role in migration, we next tested if NRP2 depletion affected the
migration of macrophages into the TME, using F4/80 as a macrophage marker.
We did not observe any significant difference in the number of macrophages in the
control and test tumors (Fig. 4.10 A and B). We did not observe any significant
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difference in the CD8+ T cell infiltration or CD31+ vessel density in control versus
test tumors (Fig. 4.10 C-F).
(2) NRP2 in macrophages affects tumor growth and suppresses anti-tumor
immune responses: We repeated our subcutaneous tumor progression experiment
(n=5). This time, we subcutaneously implanted 500,000 UNKC-6141 cells mixed
with Matrigel into the right flank of CSF-1R-iCRE;NRP2f/f mice. Once the tumors
became palpable, tamoxifen was administered as described earlier and tumor
progression monitored for a period of 25days. We observed a decrease in tumor
size in the test tumors where NRP2 was genetically knocked out from TAMs (Fig.
4.11 A). Tumor growth was regularly monitored, and tumor volume calculated
using the formula v=0.5(LXBXB) where L=longest diameter and B=widest diameter
of the tumor. Fig. 4.11 B shows the line plot for tumor growth in control and test
animals over the indicated time point. Importantly, NRP2 depletion in macrophages
showed a cytostatic effect on tumor growth after day 17 and the growth curve for
test tumors reached a plateau after this time. In contrast, there was a steady
increase in the average volume of the control tumors. The excised tumors were
weighed and measured. The average volume of the control tumors was 325 mm 3
and that of test tumors was 132 mm3, indicating there was a 59.38% reduction in
average tumor volume following NRP2 depletion in TAMs (Fig. 4.11 C). The
average weight of the control tumors was 0.42 gm compared to 0.21 gm in the test
group, suggesting a 50% decrease in tumor weight following NRP2 depletion (Fig.
4.11 D). Importantly, TUNEL staining of the tumor sections revealed an increase
in the necrotic area in the test tumors (Fig. 4.11E). We believe NRP2 depletion in
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macrophages resulted in inefficient clearance of apoptotic tumor cells, which
eventually underwent secondary necrosis and spilled their nuclear and cellular
components. Fig. 4.11 G shows immunoblot for knock out efficiency of NRP2 in
bone marrow derived macrophages in the test mice, following Tamoxifen
administration. NRP2 is well known for its role in migration. We questioned if the
increase in necrotic foci in test tumors were a consequence of impaired recruitment
of macrophages to the site of the tumor or their delayed clearance stemming from
downstream phagosomal maturation defect in absence of NRP2. Staining with anti
F4/80 antibody revealed no notable change in macrophage migration and
recruitment in control and test tumors (Fig. 4.12 A and B). This indicates that
NRP2 probably is dispensable for the migration of macrophages to the site of
tumor. Also, it suggests that recruited TAMs display dampened efferocytic ability
in absence of NRP2 which resulted in increased accumulation of apoptotic or
necrotic cells in the TME. Staining with anti CD31 antibody revealed no significant
difference in average vessel density between the control and test tumors,
suggesting there intratumoral angiogenesis was unaffected following NRP2
depletion in TAMs (Fig. 4.12 C and D). However, further tests are required to affirm
if there is any difference in the level of vessel normalization in control versus test
tumors. Expression of alpha smooth muscle actin (α SMA) has been shown to
correlate with poor prognosis in many tumors. However, staining with anti- α SMA
showed no significant difference between control and test tumors (Fig. 4.14 E and
F). One drawback of the current work is that being a subcutaneous tumor
progression model, it does not entirely mimic the natural tissue architecture or
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tumor growth conditions as in an orthotopic model. Also, the presence of skin
fibroblasts is unavoidable in the current model.
One of the major contributing factors to tumor growth is suppression of effector
and cytotoxic T cell activation. Tumor cells as well as other immune and stromal
cells in the TME secrete a wide array of chemokines, cytokines and other factors
which interfere with recruitment and activation of effector and cytotoxic T cells.
Interestingly, we observed a ~3-fold increase in intratumoral infiltration of cytotoxic
CD8+ T cells in the test tumors following NRP2 depletion. This data suggests
NRP2 in macrophages suppresses anti-tumor immune response and that its
depletion in macrophages results in enhanced recruitment of CD8+ T cells into the
tumor (Fig. 4.13 A and B). Staining with anti-Granzyme B (GrB) antibody revealed
a mild increase in the average number of GrB+ cells in 3 out of 5 test tumors,
however, this did not reach statistical significance (Fig. 4.13 C and D).
Interestingly, staining with anti CD4 revealed an infiltration along the periphery in
3 of the 5 test tumors in comparison to control tumors (Fig. 4.13 E and F); however,
this did not attain statistical significance.
Taken together, the results indicated a role for NRP2 in regulating tumor growth
and immune response against the tumor, without affecting macrophage
recruitment and intratumoral angiogenesis.
Transcriptome analysis of TAMs using next generation RNA-Sequencing.
To better understand how NRP2 in TAMs mechanistically regulates tumor growth
and T cell responses, we monitored the growth of subcutaneous PC tumor (n=3)
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for 15days, following which the animals were sacrificed, and tumors excised. Fig.
4.14A summarizes the experimental design. The average volume of the control
tumors was 324.8mm3 whereas that of the test tumors was 129.8mm3, indicating
a 60% decrease in the average volume of the test tumors (Fig. 4.14 B). The
average weight of the control and test tumors were 0.27gm and 0.166gm
respectively, indicating a decrease in the average weight of the test tumors by
38.51% (Fig. 4.14 C). CD11b+ TAMs isolated using magnetic beads. RNA was
isolated and pooled from n=3 animals in either control or test group. This was done
in order to obtain sufficient amount of RNA. RNA-Sequencing was performed as
mentioned in the methods section. A paired end read 2x75bp sequencing run of
RNA libraries were performed using the Illumina NextSeq 500 instrument. For
analysis, raw reads were de-multiplexed by barcode and output into FASTQ
format. Cutadapt was used to filter out adapter sequences and low-quality bases.
Filtered sequence reads were aligned to mouse reference genome mm10 using
HISAT2 aligner. Reads mapping to exon regions as defined by Ensembl gene
annotations were counted using FeatureCounts. We analyzed our data on the
basis of log fold change value. We considered transcripts which were differentially
expressed more than 2 fold (log2 fold change 1) in either control or test sample and
eliminated all transcripts with zero counts in either sample to maintain stringency.
After applying the cutoff, we had 3616 genes whose expression was altered by
atleast 2 fold following NRP2 depletion in macrophages. Out of these, 1567 genes
were differentially up-regulated whereas 2049 genes were downregulated
following NRP2 depletion (Fig. 4.14 D). These differentially expressed transcripts
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were uploaded to the IPA database to identify the major enriched cellular and
molecular functions in the absence of NRP2 in macrophages. We observed that
pathways related to immune responses as well as phagosome formation were
most significantly affected. The top 20 significantly pathways from IPA analysis
included communication between innate and adaptive immune cells, altered T cell
and B cell signaling, Th1 and Th2 activation pathway, Primary immunodeficiency
signaling, Th1 pathway, autoimmune thyroid disease signaling and phagosome
formation. Among other significantly altered pathways, we detected leucocyte
extravasation signaling, inhibition of matrix metalloproteases, role of cytokines in
mediating communication between immune cells, micropinocytosis signaling and
caveolar mediated endocytosis. Representative IPA pathways related to immune
responses and phagocytosis pathways with gene enrichment and statistical
significance is shown in Fig. 4.15 A.
To gain a better understanding for the functional processes affected by NRP2
depletion, we determined the biological process gene ontological classification for
each altered transcript using the DAVID and KEGG databases in combination with
extensive review of published literature. As observed with IPA analysis, with
DAVID,

we

observed

that

genes

related

to

immune

response

and

leucocyte/lymphocyte regulation were abundantly regulated. Also, clusters
comprising of genes functionally annotated to cytokine and chemokine signaling,
wounding response, endocytosis or vesicle mediated transport, microtubule
organization were enriched. Since our in vitro and in vivo data indicated a role of
NRP2 in the regulation of phagocytosis and efferocytosis as well as activation of
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CTL response in tumors, we selected representative annotation clusters enriched
for these functions. Genes from IPA, KEGG and DAVID clusters for T cell related
immune response, cytokine/chemokine signaling pathways and phagocytosis and
phagosome maturation were compiled and a unique gene list was created for each
function and compared with our dataset of 3616 differentially regulated genes. Fig.
4.15 B and C show representative functional annotation clusters for differentially
expressed genes in TAMs following NRP2 depletion.
NRP2 depletion deregulates phagocytosis and endocytosis related
pathways in TAMs
For assessing the effect of NRP2 depletion in the phagocytic activity of TAMs, we
carefully analyzed the expression pattern of genes detected by IPA (canonical
pathway: phagosome formation) and DAVID (annotation clusters 91 and 92) as
well as additional genes from our dataset. We detected altered expression of
several genes belonging to the Rab family of proteins. Genes like Rab15, Rab3a,
Rab6B, Rab34, Rab39, RabL3, Rab36, Rab13, Rab27B were affected following
NRP2 depletion in macrophages. Several other genes associated with
phagocytosis or phagosome/endosome maturation like, Tubb4a, TubA8, Rufy4a,
Zap70 were deregulated. Interestingly, we detected elevated expression of genes
encoding Rab7 GTPase activating proteins, TBC domain 1 member 15 and TBC
domain 1 member 2. Several Guanine Nucleotide Exchange Factors, like Rho GEF
15, Cdc42 GEF 9, FYVE Rho GEF, RhoD among others were also differentially
expressed. These indicate that NRP2 is important for endocytosis and
phagocytosis pathways in macrophages. Interestingly, we found one mircroRNA,
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mir-24 to be significantly upregulated in NRP2 depleted TAMs. This mir has been
reported to attenuate phagocytosis as well modulate inflammatory cytokines in
macrophages and DCs (251). Interestingly, several molecules like Elmo-3, Alox15,
CD4, IgM, CD209 (DC-SIGN), OC-STAMP involved in phagocytic uptake or
clearance of apoptotic cells were downregulated, although other molecules like
Stabilin1, Marco that too can bind to and are important for the clearance of
apoptotic cells were upregulated. CX3CL1 secreted from apoptotic cells bind to
CX3CR1 expressed on macrophages and induce chemotaxis for efficient
clearance of the apoptotic cells. We observed a significant downregulation in the
expression of CX3CR1 in NRP2 depleted TAMs. Downregulation of phagocytic
cargo-uptake related receptors and molecules may be either a secondary effect of
impairment of phagosome maturation following NRP2 depletion, as it has already
been reported that a defect in phagosome maturation can dampen the
internalization process. Also, it may be possible that downregulation of the
efferocytosis related receptors may be a tumor microenvironment specific effect.
Known representative genes whose expression altered following NRP2 depletion
in macrophages are shown in Fig. 4.16 A. In conclusion, the gene expression data
indicated the potential involvement of genes present in macrophages, which are
important for NRP2-mediated efficient clearance of apoptotic cells. Intriguingly,
phagosomes containing different cargo often recruit functionally similar but distinct
molecules for phagosome maturation or phagolysosome biogenesis and often
follow different maturation kinetics. The exact molecular mechanism of how these
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NRP2-regulated genes involve in the phagosome maturation is currently unknown
and merits further investigation.
NRP2

depletion

alters

genes

in

TAMs

related

to

inflammation,

immunosuppression, tissue remodeling, chemokines and cytokines
Our analysis from IPA software, DAVID and KEGG pathways revealed many of
the immunosuppressive genes and those associated with EMT and metastasis,
like, IL-4, IL-10, TGF-α, IL-21R, IL-33, IL-34, IL-23a, IL-1β were downregulated in
TAMs following NRP2 depletion. Genes associated with ECM remodeling like
MMP9, MMP13, MMP11, MMP23, MMP25 were also downregulated. Among the
inflammatory genes, we observed a mixed signature. There was an upregulation
of IFN-β1, IL-12a, Gr-K, Gr-F, IL-15Ra, IL-1RL2, whereas IFN-γ, IL-12b, Gr-A, GrB, Gr-C, IL23a were downregulated among others. It is known that efferocytosis
upregulates the immunosuppressive genes in macrophages. Inefficient clearance
of apoptotic cells reduces the immunosuppressive genes and induces the
expression of inflammatory genes. For instance, cytosolic DNA from dead cells
can trigger the expression of IFNβ. IL-12a expression is induced under
inflammatory conditions and due to its low abundance, its induction is considered
to be the rate limiting step in the production of biologically active IL-12. Gr-K has
been reported to be upregulated in sepsis and acute airway inflammation, and
plays a role in inflammatory responses in macrophages. Further, it can get
activated in conditions where Gr-A activity is compromised. Additionally, Gr-K and
Gr-F both have cytolytic potential and can be tumoricidal. These observations are
in support of our hypothesis and indicate that NRP2 depletion affects efferocytosis.

206

This in turn downregulates the expression of immunosuppressive genes and
upregulates the inflammatory genes. IL-12b subunit can homodimerize and bind
to IL-12 receptor but does not mediate signaling and it therefore a strong
antagonist for biologically active IL-12. We speculate the decrease in IL-12b
transcript may be an effort to avoid formation of the antagonist (IL-12b)2
homodimer. IL-23 (heterodimer of IL-23a and IL-12b) can also promote tumor
progression by suppressing T and NK cells effector functions (252). Therefore,
downregulation of IL-12a transcript may possibly be an effort to decrease the
biologically active form of IL-23. Also, mir-24 that was significantly upregulated in
NRP2 depleted TAMs has been reported to affect the expression of TNF-α, IL-6
and IL-12b at the transcription level (251). These indicate an effect of NRP2
depletion on dampening phagocytosis and a complex interplay among various
molecules to affect the phenotype TAMs.
Interestingly, several genes associated with the maintenance of stem cell niche
and metastasis like MUC1, WISP1, Angptl2, CXCR4 were downregulated in NRP2
depleted TAMs. TAMs are considered one of the important players in intratumoral
vasculature. Interestingly, following NRP2 depletion, some of the genes
associated with the endothelial cell like behavior, like, SOX7, Angptl2, Angptl7
were downregulated. Angptl2 can regulate metastasis through CXCR4 signaling
pathway and MMP13 mediated degradation of the collagen. It also has direct proangiogenic activity. However, we did not observe any change in average vessel
density in tumors following NRP2 depletion in macrophages. We also analyzed the
chemokine gene profile in control versus test tumors. We detected that
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chemokines like CXCL13, CCL25 that have been reported to promote migration of
DC, activated T cells were upregulated in NRP2 depleted TAMs. Expression of
CCL22 (known for attracting Th2, Treg or Th17 cells) and CXCL12 (may promote
TAM differentiation) were downregulated in NRP2 deficient TAMs.
In brief, these indicate that in NRP2 depleted condition, TAMs suppress
immunosuppressive genes and upregulates several inflammatory pathways.
Known representative genes pertaining to macrophage polarization are shown in
Fig. 4.16 B.
Effect of NRP2 depletion in macrophages on T cells
We observed that NRP2 depletion affects the clearance of apoptotic cells in
macrophages as well as TAMs in vitro. Our in vivo observations suggested NRP2
depletion in macrophages resulted in an increased infiltration of cytotoxic CD8 +
and CD4+ T cells (in 3 out of 5 tumors) into the tumor. We analyzed the
transcriptome data in our quest to search for changes in expression of genes that
could explain the increased infiltration of activated T cells into the tumors following
NRP2 depletion in macrophages. As mentioned earlier, NRP2 depletion affected
the expression pattern of several immunosuppressive genes, like IL-4, IL-10, TGFα, IL-21R, IL-33, IL-34. IL-4, IL-10, TGF-α can potentially induce the formation of
Treg cells. TGF-α can also interfere with T cell activation, proliferation and
migration to the tumor tissue. Also, IL-12α and IFN-β1 were upregulated in the
NRP2 depleted TAMs which can potentially activate T cell responses. Additionally,
our analysis revealed an increased expression of CXCL13 and CCL25 that can
recruit effector T cells whereas molecules like CCL22, Sema-7A and Sema-3E that
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can either recruit Treg cells or interfere with T cell migration or their activation were
downregulated in the NRP2 deficient TAMs. Additionally, molecules like Foxp3,
PDL2, TIGIT that can either induce immunosuppression in macrophages and
indirectly dampen T cell response or provide co-inhibitory signal to T cells were
downregulated following NRP2 depletion (253-255). Therefore, we believe that
NRP2 deletion in macrophages affects the expression of several immune response
genes that act in consort and facilitates the infiltration of cytotoxic CD8 + and CD4+
T cells. Further, we observed inefficient clearance of dead cells in tumors where
NRP2 was depleted from macrophages. Apoptotic cells if not removed, form
secondary necrosis and the nuclear and cellular contents leak outside as a result
of loss of membrane integrity. This was observed from TUNEL staining where we
found an increase in the number of necrotic zones in the tumors following NRP2
depletion from macrophages. The leaked cellular contents from cells undergoing
secondary necrosis can also potentially attract CD8+ T cells. Overall, we believe
that the components of the necrotic cells and altered expression of several
cytokines, chemokines and other signaling molecules following NRP2 depletion in
macrophages act synergistically and result in robust infiltration of CD8+ T cells in
to the tumors. Known representative genes that can potentially work in consort for
T cell activation are shown in Fig. 4.16 B.
Summary and Discussions
Apoptosis is a highly orchestrated cell death modality and clearance of
apoptotic cells by efferocytosis for removing aged or damaged cells in an
immunologically silent manner is essential for maintenance of physiological
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homeostasis. Impaired efferocytosis results in secondary necrosis and leakage of
necrotic cell contents into the tissue milieu and can aberrantly activate adaptive
immune responses. Efficient efferocytosis of cells infected with microbes (e.g.
influenza virus, Mycobacterium tuberculosis) results in pathogen destruction. Cells
infected with the pathogen can be taken up and degraded simultaneously by
macrophages (230). Additionally, macrophages also efficiently remove the
apoptotic or infected neutrophils that invade the site of injury or infection (256).
This process of cleaning up further evokes non-inflammatory cascades, such as,
production of IL-10, TGF-β in engulfing cells and polarizes the efferocytic
macrophages towards an immunosuppressive phenotype and is important for
resolution of inflammation and wound healing post infection or injury. Despite
extensive research over the past decade, knowledge about the molecular
pathways that link the processes of efferocytosis and immune suppression in
macrophages is limited. Our data reveal a novel role of NRP2 in regulating
efferocytosis in macrophages. We provide evidence to suggest that NRP2
promotes rapid and efficient clearance of engulfed apoptotic cells and its absence
significantly delays the overall clearance process. NRP2 is a cell surface receptor.
Hence, the question arises, does it interact with any of the ‘find me’ or ‘eat me’
molecules expressed on the surface of dying cells and affect the uptake process.
However, after initial incubation with apoptotic cells (0 min chase), our data
suggest that NRP2 does not affect the uptake process. Of note, NRP2 depletion
does not block the clearance of apoptotic cellular debris, but delays the overall
clearance process. Macrophages were monitored for upto 12 hrs for their ability to
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clear engulfed apoptotic debris in the presence and absence of NRP2. We
observed that in absence of NRP2, the degradation and clearance of apoptotic
cells was significantly delayed in the macrophages. This suggested that NRP2
regulates the maturation of phagosomes containing apoptotic cells in
macrophages. Our earlier data suggested that depletion of NRP2 resulted in an
accumulation of Rab5+ vesicles and a concomitant decrease in the number of
Rab7+ positive vesicles in the cells. Although it is now accepted that the processes
of endocytosis, phagocytosis and efferocytosis share similarities, each of these
processes are distinct and may recruit unique effector molecules at each stage.
Therefore, it is possible that NRP2 may interact with different effector molecule for
efferosome maturation and apoptotic cell clearance. Further studies are required
to investigate the molecular players that interact with NRP2 in apoptotic cell
clearance process. Another important question is whether efferosome maturation
and autophagy share a common mechanism. Recently, LC3 associated
phagocytosis (LAP) has been proposed as an alternative pathway for clearance of
apoptotic cells. We have previously reported a role for NRP2 in regulating
autophagy in cancer cells. Whether NRP2 regulates efferocytosis through LAP
needs further studies. Also, it is important to know if LC3 overlaps with Rab5 or
Rab7 in phagosomes containing apoptotic cells and interact with each other in the
presence and absence of NRP2.
It is important to estimate the implications of our findings. Efficient
efferocytosis and clearance of engulfed apoptotic cells are indispensable for the
maintenance of cellular homeostasis. As mentioned earlier, defective efferocytosis
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gives rise to pathological conditions like autoimmunity, systemic lupus
erythematosus (SLE), atherosclerosis among others. Interestingly, delayed
phagosome maturation arising either as a consequence of impaired fusion with
lysosome or failure in the acquisition of degradative enzymes helps preserve
antigenic epitopes and favors cross presentation. Since we observed that NRP2
depletion significantly delays apoptotic cell clearance, it is plausible that its
depletion or deficiency will increase the chance for cross presenting the apoptotic
cell derived peptide and activate CD8+ T cell responses and aggravate
inflammation related clinical disorders.
Phagocytosis of cancer cells by APCs in the TME is a contentious topic.
Cancer cells over-express ‘don’t eat me’ molecules to evade APC mediated uptake
and presentation to the T cells. Additionally, TAMs have recently been shown to
express PD-1 that negatively correlates with their phagocytic capacity of tumor
cells. Further, blocking of interaction between PD-1 and PD-L1 increased
phagocytosis and reduced tumor growth in a macrophage dependent manner.
However, TAM mediated phagocytosis of tumor cells can act as a double-edged
sword in tumor progression and metastasis. Most of the patients undergoing
treatment for cancer, including Pancreatic Cancer receive either chemotherapy
(CT) (such as Gemcitabine) or radiotherapy (RT). These conventional treatment
modalities interact in a complex way with the dense stroma that is the hallmark
feature of PC and can be detrimental. There are now evidences to show that there
is increased infiltration of myeloid cells in to the TME following CT or RT that limits
the anti-neoplastic efficacy and are associated with tumor protective function and
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disease recurrence with more aggressive features. This can be attributed to
increased apoptotic index in the TME following therapy and increased efferocytosis
by the freshly recruited TAMs. This triggers anti-inflammatory cascades and elicit
a

misdirected

tissue

repair

response,

eventually

resulting

in

further

immunosuppression and tumor relapse. Blocking efferocytosis holds promise by
increasing anti-tumor immune response. For example, Bavituximab, a PS targeting
antibody is currently being assessed in multiple clinical trials and has shown
considerable

benefit

(https://clinicaltrials.gov/ct2/show/NCT03139916)(

http://www.peregrineinc.com/clinical-trials.html)

(240,

257).

We

previously

observed a role for NRP2 in regulating efferocytosis of apoptotic cells. Previous
studies have briefly reported the presence of NRP2 expressing macrophages in
lung carcinoma (human) and mouse tumor. In the current study, we detected
NRP2 expressing TAMs in primary lesions of PDAC patients as well as in mouse
PC tissue. We further observed that treatment of macrophages with conditioned
media from human and mouse PC cell lines exhibited phagosomal maturation
defect when challenged with E.coli in absence of NRP2, indicating a requirement
for NRP2 in phagocytosis in TAMs. Next, in our assessment of the ability of TAMs
to efficiently clear apoptotic debris in presence and absence of NRP2, we observed
that in comparison to the WT TAMs, NRP2 depleted macrophages failed to
completely degrade and clear apoptotic cells even after 12 hrs. Interestingly, the
effect was more robust in the presence of tumor cell derived conditioned media
compared to MCSF treatment. Of note, we did not notice any uptake defect in
NRP2 deficient TAMs. These results indicated that NRP2 is important for
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phagosome maturation in TAMs and regulates the clearance of apoptotic cells by
TAMs.
To test how delayed clearance of apoptotic tumor cells may affect PC growth,
we used a subcutaneous tumor progression model. Genetic ablation of NRP2 in
TAMs reduced tumor growth. However, we did not notice any changes in
intratumoral macrophages following NRP2 depletion, indicating NRP2 is
dispensable for TAM recruitment. Interestingly, when we implanted 2X10 6 cells,
we observed a significant increase in the percentage of necrotic area in tumors
where NRP2 was depleted in TAMs. This could be attributed to a rapid growth of
the tumor cells and high apoptotic index and impaired efferocytosis by NRP2
depleted TAMs and secondary necrosis resulting from the dying tumor cells.
Macrophages are the major source of intratumoral angiogenesis. However, NRP2
depletion in TAMs did not significantly affect intratumoral angiogenesis. Also, we
did not see any increase in CD8+ T cells infiltration in test tumors. We do not know
if this was because the time period we monitored the tumor progression was not
optimal for noticing a change in CD8+ T cell infiltration.
Interestingly, when we repeated the experiment using 500,000 cells and
monitored tumor growth, we once again observed a decrease in tumor growth rate
following NRP2 depletion in TAMs. More importantly, growth curve for test group
reached a plateau after day 17, indicating a cytostatic effect of NRP2 deletion in
macrophages. Hence, it is conceivable that NRP2 depletion in macrophages can
potentially harness tumor growth. TUNEL staining revealed an increased number
of necrotic foci in tumors following NRP2 depletion in macrophages. We believe
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the increase in the number of necrotic foci resulted from inefficient clearance of
apoptotic tumor cells and eventual secondary necrosis that led to leakage of
nuclear and cellular contents. NRP2 depletion did not affect macrophage
recruitment to the site of the tumor, hence we conclude that the increase in the
necrotic area is a consequence of inefficient apoptotic cell clearance in the TME.
It is known that accumulation of apoptotic cells that eventually result in leakage of
cellular contents due to secondary necrosis can potentially activate CD8+ T cells.
Indeed, NRP2 depletion in TAMs significantly increased the infiltration of cytotoxic
CD8+ T cells in test tumors (~3 fold). Interestingly, we did not observe any change
any intratumoral angiogenesis following NRP2 depletion in TAMs. Stromal
desmoplasia is a hallmark feature of PC and it has been shown to act as a physical
barrier to therapy efficacy. High α-SMA has been associated with worse prognosis
in PC. Although we did not observe any notable change in the α-SMA in test
tumors, one must note that the subcutaneous tumor microenvironment does not
mimic that of the natural PDAC (as found in orthotopic tumors). Further, pericytes
often express α-SMA that can interfere with the conclusion.
We have concluded from our earlier experiments that NRP2 regulates the
clearance of E.coli, zymosan and apoptotic cells by modulating the phagosome
maturation process. Whole transcriptome sequencing of TAMs in conjunction with
pathway analysis revealed an altered expression of several Rab family proteins.
For instance, Rab15, Rab3a, Rab6B, Rab34, Rab39, RabL3, Rab36, Rab13,
Rab27B were affected following NRP2 depletion in macrophages. Some of these
like, Rab36, Rab13, Rab27B have potent roles in retrograde transport, recycling
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or exocytosis pathways. Several other genes associated with phagocytosis or
phagosome/endosome maturation like, Tubb4a, TubA8, Rufy4a, Zap70 were
deregulated suggesting a phagosomal maturation defect. Proteins like Rufy have
a C-terminal FYVE domain for interaction with PI3P on the early phagosomes or
endosomes and can interact with GTP-bound Rab5 and hence maybe a potential
candidate for regulating the recruitment of downstream effector molecules for
phagosome maturation. Interestingly, we detected elevated expression of genes
encoding Rab7 GTPase activating proteins, TBC domain 1 member 15 and TBC
domain 1 member 2. Increased expression of these proteins can potentially
inactivate GTP-bound Rab7 recruited to the phagosome membrane and interfere
with phagosomal maturation. Several Guanine Nucleotide Exchange Factors, that
may be involved in actin cytoskeleton reorganization, like Rho GEF 15, Cdc42 GEF
9, FYVE Rho GEF, RhoD among others were also differentially expressed. These
indicate that NRP2 is important for endocytosis and phagocytosis pathways in
macrophages. Interestingly, several molecules like Elmo-3, Alox15, CD4, IgM,
CD209 (DC-SIGN), OC-STAMP involved in either phagocytosis or clearance of
apoptotic cells were downregulated, although Stabilin1, Marco, two of the
molecules involved in binding and recognizing apoptotic cells, were upregulated.
Downregulation of efferocytosis related receptors and molecules may be either a
secondary effect of impairment of phagosome maturation following NRP2
depletion. It has already been reported that a defect in phagosome maturation can
dampen the internalization process, although we did not observe any
internalization defect in NRP2 depleted macrophages in vitro. However, it may be
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possible that downregulation of the efferocytosis related receptors may be a tumor
microenvironment specific effect. Taken together, this supports our observations
that NRP2 is important for the efficient clearance of apoptotic cells by
macrophages by favoring phagosome maturation and also indicates that apoptotic
tumor cells were inefficiently removed by NRP2 depleted TAMs owing to either
dampened uptake (may arise as a secondary effect) or a defect in the downstream
events of phagosome maturation. Intriguingly, phagosomes containing different
cargo often recruit functionally similar but distinct molecules for phagosome
maturation or phagolysosome biogenesis and often follow different maturation
kinetics. Enrichment and identification of differential recruitment of proteins during
maturation is best observed following isolation of phagosome membranes. It may
be possible that NRP2 interacts with a common adapter molecule and regulates
the recruitment of several effector molecules at various stages of phagosome
maturation. The exact molecular mechanism how NRP2 regulates the phagosome
maturation is currently unknown; the differentially expressed genes from our RNASeq data does not readily indicate how NRP2 regulates phagosome maturation at
the molecular level and merits further investigation.
The hallmark feature of efferocytosis is that it is immunologically silent and
induces the expression of immunosuppressive genes in macrophages. Blockade
of efferocytosis or inefficient clearance of apoptotic cells removes that suppressive
effect and activates the inflammatory pathway. Our RNA sequencing analysis
identified suppression of several immunosuppressive genes, for example, IL-4, IL10, TGFα, CCL22 were downregulated whereas inflammatory genes like IFN-β1,
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IL-12a, Gr-K, Gr-F were upregulated. Additionally, we observed some chemokines
or chemokine receptors like CCL25 or CXCL13 that can potentially recruit cytotoxic
CD8+ or effector CD4+ T cells were upregulated in NRP2 depleted condition. Also,
increase in IFN-β1, Il-12a may act to activate T cell response. A lot of effort is
currently being given to harness checkpoint inhibitor molecules like CTLA-4, PDL2, PDL-1, PDL-1 which interfere with T cell activation and help maintain a local
environment of immunosuppression in the TME. Interestingly, PDL-2 was
downregulated in TAMs following NRP2 depletion. Additionally, molecules that can
either activate T cell death, like FasL or indirectly interfere with T cell activity by
promoting immunosuppression in macrophages (like TIGIT, Foxp3) were also
downregulated. However, some of the altered genes showed a mixed signature. It
is important to remember that TAMs are a complex population and often show a
mixed phenotype, highlighting their plasticity. Taken together, we conclude that
NRP2 depletion affects a wide array of molecules associated with the immune
response that act in consort and result in CD8+ T cell activation. It is important to
remember that the time point selected for RNA-seq (15 days post tumor
implantation) provides us a snapshot of the changes occurring in TAM during that
time point. Many important changes in gene profile that may reflect further
deregulation of efferocytosis and therefore activation of M1-type inflammatory
pathways in TAMs may have either happened before or would take place at later
time points.
Tumors manipulate the immune system in multiple ways, eventually
shaping it to promote tumor growth and metastasis. One of the key mechanisms
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by which this is achieved is through suppression of effector and cytotoxic T cell
recruitment to the tumor bed and their activation, and through recruitment of
suppressor T cells. In summary, based on our current findings that NRP2 depletion
in macrophages suppresses the immunosuppressive genes robustly increases
CD8+ T cell infiltration, we propose NRP2 may be a potential candidate for
therapeutic intervention in treating solid tumors, including PC. However,
considering targeting NRP2 in TAMs to dampen efferocytosis and activate antitumor immune response as a potential strategy for treating cancer, one must weigh
the risks associated with necrotic cell death and leakage of necrotic cellular
components, hyper activation of T cells, autoimmunity and tissue damage. For
example, impaired efferocytosis of apoptotic cells in post-partum condition results
in tissue scarring and inflammation and interferes with lactation ability. Also,
inflammation resulting from blockade of NRP2 mediated efferocytosis may
adversely promote tumor associated inflammation and aid in tumor progression.
Therefore, it is important to identify the optimal therapeutic window for targeting
efferocytosis in cancer.
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Fig. 4.1 NRP2 is expressed by tumor infiltrating macrophages in pancreatic
cancer. (A) Representative confocal image showing the presence of NRP2
expressing TAM in human PDAC tissue. The first panel shows only NRP2 positive
cells in the tumor section (red). The second panel shows CD68+ macrophages
(green). The third panel represents merged image showing NRP2+CD68+
macrophage in the tumor tissue. Scale bar, 50µm. Inset shows magnified image
of a single macrophage. Arrows indicate NRP2+CD68+ macrophage while *
indicate NRP2 expressing non-macrophage type cells. Dapi was used to stain the
nucleus. (B) Representative confocal image showing the presence of NRP2
expressing F4/80+ macrophages in mouse pancreatic tumor. The first panel shows
cells that stained positive for NRP2 (green). The second panel represents F4/80+
cells (red). The third panel represents merged image showing NRP2+F4/80+
macrophages in the tumor section. Scale bars, 20µm. Inset showing magnified
image of an individual NRP2+ macrophage. Arrows indicate NRP2+F4/80+ cells
while * indicate NRP2 expressing other cell types in the tumor section.
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Fig. 4.2 Expression of NRP2 in human and mouse TAMs generated in vitro.
(A-C) Immunoblot analyses showing NRP2 expression in TAMs generated in vitro.
Freshly isolated human monocytes or bone marrow cells from WT mice were
differentiated to TAMs with CM from Panc-1 (human) or UNKC-6141 or KPC cells
(mouse) for 7days. Significant NRP2 expression was observed in both human and
mouse TAMs generated in vitro.
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Fig. 4.3 NRP2 regulates phagosome maturation in TAMs in vitro. Human
macrophages treated with CM from Panc-1 cells were used for phagocytosis assay
with pHrodo E.coli bioparticles. Phagosome maturation was scored from visible
red puncta under the microscope. (A) Representative confocal microscopy image
showing NRP2 depletion impaired phagosome maturation in Panc-1 CM treated
macrophages. Inset shows magnified image of an individual cell. Scale bar, 10µm.
(B) Phagosome maturation was quantified as total cellular fluorescence using
Image J software and represented in a bar graph. (C) western blot showing NRP2
depletion. (D,G) Mouse bone marrow derived macrophages treated with CM from
UNKC-6141 or KPC cells were exposed to pHrodo E.coli bioparticles. Phagosome
maturation was assessed from the intensity of visible red puncta under the
microscope. Representative confocal microscopy image is shown. Inset shows
magnified image of an individual cell. Scale bar, 20µm. (E,H) Phagosome
maturation was quantified as total cellular fluorescence using Image J software
and represented in a bar graph. All values as mean ± SEM. Dapi was used for
staining the nucleus in all the experiments. Student t test was used for comparison
between 2 groups of cells. *P < .05; **P < .005; ***P < .0005. ns=not significant.
(C,F, I) Western Blots for NRP2 depletion for each experiment is shown.
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Fig. 4.4 NRP2 regulates efferocytosis of apoptotic cells in bone marrow
derived macrophages. Efferocytosis assay to assess the effect of NRP2
depletion on the ability of macrophages to mature the efferosomes and degrade
the apoptotic cells. (A) A schematic diagram showing the experimental design. (B)
Bone marrow cells isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7days
with M-CSF. Macrophages were then challenged with apoptotic Jurkat cells for 1hr
(pulse). Non-engulfed or loosely adherent apoptotic cells were removed and
macrophages were then microscopically assessed for their ability to degrade the
apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 12hr. Scale bars,
10µm. Magnified images within the insets show single cell containing apoptotic
body at each indicated time point for the panels. (C) Intensity of cellular
fluorescence (red) was analyzed using Image J software and used as a measure
for the ability of the macrophages for efferosome maturation and to degrade the
apoptotic cargo. Cells were analyzed at the time points indicated in the graph
abscissa and results represented as bar graphs. Values are mean ± SEM. (D)
Immunoblot to show knock out of NRP2 following addition of (Z)-4-Hydroxy
Tamoxifen. Dapi was used for staining the nucleus in all experiments. Student t
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P
< .0005. ns=non-significant.
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Fig. 4.5 NRP2 regulates efferocytosis of apoptotic cells in peritoneal
macrophages. Efferocytosis assay to assess the effect of NRP2 depletion on the
ability of macrophages to mature the efferosomes and degrade the apoptotic cells.
(A) Peritoneal macrophages isolated from NRP2fl/flCSF1R-iCre mice were cultured
for 3 days with M-CSF. Macrophages were then challenged with apoptotic Jurkat
cells for 1hr (pulse). Non-engulfed or loosely adherent apoptotic cells were
removed and macrophages were then microscopically assessed for their ability to
degrade the apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 8hr. Scale
bars, 10µm. Magnified images within the insets show single cell containing
apoptotic body at each indicated time point for the panels. (B) Intensity of cellular
fluorescence (red) was analyzed using Image J software and used as a measure
for the ability of the macrophages for efferosome maturation and to degrade the
apoptotic cargo. Cells were analyzed at the time points indicated in the graph
abscissa and results represented as bar graphs. Values are mean ± SEM. (C)
Immunoblot to show knock out of NRP2 in peritoneal macrophages following
addition of (Z)-4-Hydroxy Tamoxifen. Dapi was used for staining the nucleus in all
experiments. Student t test was used for comparison between 2 groups of cells.
*P < .05; **P < .005; ***P < .0005. ns=non-significant.
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Fig. 4.6 NRP2 regulates the clearance of apoptotic cells in TAMs in vitro.
Efferocytosis assay to assess the effect of NRP2 depletion on the ability of TAMs
to mature the efferosomes and degrade the apoptotic cells. (A) bone marrow cells
isolated from NRP2fl/flCSF1R-iCre mice were cultured for 7 days with CM from
UNKC-6141 cells. Macrophages were then challenged with apoptotic Jurkat cells
for 1hr (pulse). Non-engulfed or loosely adherent apoptotic cells were removed
and macrophages were then microscopically assessed for their ability to degrade
the apoptotic cell cargo for the chase time points= 0hr, 2hr, 6hr, 12hr. Scale bars,
10µm. Magnified images within the insets show single cell containing apoptotic
body at each indicated time point for the panels. (B) Intensity of cellular
fluorescence (red) was analyzed using Image J software and used as a measure
for the ability of the macrophages for efferosome maturation and to degrade the
apoptotic cargo. Cells were analyzed at the time points indicated in the graph
abscissa and results represented as bar graphs. Values are mean ± SEM. (C)
Immunoblot to show knock out of NRP2 following addition of (Z)-4-Hydroxy
Tamoxifen. Dapi was used for staining the nucleus in all experiments. Student t
test was used for comparison between 2 groups of cells. *P < .05; **P < .005; ***P
< .0005. ns=non-significant.
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Fig. 4.7 Scheme of subcutaneous tumor growth model. Schematic diagram for
subcutaneous tumor growth model. UNKC-6141 cells were mixed with Matrigel
and subcutaneously implanted into the right flank of NRP2fl/flCSF1R-iCre mice.
Once the tumors became palpable, animals were randomly divided into control and
test groups (n=5). The test animals received daily intraperitoneal injection of
Tamoxifen (20mg/kg body weight) to knock out NRP2 from the macrophages.
Tumor growth was monitored for time periods indicated in Fig. 4.8 and Fig. 4.9.
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Fig. 4.8 NRP2 in macrophages affects tumor progression. (A) Representative
image of the harvested tumors from the control and Tamoxifen treated mice,
showing moderate decrease in the test group tumors following NRP2 depletion in
macrophages. (B) Tumor growth was monitored regularly for the indicated time
period and represented as a line graph. * indicates p=0.05. (C) Scatter plot
comparing the volume of the control and test tumors after they were harvested. (D)
Graphical representation of weight of harvested tumors. (E) Western Blot showing
NRP2 was completely knocked out from the bone marrow macrophages following
Tamoxifen injection into the test animals. (F) graph showing weight of animals
before and at the end of the study.
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Fig. 4.9 Depletion of NRP2 in macrophages increases the necrotic area in
tumors. (A) Representative image H&E images from control and test tumors
showing increase in necrotic area following NRP2 depletion in macrophages. (B)
Necrotic areas were marked using Image J software and the areas calculated.
Result represented as box plot. Values are mean ± SEM. * indicates p=0.05.
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Fig. 4.10 Effect of macrophage NRP2 depletion on TAM recruitment,
angiogenesis and CD8+ T cell infiltration. (A) representative confocal image of
F4/80+ macrophages (red) infiltrating control (top) and test tumors (bottom). The
first column shows only F4/80+ staining. The second column shows DAPI staining
of the tissue. The third column represents merged picture for F4/80 + cells in the
tissue section. Images acquired at 20X magnification. Dapi was used for nuclear
staining. Inset shows individual macrophage. (B) The number of F4/80 +
macrophages per field were counted for 10 random fields using Image J software
and represented as a box plot. (C) Representative images of
immunohistochemistry showing CD8+ T cell infiltration (brown) in control and test
tumors. Image scale, 20X magnification. (D) Number of CD8+ T cells per field was
counted using Image J software, for 10 random fields and represented as a vertical
scatter plot. (E) Representative immunohistochemistry image showing CD31+
vessels in control and test tumor. Image scale, 20X magnification. (F) Number of
CD31+ vessels per field was counted (vessel density) using Image J software, for
10 random fields and represented as a vertical scatter plot. All values are mean±
SEM. Student t test was used for comparison between control and test. *P < .05;
**P < .005; ***P < .0005. ns=non-significant.
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Fig. 4.11 NRP2 in macrophages regulates tumor growth. 500,000 UNKC-6141
cells were mixed with Matrigel and subcutaneously implanted into the right flank of
NRP2fl/flCSF1R-iCre mice. Once the tumors became palpable, animals were
randomly divided into control and test groups (n=5). The test animals received
daily intraperitoneal injection of Tamoxifen (20mg/kg body weight) to knock out
NRP2 from the macrophages. Tumor progression was monitored for 25days. (A)
Representative image of the harvested tumors from the control and Tamoxifen
treated mice, showing moderate decrease in the test group tumors following NRP2
depletion in macrophages. (B) Tumor growth was monitored regularly for the
indicated time period and represented as a line graph. * indicates p=0.05. (C)
Scatter plot comparing the volume of the control and test tumors after they were
harvested. (D) Graphical representation of weight of harvested tumors. (E) TUNEL
staining showing increased number of apoptotic or necrotic cells in tumors
following NRP2 depletion in myeloid cells. (F) Graphical representation of
increased number of apoptotic or necrotic cells in tumors deficient in NRP2 in
myeloid cells. (G) Western Blot showing NRP2 was completely deleted from
macrophages following Tamoxifen administration. (H) graph showing NRP2 was
knocked out from intratumoral TAMs following Tamoxifen administration.
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Fig. 4.12. Effect of NRP2 depletion in macrophages on TAM recruitment,
angiogenesis and α-SMA. (A) Representative confocal microscopy image
showing NRP2 does not have any role in the migration of macrophages (F4/80+,
red) to the tumor. The first column shows only F4/80 staining in red, in control
(upper) and test (bottom) tissue. The second column represents only DAPI staining
for nucleus in control (upper) and test (bottom) tissue. The third column shows
merged images with F4/80 and DAPI staining, for both control (upper) and test
(bottom) tumors. Scale bar, 20µm. Inset shows magnified image of a single F4/80+
macrophage. (B) the number of F4/80+ cells per field (for 10 random field, 20X
magnification) were counted using Image J software and represented graphically
in a scatter plot. (C) Representative immunohistochemistry image showing CD31+
vessels in the control and test tumors. (D) The number of CD31+ vessels per field
were counted (20X magnification, 10 random fields) using Image J software and
represented as average vessel density in a vertical scatter plot. (E) Representative
image showing α-SMA in control and test tumors. (F) Graphical representation of
the result. All values are represented as mean± SEM. Student t test was used to
compare between the control and test tumors. ns= not significant.
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Fig. 4.13 NRP2 depletion in macrophages affects T cell response in tumor.
(A) Representative images of immunohistochemistry showing significantly higher
CD8+ T cell infiltration in test tumors in comparison to control tumor. Image scale,
20X magnification. (B) Number of CD8+ T cells per field was counted using Image
J software, for 10 random fields and represented as a vertical scatter plot. (C)
Representative image showing Granzyme B positive cells in tumor. (D) Graphical
representation of relative numbers of Granzyme positive cells per field in control
and test tumors. (E) Representative confocal microscopy image for CD4+ T cell
infiltration (red) in the control and test tumors. Scale bar 20µm. Inset shows
magnified image of individual CD4+ T cell. Dapi was used to stain the nucleus. (F)
Number of CD4+ T cells per field was counted using Image J software and
represented in a scatter plot. All values are mean± SEM. Student t test was used
for comparison between control and test. *P < .05; **P < .005; ***P < .0005.
ns=non-significant.
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Fig. 4.14 Transcriptome analysis from CD11b+ cells by RNA-Sequencing
analysis. (A) Schematic diagram showing the experimental design for the study.
(B) Graphical representation of the volume of the harvested tumors. (C) Graphical
representation of weight of excised tumors. (D) Pie chart showing number of genes
(upregulated and downregulated) whose expression altered by atleast log 2 fold
change 1 following NRP2 depletion in macrophages.
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Fig. 4.15 Analysis of differentially expressed genes using Ingenuity Pathway
Analysis and DAVID functional annotation bioinformatics microarray
analysis. (A) Representative canonical pathways enriched in IPA analysis. (B)
Functional annotation clusters for the differentially expressed genes from DAVID
database. (C) Representative functional annotation clusters related to immune
response phagocytosis from DAVID database analyses.
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Fig. 4.16. Representative genes for phagocytosis pathway (A) and immune
response related functions (B) are shown. (C) Representative genes encoding
wound healing and immunosuppressive molecules in macrophages, that were
altered following NRP2 depletion.
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Chapter V

Future Directions
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5.1 Central theme of dissertation and approach
The central theme of the dissertation is to identify the role of NRP2 in macrophages
and how it affects the pro-tumorigenic activities of TAMs in PC. Others and we
have shown NRP2 is expressed in macrophages and TAMs. However, the exact
function of NRP2 in macrophages and the signaling pathways it governs is still
elusive. To clearly understand the effect of NRP2 in macrophages, we have used
siRNA approach in human monocyte derived macrophages as well as genetically
depleted NRP2 in inducible manner in mouse macrophages in vitro as well as in
vivo studies. We also tested the effect of NRP2 depletion in TAMs in tumor
progression, using a subcutaneous PC model, to identify the role of NRP2 in tumor
progression and identify novel treatment modality for PC.
5.2 Current understanding
In summary, data presented in this dissertation indicate that the expression of
NRP2 in macrophages is essential for phagocytosis. We show that NRP2
promotes the degradation and clearance of microbes (E.coli, zymosan) by
promoting the maturation of early to late phagosomes. This was attributed to an
increase in Rab5+ vesicles and a concomitant decrease in Rab7+ late
endosomes/phagosomes in absence of NRP2. We further show that NRP2 is
important for efferocytosis of apoptotic cells, a process although similar, but distinct
from phagocytosis. The process of efficient cleaning up by macrophages is
important for maintenance of physiological and immunological homeostasis,
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however, it can also act as a double-edged sword in malignancies. Efferocytosis
of dying tumor cells in the TME polarizes the macrophages towards an
immunosuppressive phenotype and triggers non-inflammatory signaling cascades,
such as, production of TGF-β, IL-10. This helps maintain an overall
immunosuppressed environment in the TME by silencing effective T cell response,
and creates a niche for tumor survival, growth and metastasis. Most of the patients
undergoing treatment for cancer, including PC, receive either CT or RT as
conventional treatment modalities. Intriguingly, these treatments result in
increased recruitment of TAMs and trigger a TAM-mediated misdirected tissue
repair response and immunosuppression by increasing efferocytosis of apoptotic
tumor cells by TAMs. Pharmacological blockade of efferocytosis has been shown
to reduce tumor burden by activating inflammatory responses in macrophages and
activating T cell responses. We observed a slower tumor growth following
depletion of NRP2 in macrophages. We attribute this to delayed clearance of dying
tumor cells in the TME and subsequent activation of tumoricidal CD8+T cells in
absence of NRP2 in TAMs. Thus, this study led to the identification of NRP2 in
TAMs as a potential therapeutic strategy for treatment of PC and other cancers in
the future.
5.3 Future Directions
There are a few open ends to this study that warrant further investigation. The next
step for this work would be to understand the following:
How NRP2 regulates phagosome maturation at the molecular level: We have
previously shown that NRP2 regulates maturation of early to late phagosomes and
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that in its absence there is an increase in the number of Rab5+ early
endosomes/phagosomes and a concomitant decrease in the number of Rab7+ late
endosomes/phagosomes. This indicated a defect in the switch from Rab5 to Rab5,
a step that is essential for phagosomes (and endosome) maturation. Although
details about phagosome maturation is currently limited, it is believed that first
Dynamin is recruited to the phagosome membrane, which then interacts with
Vps34 (a PI3 Kinase) and helps recruit Rab5 to the phagosome surface. Rab5, is
activated by Gapex-5 (Rab5 GEF), and further promotes Vps34 activation. Vps34
then generates PtdIns(3)P on the phagosome surface where the vacuolar fusion
protein complex, Mon1A-Ccz1, is recruited. This complex recruits Rab7 and act as
its effector. Rab7 next interacts with homotypic fusion and vacuole protein sorting
(HOPS) complex to facilitate phagoslysosome generation. Since our data suggest
NRP2 regulates the switch from Rab5 to Rab7, we hypothesize that NRP2 regulate
the steps downstream of Rab5 recruitment, such as activation of Rab5, Vps34 or
membrane recruitment of the Mon1a-Ccz1 complex. Additionally, differentially
expressed genes from our RNA-Sequencing analyses revealed several molecules
involved in either phagosome maturation, endocytic recycling, exocytosis were
affected following NRP2 depletion. These need to be investigated to understand
how NRP2 mechanistically regulate phagosome maturation.
Does NRP2 activate LAP pathway for clearance of apoptotic cells: LC3 associated
phagocytosis has recently been shown to be important for clearance of fungal
particles as well as engulfed apoptotic cellular debris in macrophages. We have
previously reported that NRP2 regulates autophagy in cancer cells. Whether NRP2
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promotes clearance of dead cells through activation of LAP pathway needs further
investigation.
Does delayed phagosome maturation or efferocytic clearance in absence of NRP2
promote cross presentation: Our results indicated that NRP2 promotes the
maturation of phagosomes. In NRP2 depleted conditions, phagosome maturation
is delayed which subsequently results in significantly delayed clearance of
phagocytosed cargo (E.coli, zymosan, apoptotic cells). It is now well understood
that delayed phagosome maturation helps preserve antigenic peptides against
degradative enzymes in the phagolysosome and favors antigen loading to the
MHC complexes and subsequent presentation to the T cells. This is of particular
importance in case of solid tumors where following NRP2 depletion in
macrophages, we observed a robust infiltration of cytotoxic CD8+ T cells. It is
plausible that delayed phagosome maturation in NRP2 depleted TAMs augmented
cross presentation of tumor cell derived antigens to the CD8+ T cells. This needs
to be tested in more details in the future.
Effect of NRP2 on PDAC metastasis: Previous studies have shown efferocytosis
increases the risk for metastasis in a model of post-partum breast cancer (ppBC)
by 10-fold. Pharmacologically blocking efferocytosis significantly reduced the
metastasis in ppBC as well as therapy induced metastasis in tumor bearing
animals. Since our current findings suggest a role for NRP2 in efferocytosis, and
also it can affect tumor growth, the next step for the study would be to identify the
role of NRP2 in TAMs on metastasis in PDAC. One of the limitations of the
subcutaneous tumor progression model used in the current study is that it does
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not mimic the natural PDAC TME. Orthotopically implanted tumors closely
resemble the natural pattern of human PDAC development and progression. To
test if blocking NRP2 mediated efferocytosis affects distant metastasis, we will
orthotopically implant GFP- expressing UNKC-6141 clone into CSF1RiCre;NRP2f/f mice. UNKC-6141 cells have previously been shown to develop
metastatic lesions in the liver, spleen, small intestines and mesenteric lymph nodes
within 1 month of implantation. We have observed in our mouse model, that tumors
are established within 6-7 days of implantation. Once the tumors are established,
NRP2 will be genetically knocked out from macrophages by daily intraperitoneal
injection of Tamoxifen (75mg/kg body weight). Tumors will be allowed to grow for
1 month and then excised; spleen, liver, intestine and lungs will be harvested for
metastatic foci. Metastasis was assessed by monitored by in vivo optical imaging
for GFP expression using a Xenogen-IVIS cooled CCD optical system.
It is important to note that blockade of efferocytosis may increase inflammation that
may potentially augment tumor progression and metastasis. Therefore, it is
extremely important to optimize at what stage of the tumor NRP2 may be targeted
for therapeutic efficacy.
Correlation between NRP2 expression in TAMs and PDAC stage:
In the current study, we tested a small cohort of patients (obtained from UNMC
Pancreatic Cancer Rapid Autopsy Program), who died of PDAC with no prior
history of treatment. We observed a high infiltration of NRP2 expressing
macrophages in almost all of the tissues. Treatment with either radiation,
chemotherapy or any other adjuvant therapy is known to modify the tissue
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architecture and results in recruitment of myeloid cells to orchestrate tissue repair
in response to therapy induced damage. Further, following any type of therapy,
apoptotic index in the TME is high and the freshly recruited macrophages efficiently
remove the dead tumor cells. This process has been reported to give rise to further
immune suppression in post-partum breast cancer. Based on our current data that
NRP2 regulates efferocytosis by macrophages as well as TAMs, and that it can
regulate T cell responses, it will be interesting to see if there is any correlation
between NRP2 expression in macrophages or their relative numbers in the TME
with different stage of PDAC, metastasis or overall survival post therapy.
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